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QUILL ON SCALPEL

Nonoperative Management for Adults
With Blunt Splenic Trauma
W.J. Temple, MD, FACS, FRCSC
Director o f surgery, Tom Baker Cancer Centre, Calgary. Member, Editorial Board, Canadian
Journal o f Surgery

this issue (pages 27 to 29)
I nStephen
and colleagues show
that, by clinical assessment, some
patients with lacerated spleens from
blunt trauma may be managed safe
ly without laparotomy. It is evident
that these patients were a very
select group. In the nonoperative
group, 24% of the patients present
ed with delayed signs and symp
toms, blood transfusion require
ments were less and a peritoneal tap
was not performed. All these fea
tures were in sharp contrast to
those in the surgically managed
group. The findings of Stephen and
colleagues support those of a simi
lar, retrospective study done in our
centre.1
However, this conservative ap
proach, as indicated by Stephen and
colleagues, is fraught with hazards
if strict criteria are not adhered to. I
would like to re-emphasize them,
because, in our centre over the last
few years, inappropriate application
of these principles has resulted in
patients suffering substantial mor
bidity.
The criteria that I believe should
be applied for nonoperative man
agement of adults with blunt sple
nic trauma are as follows:
• Minimal abdominal signs, iso
lated to the left upper quadrant.
• A negative abdominal tap, if
performed.

• A clinically stable patient re
quiring less than 2 units of blood to
stabilize blood pressure and main
tain vital signs.
• A splenic or perisplenic lesion
documented radiologically.
In making a decision to use a
nonoperative approach, the surgeon
must carefully weigh the risks and
benefits of observation for a docu
mented splenic injury. The risk of
overwhelming sepsis after splenec
tomy is lower in adults than in
children but is still of some con
cern. When surgery is delayed after
conservative management has
failed, a much lower splenic salvage
rate and higher transfusion require
ments have been reported.2 Trans
fusion of more than 2 units of
blood is associated with as much
morbidity from the risk of hepatitis
as is the potential for overwhelming
pneumococcal sepsis if splenectomy
is performed. Rebleeding after dis
charge in patients treated conserva
tively has not been documented, but
this risk appears to be negligible.
The potential morbidity of con
servative management must be
weighed against the dramatic im
provements in splenorrhaphy,
which can be performed successful
ly in 88% of grades I and II and in
60% of grade III splenic injuries,
found in the majority of patients
suitable for a conservative ap

proach.3 My own modification of
the Dexon-mesh wrap technique
salvaged the spleen in six consecu
tive patients with grade III or IV
splenic injuries. This technique has
controlled blood loss quickly with
out subsequent rebleeding. It is best
described as a compression sple
norrhaphy. The technique is as fol
lows: The spleen is mobilized rapid
ly into the midline from its peritone
al and retroperitoneal attachments,
as in a standard splenectomy. A
vascular clamp may be applied
across the pedicle for a few min
utes. The clamp, which immediately
stops the bleeding and gives the
surgeon time to work on the spleen,
is removed as soon as possible. A
piece of Dexon mesh is used to
wrap the entire spleen, leaving a
small opening for the pedicle in the
following manner. The mesh is cut
half-way along one side to the cen
tre. The pedicle is placed at the
centre of the mesh. The short gastr
ic vessels may be ligated to decrease
the width of the pedicle. The cut in
the mesh is then closed with a
running suture, starting snugly at
the pedicle and progressing to the
edge of the mesh. Malitene may be
applied over the bleeding areas or
placed into the laceration to assist
hemostasis. The mesh is then
wrapped over the spleen, as one
would wrap a gift, and the excess
CJS, VOL. 34, NO. 1, FEBRUARY 1991
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trimmed. A running suture is used
to close the mesh, making it into a
bag. The key to success is to de
crease the size of the mesh bag
progressively with running sutures
until the spleen is compressed
enough that the bleeding stops.
This may result in the spleen being
smaller than its original size but is
likely a temporary condition.
This compression technique is
quick and effective, taking only 10
to 15 minutes, and is a dependable

alternative for any patient with sple
nic injury not fulfilling the criteria
for conservative management. The
preliminary results of this technique
are so impressive that it will likely
prove useful in avoiding splenecto
my in some patients, even when
there is associated splenic damage
and multiple intra-abdominal inju
ries.
Stephen and his colleagues are to
be congratulated for bringing this
subject once more to our attention.
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Fear of Flying and Surgery
Nelson S. Mitchell, MD, FRCSC
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during World
A sWara schoolboy
II, I was obsessed with
aircraft and flying. Spitfires, Hurri
canes, Me 109s and 110s, drawn in
various configurations of flight,
took up every available space in my
school books. I built and flew — or
more often crashed — countless
balsa models.
About the time I began training
in surgery I learned that 1 was
afraid of flying. Trips to meetings
or courses in Toronto, Chicago or
points distant, presented great lo
gistical problems . . . how to avoid
the jet and travel on the ground.
At the beginning of my surgical
practice a surgical acquaintance
took me flying in his two-seater
Super-Cub. As I sat behind him,
unable to protest, we flew under a
bridge in the Halifax harbour. For
tunately this act of wanton foolish
ness was followed by a ride in a
float plane where the great safety of
flight was emphasized. I began fly
ing lessons shortly thereafter. Pilot
licence, night flying and instrument
ratings and the purchase of an
aircraft soon followed. Eighteen
years later I have spent 1500 hours
flying all over North America and
five times that time in the operating
room. I have found that much of
pilot training has implications for
the surgeon.
Before each flight the charts, the
weather at departure, en route and
at the destination must be evaluated
for an expeditious and safe trip.
The surgical approach must also be
planned with knowledge of anatom
ical charts, taking into account the
objective of surgery, possible devia
tions and obstacles that might arise.
If the weather at the destination is

marginal an alternative aerodrome
must be selected . . . . Will the
patient need to be transferred to the
intensive care unit postoperatively?
Is a bed available?
Before starting the engine(s) the
pilot must be completely familiar
with the equipment he is using. He
walks around the aircraft inspecting
it and its systems. In the cockpit,
further static and operational
checks are made according to a
prearranged plan. A complete un
derstanding of the structure and
functions of the patient is taken for
granted, but how many of us ensure
that we have done so with a check
list? How many operations have
been delayed or the result compro
mised by faulty or absent equip
ment, which a preoperative check
might have turned up?
During the taxi and take-off
phase, while the flight can still be
aborted, further regimented system
checks are made. Aloft the pilot
continuously monitors his engine
and system instruments and his
progress. He constantly contem
plates what could go wrong with
machine or weather and how he
would deal with it. The surgeon,
likewise, should continuously con
sider if the procedure is going ac
cording to plan. As the dissection
proceeds he should look for danger
signals and contemplate what com
plications might occur and how
best to avoid them. Is there a
danger of entering bowel or a ves
sel? How can the risk be minimized
and what to do if the dreaded event
occurs?
As prelanding checks are read off
on the approach to the airport, so
the end of the operation is a time to

review postoperative orders and re
habilitation plans. Upon landing a
debriefing is carried out and points
of interest are recorded in the log.
How often does the surgeon discuss
with the operating team the con
duct of a operation with a view to
improving performance?
In all of the above my pilot
training was the most useful to me
in risk management and damage
control. The surgeon can avoid
most intraoperative complications
by anticipating them, but when they
arise, panic can be avoided by hav
ing a predetermined plan. Even in
its absence, the conviction in
grained during training that virtual
ly every problem is solvable will
stand both pilot and surgeon in
good stead.
I am mildly apprehensive during
every flight. I have been truly
frightened only twice, both times
because of unfamiliarity with a sys
tem or failure of planning. I have
had two engine failures, but these
were without consequence as con
tingency plans were available and
were used. Early in my pilot train
ing, before these responses were
developed, I wrecked an aircraft.
The operating room has always
been a place in which I am some
what frightened. When complica
tions arose I had to train myself to
remain calm. Anticipation and con
tingency planning has reduced
these to rare occurrences. Those
surgeons who disclaim any fear in
the operating room are likely to
have at least some “incidents” dur
ing their careers: the Department of
Transport calls a wreck without
injury an incident, reserving “acci
dent” for a worse occurrence. ■
CJS, VOL. 34, NO. 1, FEBRUARY 1991
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Ergamisol* + 5-FU.
The first adjuvant therapy proven to
reduce recurrence by 41%.
LEVAMISOLE AND FLUOROURACIL FOR ADJUVANT THERAPY OF
RESECTED COLON CARCINOMA
Abstract Twelve hundred ninety-six patients with resected
colon cancer that either was locally invasive (Stage B2) or
had regional nodal involvement (Stage C) were randomly
assigned to observation or to treatment for one year with
levamisole combined with fluorouracil. Patients with Stage
C disease could also be randomly assigned to treatment
with levamisole alone. The median follow-up time at this
writing is 3 years (range, 2 to 5%).
Among the patients with Stage C disease, therapy with
levamisole plus fluorouracil reduced the risk of cancer
recurrence by 41 percent (P < 0.0001). The overall death
rate was reduced by 33 percent (P ~ 0.006). Treatment
with levamisole alone had no detectable effect. The results
in the patients with Stage B2 disease were equivocal and

too preliminary to allow firm conclusions. Toxic effects of
levamisole alone were infrequent, usually consisting of
mild nausea with occasional dermatitis or leukopenia,
and those of levamisole plus fluorouracil were essentially
the same as those of fluorouracil alone-i.e., nausea,
vomiting, stomatitis, diarrhea, dermatitis, and leukopenia.
These reactions were usually not severe and did not greatly
impede patients’ compliance with their regimen.
We conclude that adjuvant therapy with levamisole and
fluorouracil should be standard treatment for Stage C
colon carcinoma. Since most patients in our study were
treated by community oncologists, this approach should
be readily adaptable to conventional medical practice.
CN Engl J Med 1990; 322:352-80’
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New Bronchoscopic Instruments:
a Toothpick and a Corkscrew
C.L.N. Robinson, MD, FRCS, FRCSC
foreign bodies require
U nusual
ingenuity to remove. I describe

too slippery, and attempts to re
move it simply pushed it further
down the bronchus.
To overcome this I had a “tooth
pick” instrument made (Fig. 2). It
was 50 cm long, had a thickened,
serrated handle and a small, sharp,
angled point.
Two days later I made another
attempt to remove the crown. With
an assistant holding the broncho-

here two cases in which unusual
instruments were used to remove
unusual foreign bodies from the
right and left lower-lobe bronchi of
a 55-year-old man and a 6-year-old
boy.

Case Reports
Case 1
A

During the fitting of a gold
crown to a defective molar a
55-year-old dentist accidentally in
haled the crown when it slipped his
colleague’s fingers. The crown set
tled in the right lower-lobe bron
chus (Fig. 1). Although the dentist
did not experience any serious
symptoms he did have minor
wheezing on the right side of the
chest. When I first saw the patient
in the Emergency Department I
thought the crown could be re
moved easily by bronchoscopy.
However, when I tried to grasp the
crown, which was lying with the
blunt side down and was quite firm
ly impacted, with an angled alliga
tor forceps, the leading edge was

FIG. 1. Posteroanterior and lateral
views showing metal (gold) crown in
right lower-lobe bronchus.

Emeritus clinical professor o f surgery, Faculty o f Medicine, University o f British Columbia,
Vancouver
Accepted for publication Nov. 27, 1989
Reprint requests to: Dr. C.L.N. Robinson, 604 -7 5 0 West Broadway, Vancouver, BC V5Z1H 5
* - For prescribing information see page 36

FIG. 2. “Toothpick” with 50-cm long
handle and fine angled tip.
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FIG. 3. Long instrument with cork
screw at end.

scope steady I was able to get the
toothpick around the edge of the
crown, rotate it enough to grasp
the sharp edge firmly with an alliga
tor forceps and remove it trailing.
The crown was fitted correctly a
few days later.
Case 2
A 6-year-old boy accidentally in
haled a plastic, cone-shaped head of
a toy bullet, which became lodged
in the left lower-lobe bronchus. It
was pointed down and firmly im
pacted. The cylinder-like end of the
bullet was pointed upwards making
it impossible for me to grasp the
bullet without damaging the wall of
the bronchus. The cone end of the
bullet had a tiny hole. Therefore I
had a long instrument made with a
corkscrew at one end (Fig. 3). The
corkscrew was inserted through the
hole, and the bullet was removed
safely, trailing, without damaging
the bronchial wall.
I wish to thank Keir & Sons, Vancouver
for making the two instruments.*
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SESAP VI Question
A

Item 145

Administration of polyvalent pneumococcal vaccine to a child who has
undergone splenectomy
(A) virtually eliminates the risk of overwhelming postsplenectomy
infection (OPSI)

-‘U

4

(B) reduces the risk of OPSI by approximately one third
(C) is of no benefit unless given prior to splenectomy

X

(D) is of no benefit because many of the bacteria causing OPSI are
not pneumococci
(E) is contraindicated for children who have undergone splenecto
my for hematologic diseases. For the incomplete statement
above select the best of the five completions.
For the critique of Item 145 see page 69.
(Reproduced by permission from SESAP VI Syllabus; Surgical Educa
tion and Self-Assessment Program No. 6. For enrolment in the Surgical
Education and Self-Assessment No. 6, please apply to the American
College of Surgeons, 55 East Erie St., Chicago, IL 60611.)
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Detection of Micrometastases
From Primary Breast Cancer
D.J. Courtemanche, MD;* A.J. Worth, MD, FRCPC;t R.W. Coupland, MD, FRCPC;$
J.K. MacFarlane, MD, MSc, FRCSC§

The monoclonal antibody LICR-LON-M8 was used in a series of experiments to
determine how an immunohistochemical technique could be used as a diagnostic test
for micrometastatic disease in patients with operable, primary breast carcinoma.
Optimal tissue and antigen preservation was obtained with fixatives containing
either picric acid or a heavy metal such as mercury to allow staining with the
monoclonal antibody diluted to 1:12 000 to 1:16 000 from unpurified mouse ascites.
Tissue affected by primary and metastatic disease stains in a characteristic fashion,
which is distinct from benign breast tissue. All the ductal tumours stained positively
for malignant cells with the monoclonal antibody preparation. Within the bone
marrow, occasional granulocytes and granulocyte precursors stained positively if the
endogenous peroxidase activity was incompletely blocked. These cells were readily
differentiated from tumour cells on cytologic examination.
With these monoclonal antibody and immunohistochemical staining techniques it
may now be possible to detect early micrometastatic disease in the bone marrow
patients with primary breast cancer.

reast carcinoma is the most
common carcinoma in women,
affecting approximately 6% o f all
women in their lifetime.1 The bio
logic behaviour o f breast cancer

B

From the Department o f Surgery and De
partment o f Pathology, University o f British
Columbia, Vancouver
Presented at the annual m eeting o f the
Canadian Oncology Society, held in conjunc
tion with the 58th annual m eeting o f the
Royal College o f Physicians and Surgeons o f
Canada, Edmonton, Sept. 23, 1989
Supported by grant 86-0504 from the Re
search Coordinating Committee o f the Uni
versity o f B ritish Columbia, Vancouver

L’anticorps monoclonal LICR-LON-M8 a ete utilise dans une serie d’experiences
visant a determiner comment une methode immunohistochimique pouvait etre
utilisee comme epreuve diagnostique des micrometastases chez les patientes
souffrant d’un cancer primitif operable du sein.
Une conservation optimale des tissus et de l’antigene fut obtenue a l’aide de
fixatifs renfermant soit de l’acide picrique ou un metal lourd tel que le mercure et
permettant une coloration avec l’anticorps monoclonal dilue a 1:12 000 ou 1:16 000
provenant d’ascite non purifie de souris. Les tissus atteints d’un cancer primitif ou
envahis par des metastases se colorent de fa?on caracteristique, ce qui les
differencient des tissus mammaires sains. Toutes les tumeurs canaliculaires ont
donne une coloration positive en presence des preparations d’anticorps monoclonaux. Dans la moelle osseuse, quelques granulocytes et des precurseurs des
granulocyctes ont pris la coloration quand l’activite de la peroxydase endogene etait
incompletement bloquee. Ces cellules se differenciaient nettement des cellules
tumorales a l’examen cytologique.
Avec ces anticorps monoclonaux et les techniques de coloration immunohistochimiques, il pourrait maintenant etre possible de deceler precocement les micrometas
tases dans la moelle osseuse des patientes souffrant de cancer primitif du sein.

*C hief resident in plastic surgery, Depart
ment o f Surgery, University o f B ritish Co
lumbia, Vancouver
fCIinical professor, Department o f Patho
logy, University o f B ritish Columbia, Van
couver
tC lin ica l assistant professor. Department o f
Pathology, University o f B ritish Columbia.
Vancouver
§Professor and head, Division o f General
Surgery and head, Department o f Surgery,
St. Paul's Hospital, Vancouver
Accepted fo r publication Nov. 1, 1989
Reprint requests to: Dr. D.J. Courtemanche,
c / o Dr. J.K. MacFarlane, Department o f
Surgery, St. Paul's Hospital, 1081 Burrard
St., Vancouver, BC V6Z 1 Y6
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appears to be inadequately predict
ed by standard staging methods. It
remains unclear if this is a “system
ic” disease at the time of diagnosis
or if the tumour invades locally,
nodally and then distantly over
time. Some patients with locally
advanced disease remain diseasefree after treatment, and, in con
trast, some patients with stage I
lesions die early after treatment.
For patients with stage I disease,
the 5-year survival rate is 85% and
for those with stage II disease it is
70%.2 Clearly, a large number of
patients are “under-staged” by cur
rently available techniques.
Monoclonal antibodies provide
sensitive probes for the investiga
tion of biologic systems.3-5 Many
are reactive to breast carcinomas,
but their clinical role has yet to be
defined.6-12 LICR-LON-M8 (M8) is
one of several anti-breast monoclon
al antibodies that have been made
from membrane extracts of human
breast milk.67 The antigen is
thought to be a T- or Tn-related
precursor of the MN surface-anti
gen group.13-15 This is an immune
lipopolysaccharide, which appears
to be very stable.
We describe several experiments
using this antibody, performed in
an attempt to develop a clinical test
that would detect the presence of
micrometastatic disease in the bone
marrow of patients with primary
breast carcinoma.

Methods
The monoclonal antibody M8 was
supplied by Dr. B. Gusterson of the
Ludwig Institute for Cancer Re
search in London, England, and by
Dr. R. Buick of the Ontario Cancer
Institute as unpurified ascitic fluid
(with 0.1% NaN3 as preservative).
The technique of hybridoma pro
duction of monoclonal antibody has
been described,4 and the staining
16
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ma, a series of spread and particlesection control slides were made.
One aspiration specimen was crude
ly inoculated with dilutions of a cell
suspension prepared from a fresh
breast-carcinoma biopsy specimen.
A series of crude dilutions of tu
mour cells in suspension were
added to equal volumes of bonemarrow aspirate, and smears and
particle sections were prepared and
stained in a “spiking” experiment.
Additionally, two biopsy specimens
that yielded positive results on cyto
logic examination from patients
with metastatic breast cancer were
examined.
Slides were read independently by
two pathologists, and all specimens
had positive and negative controls.

characteristics of M8 in benign and
malignant breast tissues have been
well documented.67
Fresh tissue (surgical specimens)
and tissue previously fixed in 10%
buffered formalin (BF) or picric acid
formalin (PAF) were obtained from
the pathology departments of the
Vancouver General Hospital and the
Cancer Control Agency of British
Columbia. A variety of fixative solu
tions was used to preserve the fresh
tissue.
Immunohistochemical staining
was carried out by the avidin-biotin
peroxidase complex method,16 with
M8 as the primary antibody.
Several experiments were con
ducted to determine the optimal
method of fixing and staining the
tissues.17-18
First, serial dilutions of the anti
body were used to stain breast
carcinoma tissue that was previous
ly fixed in 10% BF or PAF to
determine the optimal dilution of
the antibody. Second, fresh tissue
was fixed in each of 10% BF,19
PAF,20 B5 (sodium acetate-merc
uric chloride-formalin fixative),21
Bouin’s solution22 or 95% alcohol
to determine the best method of
preservation of the antigen. Follow
ing this, a variety of specimens of
benign and malignant breast tu
mours were stained to verify the
staining characteristics reported in
the literature.67
From bone-marrow samples of
patients without metastatic carcino

“A

A

1
1
1

4,

Results
Initially, for the previously fixed
and blocked tissue, the best results
were obtained at a 1:16 000 dilu
tion for tissue fixed in PAF and in a
1:4000 dilution for tissue fixed in
10% BF (Table I). The original
specimen in BF was 2 years old,
and, subsequently, for freshly fixed
tissue a dilution of 1:12 000 was
found optimal for all fixatives ex
cept 95% alcohol. The quality of the
slides (freedom from artefact) was
best for specimens fixed in Bouin’s
solution (Table II).
Using the above information, we
examined breast biopsy specimens

L.

X

Table I. Determination of UCR-L0N-M8 (M8) Monoclonal Antibody Dilution for Optimal Staining
1 0% buffered form alin
(n = 1 4 )

Picric acid formalin
(n = 21)
Dilution

1:2 000
1:4 000
1:8 000
1:16 000
1:32 000

Stroma

Carcinoma

++

+++

++

+++

+

+++
++
+

-

Benign

Stroma

+
+

-

-

-

-

-

+

-

- to + + + represents an arbitrary scale of staining intensity: staining, + + , + + + = progressively stronger staining.
n = total number of sections stained.

Carcinoma

+++
++
+
-

Benign
-

—
-

= no staining, + = weak
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to confirm the staining characterist
ics of the antibody.6-7 Benign breast
tissue shows a characteristic apical
luminal membrane staining, but tis
sue from carcinomas shows staining
of the entire membrane as well as
cytoplasmic staining that varies in
intensity23 (Fig. 1). All of the ductal
carcinoma specimens tested stained
with this antibody (Fig. 2). Speci
mens of primary breast carcinoma
of other types did not stain as
consistently7 (Table III).
Normal bone marrow showed no
staining other than stain absorbed
by a few granulocytes and granulo

T a b le II. M o n o c lo n a l A n tib o d y S ta in in g Q u a lity U s in g V a rio u s F ixa tiv e s

V

Fix a tiv e
BF

A

A

cyte precursors in endogenous per
oxidase activity had not been com
pletely blocked.2425
Apart from the difficulty of plac
ing a clump of tumour cells into a
well-organized benign marrow, the
inoculation of normal marrow with
carcinoma cells worked relatively
well. At 105 and 104 cells/mL, it
was possible to differentiate clumps
of cancer cells in the particle sec
tions from the normal marrow (Fig.
3). These cells retained the cytolog
ic characteristics of malignancy. At
concentrations below 103 cells/mL
no malignant cells could be detected

X 24
X3 h

h
- 7 0 % a lc o h o l
B o u in ’s s o lu tio n x 2 4 h
x 3 h - 7 0 % a lc o h o l
PAF x 2 4 h
x 3 h - 7 0 % a lc o h o l
B5 X 2 4 h
x 3 h - 7 0 % a lc o h o l
9 0 % a lc o h o l X 2 4 h
X 3 h - 7 0 % a lc o h o l

M o n o c lo n a l antibod y dilution

Q uality*

1:1 5 0 0

Good

1 :1 2 0 0 0

E xce lle n t
(b e tte r se c tio n s )
E xcellent

1 :1 2 0 0 0
1 :1 2 0 0 0
1:1 5 0 0

* H is to lo g ic p re s e rv a tio n and fre e d o m fro m a rte fa c t.
BF = 10% b u ffe re d fo rm a lin , PAF = p ic ric a cid fo rm a lin , B5 =
c h lo rid e -fo rm a lin fix a tiv e .

Good
(b e tte r se c tio n s )
Good

s o d iu m

a c e ta te -m e rc u ric

FIG. 1. Benign breast tissue showing apical luminal membrane staining with
LICR-LON-M8 (M8) (arrow) (avidin-biotin peroxidase complex [ABC] technique
with M8 as primary antibody and hematoxylin counterstain, original magnification
X 250).

(Table IV). No malignant cells were
detected on any of the spreads. The
incidental finding of two or three
benign squamous cells contaminat
ing one of the slides emphasized
the ability of monoclonal antibody
M8 to detect cells present at low
concentrations.
Bone-marrow biopsy specimens
containing large numbers of meta
static carcinoma cells were stained
and showed the same characterist
ics as the primary tumours. The
cells had the cytologic features of
malignancy and could readily be
differentiated from the normal
bone-marrow cells.26-27 Single cells
within the section not readily seen
on hematoxylin-eosin-stained sec
tions could easily be visualized
when the monoclonal antibody was
used.28-29

Discussion
The results show that it is possi
ble to enhance the detection of
micrometastatic disease in patients
with primary breast carcinoma by
using LICR-LON-M8 as a mono
clonal antibody “probe.” This has
also been demonstrated with other
monoclonal antibodies.28' 32 These
results rest on the premise that
normal bone-marrow cells will not
stain, and that, in a patient with a
primary breast carcinoma, any cells
that stain within the bone marrow
represent metastatic disease.7
Clinical verification of this as
sumption is lacking. Detection has
been reported to correlate well with
known risk factors for a poor prog
nosis.
Redding and colleagues31 have
shown that the bone marrow of
patients with aggressive primary tu
mours, determined by standard
grading techniques, was more likely
to stain positive for carcinoma cells.
Eighty-three percent of patients
who had estrogen-receptor-negative
CJS, VOL. 34, NO. 1, FEBRUARY 1991
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membrane antigen (EMA). The pa
tients whose bone marrow tested
positive had a shorter interval be
fore clinical relapse occurred; how
ever, their overall survival was not
documented, perhaps because the
follow-up was not long enough.
Moreover, the characteristics of the
primary tumour were not noted,
therefore it is impossible to deter
mine whether the positive bone

tumours with vascular and nodal
invasion had bone marrow that
stained positively for cancer cells
compared with 11% of patients with
estrogen-receptor-positive tumours
without vascular or nodal invasion.
Dearnaley and associates28 re
ported the short-term follow-up of a
small group of patients whose bone
marrow had been examined with
the monoclonal antibody epithelial

FIG. 2. Invasive ductal carcinoma showing holomembrane staining of varying
intensity and cytoplasmic staining (compare cells indicated by arrow and arrow
head) (ABC technique with M8 as primary antibody and hematoxylin counterstain,
original magnification X 250).

marrow was an independent risk
factor.
The experience gained in this set
of experiments will be used in a
prospective clinical trial. In this trial
women who undergo surgery for
primary breast carcinoma will, with
informed consent, have four bonemarrow samples harvested at the
time of their breast surgery. The
tumours will be staged according to
standard techniques and the bonemarrow samples will be evaluated
separately in a double-blind fashion.
The results of the bone-marrow
screening will not be made available
to the patients or their treating
physician so as not to influence the
patients’ ongoing care.
Careful follow-up will be obtained
and an assessment made of the
prognostic implications of bonemarrow samples that test positive
or negative as an isolated test in
correlation with other methods of
tumour evaluation.
Several questions remain to be
answered:33
• Can positive bone-marrow
staining be reliably detected in the
clinical situation in patients with
micrometastases?
• Does detection in this manner

*

A

A

A

M

*
T a b le III. P a tte rn o f C a rc in o m a S ta in in g
T y p e of carcinom a

G ra d e

% s ta in in g (no.)

1
II
III
A ll
A ll
A ll

1 0 0 (6 )
1 0 0 (1 1 )
1 0 0 (8 )
7 5 (4 )
8 0 (5 )
1 0 0 (6 )

In filtra tin g d u ctal

M e d u lla ry
C o llo id
L o b u la r

-a

Table IV . D e te c tio n o f C a n ce r in M o c k P o s itiv e Bone M a rro w S p e c im e n s
D ilu tio n , c e ils/m L

C a n c e r*

C o m m e n ts

+
+

C e lls c lu m p e d to g e th e r
C e lls c lu m p e d to g e th e r

—

—

—

S q u a m o u s c e lls d e tected
(see te x t)
—

105
104
103
102

-

10
'P o s s ib le cancer c e lls ; + = p o s itiv e , -
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FIG. 3. Clump of malignant cells in
benign marrow at dilution of 104
cells/mL (ABC technique with M8 as
primary antibody and hematoxylin
counterstain, original magnification X
250).

BREAST CANCER MICROMETASTASES

provide any new useful information
about prognosis, compared with
current methods of staging?
• Is the information likely to be
of any benefit to the patient?
• Will patients with early meta
static disease be more likely to be
nefit from adjuvant chemotherapy?

Conclusions
Much remains to be learned
about the biology of breast cancer.
Monoclonal antibodies are just one
of the tools being used in this
learning process. At present there is
no clearly defined role for the use of
this powerful tool in the routine
diagnosis and treatment of breast
cancer.
Having shown that it is possible
to detect breast cancer cells in an
experimental situation, it is now
necessary to test this hypothesis in
the clinical setting. The monoclonal
antibody M8 is only one of many
such products being evaluated in
the hope of improving our knowl
edge of the behaviour of carcinoma
and our ability to treat patients.
The authors thank the following for
their assistance with this study: Don
Howard, Dr. B. Gusterson, Dr. A.M.
Neville and Bev Thomas.
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Monoclonal Antibody LICR-LON-M8
Does Not Predict the Outcome
of Operable Breast Cancer
D.J. Courtemanche, MD;* A.J. Worth, MD, FRCPC;f R.W. Coupland, MD, FRCPC;$, J.L. Rowell;§
J.K. MacFarlane, MD, MSc, FRCSC1
The prognostic value of the monoclonal antibody LICR-LON-M8, which has been
shown to detect micrometastatic disease, was evaluated in a prospective,
double-blind, clinical study of bone-marrow specimens from patients with operable
breast cancer.
Four bone-marrow specimens, obtained from each of 50 patients at the time of
excision of the primary breast tumour, were examined immunohistochemically, with
LICR-LON-M8 as the primary antibody.
All of the primary tumour specimens demonstrated positive staining for
malignant disease with LICR-LON-M8. The bone-marrow specimens of four patients
demonstrated positive staining: three specimens were “suspicious” for malignant
cells and one contained definite malignant cells on cytologic examination. This gave
a 2% rate of detectable micrometastatic disease at the time the primary tumour was
excised. Patient follow-up averaged 21.5 ± 9.1 months. The test results did not
correlate with outcome. A negative test result with LICR-LON-M8 did not imply a
better prognosis.
The authors conclude that examination of bone-marrow specimens stained with
LICR-LON-M8 in patients with operable breast cancer is of no clinical value.
Furthermore, the low rate of micrometastases detected is at variance with that
reported by others. In view of the natural history of breast cancer, the authors
believe that their results were not unexpected and they question the importance of
other results.

I

n the study of breast cancer,
monoclonal antibodies are a re
search tool looking for a practical
clinical application. Many laborato
ries have produced monoclonal anti
bodies that will react with human
breast cancer cells.12 Among these
are the LICR-LON-M series of mu
rine monoclonal immunoglobulin G
antibodies produced originally at
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La capacite pronostique de l’anticorps monoclonal LICR-LON-M8, lequel s’est
montre capable de deceler les micrometastases, a ete evaluee dans une etude clinique
prospective, a double insu, d’echantillons de moelle osseuse provenant de patientes
porteuses de tumeurs du sein operables.
Quatre echantillons de moelle osseuse preleves chez chacune de 50 patientes au
moment de l’excision de la tumeur primitive du sein ont fait l’objet d’un examen
immunohistochimique a l’aide du LICR-LON-M8.
Toutes les tumeurs primitives se sont revelees positives a la coloration au
LICR-LON-M8. Les echantillons de moelle osseuse de quatre patientes ont presente
une coloration positive: trois echantillons etaient “douteux” pour la presence de
cellules malignes et l’autre montrait definitivement des cellules malignes a l’examen
cytologique. Ceci donne un taux de micrometastases decelables de 2% lors de
l’excision de la tumeur primitive. La surveillance des patientes est en moyenne de
21.5 ± 9.1 mois. Les resultats des epreuves n’offrent pas de correlation avec Tissue
de la maladie. Un resultat negatif n’a pas signifie un meilleur pronostic.
Les auteurs concluent que Texamen des echantillons de moelle osseuse a l’aide du
LICR-LON-M8 chez les patientes souffrant d’un cancer du sein operable n’a pas
d’interet clinique. De plus, le faible taux de micrometastases decelees differe de ce
qui est rapporte par d’autres. Vu Thistoire naturelle du cancer du sein, les auteurs
croient que leurs resultats etaient previsibles et ils mettent en doute Timportance
d’autres resultats.
—- For prescribing information see page 72

“Chief resident in plastic surgery, Depart
ment o f Surgery, University o f B ritish Co
lumbia, Vancouver
fC linical professor. Department o f Patholo
gy, University o f British Columbia, Vancou
ver
fC lin ica l assistant professor, Department o f
Pathology, University o f British Columbia,
Vancouver
§Medical student (second year), University o f
British Columbia, Vancouver
HProfessor and head, Division o f General
Surgery and Department o f Surgery, St.
P a u l’s Hospital, Vancouver
Accepted fo r publication Nov. 1, 1989
Reprint requests to: Dr. D.J. Courtemanche,
c / o Dr. J.K. MacFarlane, Department o f
Surgery, St. P a u l’s Hospital, 1081 Burrard
St., Vancouver, BC V6Z 1Y6

CJS, VOL. 34, NO. 1, F E B R U A R Y 1991

21

COURTEMANCHE ET AL

the Ludwig Institute for Cancer
Research.34 This series of mono
clonal antibodies has been made to
resemble membrane extracts of
human breast milk.
A sample of one of these, LICRLON-M8, was made available to the
University of British Columbia for
investigation. The hybridoma tech
nique of monoclonal antibody pro
duction has been well described.5
The material is supplied in the form
of unpurified mouse ascites.
A preliminary series of experi
ments was reported in which the
optimal methods of tissue fixation
and staining were determined and
the reported properties of this anti
body verified.34-6 The antibody reproducibly stained all ductal carci
noma specimens tested.
It was also determined that micrometastatic disease in the bone
marrow could, theoretically, be de
tected, and the staining character
istics of carcinoma cells in marrow
were noted. Other investigators
have determined that as few as one
malignant cell in 10 marrow cells
may be detected in this way.7
We report a prospective study of
the value of this monoclonal anti
body as an independent staging
technique in patients with operable
breast cancer. The questions we

were trying to answer were: Can we
identify a subgroup of patients with
operable breast cancer who have
occult micrometastatic disease at
the time the primary tumour is
excised? and Does a positive test
result give any independent prog
nostic information, and, if so, will
this information benefit the patient?
To date several studies have dem
onstrated the ability to detect mi
crometastatic disease in patients
with breast cancer; however, the
value of this information remains
unknown.8 Positive test results cor
relate highly with already known
risk factors for metastatic disease.9

Methods
Patients with primary, operable,
breast cancer (stages I, II and IIIA)
who were not involved in any other
ongoing breast cancer study at the
University of British Columbia were
entered into the study. All appeared
free of malignant disease on bone
scanning and chest radiography and
had normal results of liver function
tests. No patient had a history of
remote or current malignant disease
of any other type.
Participation was voluntary. Con
sent forms were signed after an

explanation of the study. The study
protocol was approved by the Uni
versity of British Columbia, Clinical
Screening Committee for Research
and Other Studies Involving Human
Subjects and the medical ethics
committees of the individual hospi
tals involved. Study data, which
were collected on a standardized
form, included the following: demo
graphics, tumour history, clinical
staging, pathological staging and
relevant histologic detail, tumour
hormone receptor status, immunohistochemical results for the
primary tumour and the marrow
specimens and clinical follow-up
data.
The biopsies were done under
general anesthesia just before exci
sion of the primary tumour. Four
bone-marrow biopsy specimens
were obtained from each patient:
two at right angles to each other
from each posterior superior iliac
spine. The biopsy specimens were
fixed in Bouin’s solution for 40
minutes and then in 70% alcohol.10
They were dehydrated in alcohol,
embedded in paraffin, sectioned and
stained with hematoxylin and eosin
and using the avidin-biotin peroxi
dase complex method (Vector Labo
ratories, Burlingame, Calif.) with
the monoclonal antibody M8 as the

FIG. 1. Positive staining with LICR-LON-M8 antibody: (left) invasive ductal carcinoma; (right) intraductal carcinoma (avidinbiotin peroxidase complex technique with M8 as the primary antibody and hematoxylin counterstain, original magnification X

250 ).
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primary antibody.11 Positive and
negative control studies were per
formed for each specimen.
Sections known to contain tu
mour cells from the formalin-fixed,
paraffin-blocked, primary tumour
specimen, were similarly stained
with hematoxylin and eosin and
were immunohistochemically stud
ied as controls (Fig. 1).
Patients were followed up at
3-month intervals by the treating
surgeon, family doctor or breasttumour clinic of the Cancer Control
Agency of British Columbia.

ing physicians, since the implica
tions of the test result were not
known at the start of the study, and
it was important not to bias the
ongoing care of these patients in
any way.
Statistics

Data fitted to two X two tables
for comparison of results between
groups were analysed with Yates’
modification of the x 2 test. A p
value less than 0.05 was considered
statistically significant.

Ethics

Results
The immunohistochemical test
result was not released to the treat

Between March 1986 and Sep

Table 1. Comparison of Recurrence Rate and Follow-up*
Recurrence
4-

Follow-up yr

<2
> 2
A

Total

Yes

No

Total

2
7

21
20

23
27

9

41

50

*x 2 = 1-47.

Table II. Stage and Type of Carcinoma in 50 Patients Studied
Group/stage

Type

ER+, no.

V I+, no.

1/1 ( / 7 = 10)

Ductal
Lobular
Ductal
Lobular
Ductal
Ductal
Ductal
Ductal

9
1
10
2
5
12
9
1

8
1
9
1
4
12
5
-

1/11 (n= 12)
1/IIIA (n = 5*)
2/I (rr= 12)
2/II (n= 10)
2/IIIA (rr = 1)

V I - , no.

1

_
2

_
2

_
_

1
‘ One of these patients had bilateral tumours.
ER+ = estrogen-receptor positive, VI+ = vascular invasion, VI - = no vascular invasion.
Table III. Treatment Received by the Patients in the Study
Stage

Number of
patients

I

11

II
IIIA

11
8
14
1
4
1

Treatment

Segmental mastectomy and axillary dissection with radiation to the
remaining breast
Modified radical mastectomy
Segmental mastectomy and radiation to the remaining breast
Modified radical mastectomy
Segmental mastectomy and radiation to the remaining breast
Modified radical mastectomy
Bilateral lumpectomy and radiation

tember 1989, 53 patients were en
tered into the study. Complete data
and up-to-date follow-up were avail
able for 50 of these patients. One
patient was lost to follow-up, one
patient was excluded after diagnosis
of a concurrent colonic carcinoma
and one man was excluded.
Ages ranged from 28 to 93 years
(mean 57.6 ± 12.8 years). Thirty
patients were postmenopausal and
20 premenopausal.
The average follow-up was 21.5
± 9.1 months. The 50 patients
were divided into two groups:
group 1 comprised 27 patients with
follow-up of more than 2 years and
group 2 contained 23 patients with
follow-up of less than 2 years. This
was done because the difference in
recurrence rate between the two
groups approached statistical signif
icance (Table I).
In group 1, 10 patients had stage
I disease, 12 had stage II and 5 had
stage IIIA. In group 2, 12 patients
had stage I disease, 10 had stage II
and 1 had stage IIIA. There were
46 ductal and 4 lobular carcinomas.
Forty-one tumours were estrogenreceptor positive (EP+); 6 showed
vascular invasion (VI+) (Table II).
Thirty-two modified radical mas
tectomies were performed; 17 pa
tients underwent segmental mastec
tomy with axillary dissection. In
only two patients with stage I dis
ease were the results of cytologic
examination of the lymph nodes
positive (Table III). All of the prima
ry tumours stained with the mono
clonal antibody, and four bone-mar
row biopsy specimens did also.
Follow-up

Of the 22 patients having stage I
disease, 10 were followed up for
more than 1 year; 9 are alive and
well, and 1 was free of disease when
she died (Table IV). Of the 12
patients with stage I disease, fol
lowed up for less than 1 year, 11
CJS, VOL. 34. NO. 1. FEBRUARY 1991
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are alive and well and 1, a
56-year-old postmenopausal wom
an, is alive with disease. She had
local recurrence 11 months after
segmental mastectomy and axillary
dissection (0 /8 lymph nodes tested
positive for malignant cells on cyto
logic examination; tumour classifi
cation: T1NOMO, ER+, VI —).
Three patients in group 1 with
stage 1 tumours had bone-marrow
specimens immunohistologically
positive to M8; all are alive and
well.
There were 22 stage II patients:
12 were followed up for more than
2 years and 8 were alive and well at
the last follow-up, 1 who died was
disease-free and 3 were alive with
recurrent disease. These three were
a 62-year-old postmenopausal
woman who had recurrence 31
months after modified radical mas
tectomy (14/20 lymph nodes exam
ined cytologically were positive for
malignant cells; tumour classifica
tion: T2N1M0, ER+, VI+), a
94-year-old woman who had a re
currence 36 months after biopsy
and radiotherapy (tumour classifica
tion: T2N0M0, ER+, VI —) and a
54-year-old woman who had lumbar
metastases 22 months after modi
fied radical mastectomy (3/12
lymph nodes were cytologically pos
itive for malignant cells) and che
motherapy (tumour classification:
T2N0M0, ER+, V I-).
The 10 patients who had stage II
disease and were followed up for
less than 2 years were all alive and
well at the last follow-up. The bonemarrow specimens did not stain
with M8 in any of the patients with
stage II disease.
Of the six patients with stage
IIIA disease, five were followed up
for more than 2 years: one was alive
and well, and one, a 64-year-old
woman, was alive with disease. She
had a recurrence 41 months after
preoperative chemotherapy followed
by modified radical mastectomy
24
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(0/12 lymph nodes cytologically
positive for malignant disease) and
postoperative chemotherapy (tu
mour classification: T3BN0M0,
ER+, VI+).
Three stage IIIA patients died of
their disease. One was a 58-year-old
postmenopausal woman who had
recurrence 18 months after modi
fied radical mastectomy (0/18
lymph nodes cytologically positive
for malignant cells; tumour classifi
cation: T3N0M0, ER+, V I-). The
second was a 40-year-old pre
menopausal woman whose disease
recurred 22 months after modified
radical mastectomy (3/10 lymph
nodes positive for malignant cells;
tumour classification: T3N0M0,
E R - , VI+). The third was a
40-year-old premenopausal woman
whose disease recurred 17 months
after modified radical mastectomy
(8 /9 lymph nodes cytologically
positive for malignant cells; tumour
classification: T3N2AM0, ER+,
VI —).
The lone patient with stage IIIA
disease and less than 2 years’ fol
low-up, a 49-year-old premenopaus
al patient, is alive with disease. She
had recurrent disease 12 months
after bilateral lumpectomy, treated

with radiotherapy and hormone
therapy for bilateral tumours (tu
mour classification: T3BN0M0,
E R - , VI+). Her bone-marrow spec
imens stained positively for malig
nant disease with M8.
Overall, the bone-marrow speci
mens of four patients stained posi
tively with M8 (Table V). Three of
these patients had stage I disease
and were alive and well more than 2
years after treatment. The fourth
had stage IIIA disease with bilateral
aggressive disease (Fig. 2); she was
alive with disease 12 months after
initial treatment. The three patients
with stage I disease had positive
cells that were not cytologically
typical of metastatic disease (Fig.

2).
The bone-marrow specimens of
46 patients stained negatively for
malignant disease with M8. Three
of these patients died of their malig
nant disease and five had recur
rence. There was no statistically
significant difference between
groups 1 and 2 (Table VI).

Discussion
The aim of this study, which was

T a b le IV . Follow-up and Outcome by Stage and Group
G roup

1

S ta g e

I

10

II

12

IIIA

2

N u m b er of
patients

5

I

12

II
IIIA

10
1

O utcom e

N um ber

Alive and well
Died w ithout disease
Alive and well
Died without disease
Alive with disease
Alive and well
Alive w ith disease
Died of disease
Alive and well
Alive w ith disease
Alive and well
Alive w ith disease

9
1
8
1
3
1
1
3
11
1
10
1

T a b le V. Patients Whose Bone-Marrow Biopsy Specimens Stained Positive Using LICR-L0N-M8

Antibody
G roup

S ta g e

N u m b er of
p atients

1

1
IIIA

3
1

2

O utcom e

All alive and well
Alive w ith disease

C ytologic finding s

Possible malignant cells
Malignant cells
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designed in 1985, was to evaluate
an investigational tool as a practical
clinical test. Although more com
plex and expensive methods of
bone-marrow assessment, showing
a theoretically higher yield of tu
mour cells, have been described, the
techniques used in this study were
selected because they could readily
be applied to all patients.1213 This
invasive test was designed to be
acceptable to patients, surgeons
and the members of the ethics com
mittees.
At this level of sophistication the
test has not proved to be of prog
nostic clinical value. More research
needs to be done. At present we
consider other methods too invasive
or expensive to be used as routine
clinical tests.
Large volumes of aspirated bonemarrow cells can be separated on a
Ficoll-Hypaque gradient, and then
the “buffy coat” can be selectively
examined for tumour cells.12 Porro
and associates13 reported that 17%
of patients with breast carcinomas
who had no cytologically positive

lymph nodes, had cytologically pos
itive bone marrow when this separa
tion technique and immunofluorescent examination with the mono
clonal antibody MBrl were used.
This remains a research rather than
a clinical tool.
The low (2% to 8%) level of
detection in our study is not sur
prising considering the nature of
the disease and the patient popula
tion being studied.14 Given the sur
vival curves for breast carcinoma
(5-year survival for stages I, II and
IIIA: 85%, 70% and 50% respective
ly), only 13 of the 50 patients
studied would be expected to re
lapse within 5 years. How many of
these should we expect to have
cytologically positive bone-marrow

specimens at the time of surgical
management of primary tumours?
Indeed, Mansi and colleagues15
found that only 2 of 82 relapse-free
patients had cytologically positive
marrow specimens 18 months after
mastectomy. Other investigators,
reporting higher detection rates,
have not selected their patients pro
spectively and have more patients
with advanced or prognostically un
favourable tumours.16
In this prospectively studied
group of patients the rate of detec
tion is so low that a prohibitive
number of patients would need to
be accrued to show a statistically
significant difference at a twofold
difference in outcome. In addition,
although the presence of tumour

Table VI. Comparison of Recurrence of Disease and Immunohistochemistry*
Recurrence of disease
Immunohistochemistry

Yes

No

Total

Positive
Negative

1
8

3
38

4
46

Total

9

41

50

* x 2 = 0.09, not statistically significant.

FIG. 2. Positive staining with LICR-LON-M8 antibody: (left) cytologically typical malignant cells in bone marrow; (right) not
obviously malignant cells in bone marrow (avidin-biotin peroxidase complex technique with M8 as the primary antibody and
hematoxylin counterstain, original magnification X 250).
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cells in bone marrow can be detect
ed, a positive result has not yet
been shown to be an independent
prognostic factor; the positive test
results have only been correlated
with tumour stage and grade. The
cells detected may be cytologically
typical for metastatic disease. They
may theoretically also be degenerat
ing nonviable clones of tumour cells
or a reaction of myeloid cells to
circulating tumour antigen excess.
Other investigators have reported
“ suspicious” nonmyeloid cells not
definitely metastatic carcinoma.16
Many cancer researchers are hop
ing that monoclonal antibodies will
allow detection of the 15% of pa
tients with stage 1 disease who
suffer recurrence and die of their
disease. Theoretically this would
allow treatment of these patients
with adjuvant chemotherapy and
possibly improve their survival.7
Although monoclonal antibodies
have enabled the detection of micrometastatic disease, more refine
ment is required to produce a useful
clinical tool. Perhaps this type of
investigation would be better ap
plied to a subgroup of patients
selected after standard tumour stag
ing and grading.

Conclusions
In patients with operable breast
cancer monoclonal antibodies can
be used to detect occult micrometastatic disease. The rate of detectable

micrometastatic disease is low (2%).
There may be other reasons for
positive staining of bone-marrow
specimens. At present monoclonal
antibody examination of specimens
from four bone-marrow biopsy sites
with LICR-LON-M8 antibody is not
a practical prognostic test in pa
tients with operable breast cancer.
We thank the following: Drs. R.M.
Baird, M.G. Clay, J.T. Sandy, P.M.
Rebbeck, C.J. Carter, D. Chercover,
R.D. Gascoyne, and N. Chan and Bev
Thomas for their participation in the
study. The monoclonal antibody LICRLON-M8 was supplied by Dr. R. Buick
and K. Graham of the Ontario Cancer
Institute and Department of Medical
Biophysics, University of Toronto.
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Nonoperative Management of Blunt
Splenic Trauma in Adults
Wesley J. Stephen, Jr., MD;* Peter D. Roy, MD, FRCSC;t Philip M. Smith, MD;*
Wesley J. Stephen, Sr., MD, FRCSCJ
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The management of isolated blunt splenic trauma in adults is controversial. The
authors present a series of 17 patients with blunt splenic trauma who were selected
for nonoperative management. Only one patient eventually required surgery, for a
ruptured spleen. Complications included pneumonia (two cases) and pleural
effusion, atelectasis and ileus (one case each). There were no deaths. Five patients
required transfusion, for a total of 17 units of blood. The mean length of hospital
stay was 9.4 days. Comparison with a group of 17 patients treated operatively
during the same period showed that those treated nonoperatively had fewer
complications, required less blood and had a similar length of hospital stay. The
authors conclude that nonoperative management of selected patients with isolated
blunt splenic trauma is safe, if the patient’s condition is closely monitored.

Le traitement des contusions et ruptures de la rate par traumatisme ferme chez
l’adulte est un sujet de controverse. Les auteurs presentent une serie de 17 cas
initialement traites sans intervention chirurgicale. Une telle intervention ne fut
eventuellement necessaire que dans un seul cas de rupture. Parmi les complications,
il y eut deux cas de pneumonie et un cas chacun d’epanchement pleural, d’atelectasie
et d’ileus. II n’y eut aucune mortality Seulement cinq malades eurent besoin de
transfusion sanguine, pour un total de 17 unites de sang. La duree moyenne de
sejour fut de 9.4 jours. Une etude comparative de 17 malades operes pour
traumatisme de la rate pendant la meme periode de temps revele que les malades
traites sans intervention eurent moins de complications, moins de transfusions et
une duree de sejour comparable. Le traitement selectif des traumatismes fermes de la
rate par methode nonoperatoire peut etre entrepris en toute securite lors qu’il y a
surveillance clinique etroite.
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ntil recently, the standard
treatment for all injuries to the
spleen was splenectomy. Atelecta
sis, pleural effusion and early post
operative infection have long been
recognized as complications of sple

U

nectomy. In 1952, King and Schumacker1 described the syndrome of
susceptibility to late infection after
splenectomy in infants, and subse
quent studies23 outlined a small but
clear risk of overwhelming gram

positive infection in patients of all
ages after splenectomy. This led to
the landmark studies from Toron
to4-6 on nonoperative management
of splenic injury in children. How
ever, the literature is lacking, and
somewhat contradictory, with re
spect to the nonoperative manage
ment of isolated blunt splenic trau
ma in adults.
The concerns of nonoperative
management include delayed splenic
rupture, delay in recognizing other
intra-abdominal injuries and a pos
sible decrease in healing potential
within the adult splenic architec
ture. Other potential disadvantages
are increased requirement for blood
products, longer hospitalization and
the possibility of delayed operation
for ongoing hemorrhage.
The purpose of this study was to
review our experience with nonop
erative management of isolated
blunt splenic trauma in adults with
respect to success rate, hospital
stay and blood requirements. In
addition, we looked at a group of
patients who underwent early oper
ation for isolated splenic trauma
during the same period at the same
institutions.

From the Saint John Regional Hospital and Saint Joseph’s Hospital, Saint John, NB, and the
Department o f Surgery, Dalhousie University. Halifax. NS

Patients and Methods
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The charts of 66 patients who
sustained blunt splenic trauma and
were seen between January 1980
and December 1987 at Saint John
Regional Hospital and Saint Jo
seph's Hospital, Saint John, NB,
were reviewed. These two institu
tions are university hospitals that
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are staffed with attending surgeons
and general surgical residents. The
diagnosis of blunt splenic trauma
was made at laparotomy or from
liver-spleen scanning, ultrasonog
raphy, computed tomography or
from a combination of these investi
gations.
Of the 66 patients, 21 adults had
other major multiple-system inju
ries and 11 were children under 14
years of age. These 32 patients
were excluded, leaving 34 patients
for study.
Patients were treated operatively
or nonoperatively at the discretion
of the attending surgeon and
housestaff; there were 17 in each
group. There were no formal guide
lines for the choice of therapy. We
could not reliably extract from the
charts details on the presence or
absence of clinical signs, except for
evidence of hypotension on admis
sion to the emergency department.
There was no randomization of pa
tients. Interestingly, all nine sur
geons inolved in the study had
patients in both the operative and
nonoperative groups.
The patients treated nonopera
tively were managed with bed rest,
monitoring of vital signs, frequent
examination by housestaff and sur
geons and serial blood counts. Pa
tients treated operatively underwent
laparotomy promptly.

pressure less than 90 mm Hg) com
pared with only two (12%) of the
nonoperative group; four (24%) of
the nonoperative patients had de
layed presentation (at 2, 7, 15 and
21 days after trauma), but only one
(6%) of the operative group present
ed late (2 days after injury). This
suggests that the patients in the
operative group were more serious
ly injured.
The operative patients had differ
ent investigations from those in the
nonoperative group (Table III).
Thirteen (76%) of the operative pa
tients had a positive diagnostic peri
toneal lavage (DPL), whereas none
of the conservatively treated pa
tients had DPL. Three patients un
derwent immediate laparotomy on
purely clinical grounds. In another
operative patient the diagnosis was
made by liver-spleen scanning. In
the conservatively treated patients
the diagnosis was most frequently
made by liver-spleen scanning (14
T a b le 1.

Demographic Characteristics of Adults with Blunt Splenic Trauma According to Type of
Management
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N o n o p e r a tiv e
C h a r a c t e r is tic

(n -

Mean age, yr
Sex, M/F
Mechanism of injury, no. of patients
Motor vehicle accident
Sports
Fall
Assault

T a b le II.

Findings
Demographically the two groups
were similar in regard to age and
mechanism of injury (Table I). Interestingly, all six women in the
study were in the operative group.
The reason for this is not clear.
Although it was difficult to ascer
tain physical signs and symptoms
accurately, Table II compares two
objective factors at the time of
initial presentation: five (29%) of
the operative patients presented
with hypotension (systolic blood

patients), followed in frequency by
ultrasonography (5 patients) and
computed tomography (1 patient).
Several patients had multiple inves
tigations. Two patients with a nega
tive ultrasonogram and one patient
with a negative computed tomogra
phy scan subsequently underwent
liver-spleen scanning, which gave
positive results and, for the purpose
of the study, was considered diag
nostic.
There was no difference in the
length of hospital stay (Table IV),
but fewer patients treated nonoper
atively required transfusions, and
those who did so required less
blood than patients in the operative
group. Patients treated nonopera
tively had fewer complications than
those in the operative group (Table
V).
Only one patient failed nonopera
tive management and required lapa
rotomy with resultant splenectomy
on hospital day 6. In the operative

F e a tu re

Systolic blood pressure < 9 0 m m H g
Delay in presentation

T a b le III.

T ech n iq u e

Peritoneal lavage
Liver-spleen scanning
Abdominal ultrasonography
Computed tomography
Clinical diagnosis alone

O p e ra tiv e

17)

30.6
17/0

32.8
11/6

10
2
4
1

10
3
3
1

A

*
A,

Features of Presentation
N o n o p e ra tiv e , n u m b e r of
p a tie n ts (% )

O p erative, n u m b e r of
patien ts (% )

2(12)
4(24)

5(29)

<
4

1(6)

Comparison of Diagnostic Techniques
N o n o p e ra tiv e , n u m b e r of
in v e s tig a tio n s

0
14
7*
2*
0

O p erative, n u m b er of
investigations

13
1
0
0
3

'Includes two false-negative ultrasonograms and one false-negative computed tomography scan.
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BLUNT SPLENIC TRAUMA

group, 15 patients underwent sple
nectomy; 2 had already achieved
hemostasis and no further action
was required. No patient underwent
splenic repair or required reopera
tion. There were no deaths in either
group.

Discussion
The epidemiologic characteristics
of both groups of patients are con
sistent with those of previous re
ports with respect to age, sex and
mechanism of injury. Although
both of our groups appear to be
representative of isolated blunt sple
nic injury, patients in our operative
group were clearly more seriously
injured. A clear selection bias is
present, and any direct comparison
between the two groups must be
considered with this in mind. Never
theless it is equally clear that trans
fusion requirements, complications
and length of hospital stay in our
nonoperative group were entirely
within acceptable limits. Nallathambi and colleagues7 warned clinicians
about increased transfusion require
ments and longer hospital stays for
patients treated nonoperatively, but
the findings of our study do not
support this.

Only one patient in our nonoper
ative group required operation with
splenectomy after a trial of nonop
erative management, for a failure
rate of 6%. This is in keeping with
favourable reports,8' 14 citing failure
rates of zero to 41%, in which
failure is defined as the necessity
for an operation, with or without
resultant splenectomy. In sharp
contrast, other reports715-18 quote
failure rates of 67% to 78%. The
reason for this discrepancy is not
clear. Possibly the unfavourable re
ports contained “unselected” pa
tients, including those in shock, or
the indications for eventual surgical
intervention were more liberal.
It is interesting that no patient
from the nonoperative group under
went DPL, but 13 patients (76%) in
the operative group did, and all
DPLs were positive. A positive tap
was an indication for laparotomy in
this study, which is is keeping with
the Advanced Trauma Life Support
guidelines19 and current surgical
practice.
In summary, it is safe to observe
adult patients with isolated blunt
splenic trauma as long as the pa
tient’s condition is stable at the
time of presentation and close mon
itoring of clinical status is possible.

Table IV. Length of Hospitalization and Transfusion Needs*
Variable
Length of hospital stay, d
Patients transfused, no.
Mean blood transfusion, units (range)

Nonoperative

Operative

9.4

9.6
12
3.0 (0-9)

5
1.0 (0 -5 )
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W ound Infections in Orthopedic Surgery:
Effect of Extended Surveillance
on Infection Rate
P. Pearce, RN; M. McKenzie, RN, BScN; G. Taylor, MD, FRCPC
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Substantial evidence now exists that ongoing surveillance of surgical wound
infections can contribute to reduced infection rates. What is not yet determined is
whether surveillance should be limited to the postoperative hospital stay or should
be continued after patient discharge. To determine the number of infections
occurring after discharge, the authors contacted a random sample of their patients
who did not have wound infections during their hospitalization after orthopedic
surgery. This was done 30 days after the procedure. The authors selected 273
patients of 1375 who underwent orthopedic surgery over a 7-month period and were
able to contact 199 (73%). At the 30-day follow-up 23 patients (11.6%) had wound
infections, as judged by wound discharge and physician prescription of antibiotics in
20 and the patient’s description of pus issuing from the wound in 3. During the
same period postoperative wound infections were found in only 19 (1.5%) of 1278
patients who were subjected to in-hospital surveillance.
The authors conclude that, in patients who undergo orthopedic procedures, the
majority of wound infections occur after discharge from the hospital and that
infection rates based only on in-hospital surveillance greatly underrepresent true
surgical wound infection rates for orthopedic procedures.

11 existe maintenant des preuves concluantes que la surveillance suivie des
infections de plaies peut contribuer a faire diminuer le taux d’infections. II n ’a pas
encore ete determine si cette surveillance devait se limiter au seul sejour hospitalier
ou si elle devait etre poursuivie apres le conge de l’hopital. Dans le but d’etablir le
nombre d’infections qui surviennent apres la sortie de l’hopital, les auteurs ont
communique, avec un echantillonnage aleatoire de leurs patients qui n’avaient pas
souffert d’infection au cours de leur hospitalisation pour chirurgie orthopedique.
Ceci eut lieu 30 jours apres l’operation. Les auteurs ont choisi 273 patients parmi
les 1375 qui avaient subi une chirurgie orthopedique au cours d’une periode de 7
mois; ils ont reussi a en rejoindre 199 (73%). A en juger par la suppuration de plaie
et la prescription d’antibiotiques chez 20 patients, et la description par le malade de
pus s’ecoulant de la plaie chez 3 autres, il y avait infection de plaie chez 23 patients
(11.6%) au controle du 30e jour. Durant la meme periode, des infections postoperatoires de plaies ont ete observees chez seulement 19 (1.5%) des 1278 patients qui
furent soumis a une surveillance dans un hopital.
Les auteurs concluent que, chez les patients qui subissent une chirurgie
orthopedique, la majorite des infections de plaies survient apres le conge de
I’hopital, et qu’un taux d’infection base uniquement sur une surveillance hospitaliere sous-evalue considerablement les taux reels d’infections de plaies consecutives
aux interventions orthopediques.
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vidence is accumulating that
routine surveillance for surgical
wound infections with feedback of
data to practising surgeons can re
duce overall wound infection rates.
As a result there is increasing inter
est in this infection-control tech
nique.1-3 The Centers for Disease
Control in Atlanta4 and the Labora
tory Centre for Disease Control in
Ottawa5 both recommend use of
this technique, as did the Surgical
Infection Society, which also en
dorsed it as a technique effective in
reducing morbidity and costs relat
ed to surgical wound infection.6
For hospitals or surgical special
ties embarking on this form of
surveillance, consideration must be
given to the need for long-term
follow-up. A number of studies have
compared post-discharge infection
rates with those from inpatient sur
veillance alone.578 However, the
value of post-discharge surveillance
may vary from one surgical subspe
cialty to another and from one
institution to another. We have car
ried out surgical surveillance on
wound infections after orthopedic
surgery for over 2 years. We be
came concerned that our inpatient
surveillance data might be unrealis
tically low, because of the early
discharge or transfer of patients.
Therefore we undertook a tele
phone survey of patients 1 month
postoperatively to assess the value
of this surveillance technique in our
population.

E
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The University of Alberta Hospi
tals (UAH) is a 1355-bed hospital,
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acting as a tertiary referral centre
for northern Alberta and western
Northwest Territories. There are 11
practising surgeons in the Division
of Orthopedic Surgery. Inpatient
surgeon-specific wound surveillance
began in March 1987.
On a daily basis, an infection-con
trol practitioner (ICP) collects op
erating-room data sheets on all pa
tients who undergo orthopedic sur
gery. Beginning 48 hours postoperatively, the ICP observes directly all
surgical incisions not covered by
plaster casts and returns every 48
to 72 hours for 2 weeks or until the
patient is discharged. The ICP
takes wound swabs when wound
abnormalities are evident.
Wounds were classified on the
clean-dirty spectrum by standard
criteria.9 Patients who died or were
discharged less than 48 hours postoperatively were not considered in
the analysis. Patients whose inci
sions were covered by plaster casts
for the entire duration of hospital
ization but in whom there was no
suggestion of infection (e.g., fever,
pain, swelling) were considered as
noninfected and so entered into the
denominator. A wound infection
was diagnosed if: (a) the ICP ob
served pus issuing from the incision
(excluding drain sites and stitch
abscesses); (b) the ICP observed
serosanguineous drainage and
wound redness, and a culture was
positive for a known pathogen (ex
cluding common skin commensals);
(c) deep-seated surgically related
wound infection (e.g., osteomyelitis)
was diagnosed by the surgeon, and
the incision was not infected; or (d)
the surgeon diagnosed wound infec
tion associated with wound abnor
malities that did not fit into any of
the above categories.
The data were entered into a
computer, and, with the use of the
AICE software system designed for
hospital infection control surveil
lance and data management,10
32
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monthly infection rates by surgical
class were generated for each sur
geon and the division as a whole.
Surgeons were sent data on their
own infection rates, with details on
infections detected, as well as a
report on the entire division’s infec
tion rates. Summaries of 6- and
12-month rates were also distribut
ed.
Beginning in March 1988, for a
7-month period, patients who un
derwent regular inpatient wound
surveillance but did not have a
wound infection during that time
were randomly selected by means of
a random number generator in the
AICE program, and contacted 30
days after their surgical procedure.
An ICP telephoned the patients and
asked a standardized set of ques
tions. If the patient was still in the
UAH the chart was reviewed. If the
patient was in another hospital, the
nursing station at that hospital was
contacted. Patients who were not
available on the first attempt were
called on two further occasions, and
if contact was still not made the
patient was removed from the
study. At this time a wound infec
tion was diagnosed: (a) if a physi
cian had examined the incision and
had made a diagnosis of wound
infection (as stated to the patient or
implied by the prescription of treat
ment in association with wound
abnormalities) or (b) if, having not
seen a physician since discharge
from hospital, the patient described
pus issuing from the wound (ex
cluding stitch abscesses).

This information was added to
the basic information already en
tered into the computer.

*-*
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Findings
During the 7-month survey peri
od 1375 patients underwent ortho
pedic inpatient procedures: 1278
(93%) were suitable for inpatient
wound infection surveillance; 336
(26%) had plaster casts covering
their incisions up until discharge,
so the incisions were not directly
inspected but were assumed to be
noninfected. Two hundred and sev
enty-three were selected for the
30-day follow-up. Of these, 199
(73%) were contacted. The 74 not
contacted were similar by age and
sex to the group contacted. Within
the group of 199 patients contact
ed, 55 (28%) had not had the
incision inspected because they had
a plaster cast but had since had the
cast removed or changed, so pres
ence or absence of incisional abnor
malities could be determined. When
contacted 30 days postoperatively,
only 20 were still in the UAH; 141
had been discharged home, 13 to a
local community hospital and 25 to
a rehabilitation hospital. Table I
shows surgical wound infection
rates for the inpatient survey period
and the extended survey group. Of
the 23 wound infections diagnosed
in extended follow-up, 4 (17%) oc
curred in patients whose incision
was not observed during their inpa
tient stay because of a plaster cast.
Three infections (13%) were diag-
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T ab le 1. Wound Infections Found During Hospitalization and After Discharge in Patients Who

Underwent Orthopedic Surgery
T y p e of
procedure

In -h o s p ita l, no.
in fe c tio n s /n o .
p atien ts (% in le c tio n )

Clean
Cleancontaminated
Contaminated
Dirty

11/1067 (1,03)

Totals

19/1278 (1.49)

0 /4 9 (0)
0 /1 8 (0)
8 /1 4 4 (5.56)

3 0 d a fte r d isch a rg e .
no. in te ctio n s/n o .
p atien ts (% infection)

12/168 (7.1)

A

1/4
0 /2
10/25

k

(25)
(0)
(40)

23/199 (11.6)

WOUND INFECTIONS

nosed by the patient’s description of
pus and 20 (87%) by a physician’s
diagnosis (11 by the surgeon and 9
by the patient’s general practition
er); 14 patients received antibiotic
therapy.

Discussion
It is unlikely that any surveil
lance system could routinely detect
all wound infections, nor is it neces
sary that all be detected, since the
proposed mechanism by which
wound infections are reduced by
this technique is by permitting sur
geon-surgeon comparisons, not
comparison against an ideal. How
ever, a surveillance system that de
tects very few of the actual infec
tions runs the risk of being coun
terproductive by engendering a
false sense of security among the
recipients of the data. Other studies
using active case-detection tech
niques similar to ours have shown
that substantial numbers of infec
tions can be detected by postdis
charge surveillance;6-8 none have
shown such a large proportion as in
our study. If the 199 randomly
selected patients contacted 4 weeks
after surgery were representative of
the 1259 patients who did not have
a wound infection at the end of the
inpatient surveillance period, 145
wound infections would have been
detected in this group. It is clear,
therefore, not only that extended
surveillance is much more effective
at detecting wound infections but
also that, by relying on inpatient
surveillance, we have been greatly
underestimating the true infection
rate. If we add the 19 inpatient
infections detected to the 145 infec
tions that would be detected by
30-day telephone surveillance there
would potentially be 164 wound
infections in this population, only
12% of which were detected by our
current surveillance technique.

The diagnosis of wound infection
made by telephone survey may be
questioned. Certainly, routinely
bringing the patient back to the
hospital for direct examination or
even going to the patient’s home to
examine the incision11 would be
preferable. This is impractical for a
long-term program, particularly
when many patients do not reside in
the city where the surgery was
performed. We, like others, relied
on a physician’s diagnosis of wound
infection6-8 or, if the patient had
not seen a doctor, on the patient’s
description of “pus” (discharge of
opaque fluid from the incision). Ex
tending the duration of follow-up
during inpatient wound surveillance
would not appear to be effective,
since at the 30-day contact point
very few patients were still in hospi
tal. Consequently, some form of late
follow-up appears necessary if a
reasonable estimate of the true in
fection rate is to be made. Relying
on patient- or doctor-initiated re
porting of infection is most unlikely
to detect consistent numbers of
infections.1213 Some form of active
surveillance is, therefore, necessary.
The clean wound infection rate of
7.1% found in this survey is much
higher than that generally reported
for inpatient surveillance pro
grams13 but is not dissimilar to
rates found in other long-term fol
low-up studies.6-8 The number of
wound infections diagnosed is di
rectly related to the method of
detection, breadth of the definition
and the duration of follow-up. Con
sequently, comparison of rates be
tween studies should only be under
taken when these factors are avail
able. The effects of extended sur
veillance on surgical infection rates
are well documented in the medical
literature.6-814 In our patients, a far
higher percentage of wound infec
tion occurred after discharge (89%)
than previous studies have docu

mented. Those studies did not focus
particularly on orthopedic patients,
who may differ from other surgical
patients in this regard. For exam
ple, the presence of a plaster cast
prevents a proportion of inpatient
wounds from being examined. This
makes inpatient orthopedic wound
surveillance difficult; 26% of the
inpatients in our study could not
have their incisions directly inspect
ed during their hospital stay be
cause of a cast. To delete such
patients from the denominator
would create a major gap in the
completeness of our surveillance
program, and, consequently, we
chose to consider the wounds in
these patients as not infected unless
other signs of infection were pres
ent. Nevertheless, minor incisional
abnormalities diagnostic of infec
tion could be present and only
become apparent after discharge
when the cast is removed. This
factor was a major contributor to
the number of infections diagnosed
after discharge.
Orthopedic patients may be dis
charged home or transferred to re
habilitation units outside the hospi
tal more rapidly or frequently than
patients who have undergone other
types of surgery. Furthermore, be
cause our hospital is a tertiary care
hospital, many surgical patients are
transferred to their local hospital
for convalescence.
We have discussed our findings
with our orthopedic colleagues. Al
though they support the wound
surveillance program they wish to
have data that reflect more closely
the true infection rates, particularly
for patients in whom the conse
quences of infection are most seri
ous. We plan, therefore, to make
extended surveillance a permanent
part of our program for patients
who undergo joint replacement and
possibly to include other groups at
a later date.
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8
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8
1
4
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1
22
7
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7
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4
2
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4

2
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1

2
2
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3
2
2
1
1
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1
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1
1
1
2
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Detecting Breast Cancer
After Reduction Mammoplasty

V

P A. Clugston, MD; Q.R. Son-Hing, MB, ChB, FRCSC; J.K. MacFarlane, MD, FRCSC

►
Reductive breast surgery may give rise to parenchymal scarring that makes
subsequent clinical and radiologic assessment of tumours difficult. The features that
help distinguish benign from malignant lesions are discussed. Biopsy is still
necessary. A screening protocol that includes preoperative mammography in
patients at increased risk is proposed.

La chirurgie conservatrice du sein peut provoquer une cicatrisation
parenchymateuse qui rend difficile 1’evaluation clinique et radiologique future des
tumeurs. Les caracteristiques qui aident a distinguer les lesions malignes des
lesions benignes sont exposes mais la biopsie demeure toujours necessaire. Un
protocole d’examen qui comprend la mammographie preoperatoire chez les patientes
a risque eleve est propose.
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of the female
H ypertrophy
breast is common and is often

Case Reports

severe enough to cause negative
effects both physically and psycho
logically. These effects can be alle
viated by surgical reduction. How
ever, the parenchymal scarring that
may arise after surgery can interfere
with clinical and radiologic exami
nation of the breast for cancer. The
incidence of breast cancer is such
that it will develop in 1 in 11
women during their lifetime.12 It is
therefore important that we be able
to identify lesions that may be ma
lignant. We present two cases of
breast cancer after reduction mam
moplasty.

Case 1

A 53-year-old woman presented
with an 8-month history of sagging
and inversion of the right nipple.
Fourteen years earlier she had had
a bilateral mastopexy. No recent
mammogram was available. There
were no strong risk factors for
breast carcinoma. She had under
gone a hysterectomy and unilateral
oophorectomy for menorrhagia at
44 years of age.
Physical examination revealed a
mobile thickening, 2 to 3 cm in
diameter, in the upper, inner quad
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rant of the right breast. The nipple
was inverted and directed inferiorly
(Fig. 1). There were no clinical
findings to suggest metastatic dis
ease. Mammography was arranged
and she was referred to a general
surgeon.
The mammogram revealed a spiculated mass lesion suggestive of
carcinoma (Fig. 2). Fine-needle aspi
ration was carried out, and the
aspirate was positive for malignant
cells.
The patient underwent a modified
right radical mastectomy. Patholog
ical examination revealed a poorly
differentiated, infiltrating, lobular
carcinoma (Fig. 3); three of eight
lymph nodes were positive for ma
lignant cells. No signs of metastasis
were found and she was referred for
adjuvant chemotherapy.
Case 2

A 58-year-old woman had a re
mote (1973) history of stage II
infiltrating ductal carcinoma of the
right breast that had been treated
by modified radical mastectomy fol
lowed by adjuvant radiotherapy to
the chest wall and regional nodes.
She had had postmastectomy recon
struction with a myocutaneous flap.
A reduction mammoplasty of the
left breast was performed in 1984
because of asymmetry. She had a
revision of her mammoplasty in
1985. It is of note that she had
been taking Climacteron (testoster
one and estradiol in oil) from 1979
CJS, VOL. 34, NO. 1, FEBRUARY 1991
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until 1987. She had also undergone
a hysterectomy in 1968 for uterine
fibroids.
Shortly after the revision mammoplasty she had noted firmness in
the upper portion of her left breast.
In late 1987 a firm ridge developed
in the upper outer quadrant of the
left breast, associated with nipple
inversion and puckering of the
overlying skin. When she was seen
4 months later, mammography re
vealed a poorly defined, spiculated
lesion 3.7 cm in diameter. Open
biopsy was performed, and patho
logical examination confirmed a
moderately to poorly differentiated
ductal carcinoma with dermal inva
sion.
The risk factors included a
strong family history: both a firstand a second-degree relative had
died of metastatic breast carcinoma
postmenopausally. Initial mammog
raphy done in 1973 was interpreted
as being consistent with bilateral
fibrocystic disease. She had under
gone mammography annually since
her initial mastectomy until 18
months prior to this presentation.
Further examination was sugges
tive of metastatic disease in the
liver, but the results were inconclu
sive and she was placed on a treat
ment protocol for locally advanced
carcinoma.

ple graft, and proposed that damage
to the mammary ducts gives rise to
ductal stasis and may increase the
neoplastic potential.3
It has also been hypothesized
that removal of breast tissue pro
portionately decreases the number
of foci for potential neoplasia and
should therefore decrease the sub
sequent risk of carcinoma.4 This
view is supported by Snyderman
and Lizardo,5 who studied the num-

FIG. 1. Case 1. Inverted, interiorly
directed nipple in breast with carcino
ma.

ber of malignant lesions found be
fore or during surgery or in routine
sectioning of the resected tissues
after reduction mammoplasty. They
found a frequency of 0.4%. This
represents a three- to fourfold in
crease over the rate found in the
general population and suggests
that early occult lesions are being
resected.6 A recent study by Lund,
Ewertz and Schou4 supports this
concept. They found a decreased
relative risk of 0.59 for breast can
cer after reduction mammoplasty,
though this was statistically signifi
cant only after 10 years of follow
up. The relative risk was further
decreased in women with reduction
specimens weighing more than
600 g bilaterally. They concluded
that women who undergo reduction
mammoplasty for breast hypertro
phy run no greater risk of breast
carcinoma than does the general
population and that after 10 years
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Discussion
A r'

The Relation Between Breast
Surgery and Cancer

The effect of surgical reduction
of the female breast on the subse
quent incidence of breast carcinoma
is not known. Some believe that it
may increase the risk of cancer. In
1957, at a meeting of the American
Society of Plastic and Reconstruc
tive Surgery, Maliniac reported a
case of breast cancer after reduction
mammoplasty, involving a free nip
38
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FIG. 2. Case 1. Mammogram showing 4-cm spiculated mass lesion with associated
thickening and retraction of overlying skin.

BREAST CANCER AFTER REDUCTION MAMMOPLASTY

they show a significantly decreased
risk.
Differentiating Benign
Postoperative Changes From
Carcinoma

Reduction mammoplasty could,
perhaps, lead to the earlier detec
tion of evolving tumours by allow
ing more accurate clinical and selfexamination than is possible with
large, pendulous breasts.7 However,
mammography performed after re
duction mammoplasty may reveal
changes similar to those associated
with carcinoma.2 Mammographic or
clinically palpable masses seen postoperatively may represent scarring,
deep-seated hematoma, fat necrosis,
benign mammary disease or malig
nant disease; thus, assessment of
these patients is difficult.8 If mam
mography is to be of diagnostic
value we must recognize the
changes that may be seen in the
breast, after either breast biopsy or
reduction mammoplasty.
Postoperative benign mammo
graphic changes can be divided into
two major types: soft-tissue

changes and calcifications. The
soft-tissue changes include skin
thickening and retraction, architec
tural distortions and asymmetric
densities with spiculated or irregu
lar margins and typically a central
lucency.2910 Calcifications are
coarser and less clustered in lesions
that are benign. Iatrogenic lesions
are most commonly present in the
periareolar and inferior pole tissues,
representing the areas of maximal
surgical trauma and subsequent pa
renchymal scarring.2
Mammographic changes sugges
tive of malignant disease, on the
other hand, include asymmetric
densities, mass lesions with irregu
lar or spiculated margins and cen
tral opacity, thickening and retrac
tion of the overlying skin, and
punctate, clustered microcalcifica
tions.10’11
Other factors differentiating post
operative mammographic changes
from those of malignant disease
include the tendency of benign
changes to resolve naturally and the
lesser symmetry of spiculations,
which also lack continuity with any
overlying skin changes.29 Although

FIG. 3. Case 1. Section of breast tissue shows presence of poorly differentiated
infiltrating lobular carcinoma (hematoxylin and eosin, original magnification X

1000 ).

these features are helpful, they are
often inadequate, and tissue biopsy
is required to differentiate between
malignant and postoperative benign
iatrogenic lesions. Fine-wire local
ization techniques may be necessary
for abnormalities that are not palpa
ble.
Clinical findings may also be
helpful, in that palpation of a be
nign scar typically reveals a vague
thickening of a size that corre
sponds to the mammographic ab
normality, whereas an infiltrating
carcinoma typically is firmer and
larger than the mammographic ab
normality.9
Screening Guidelines

Guidelines for surveillance in
women who seek or have had breast
reduction surgery would help physi
cians identify, appropriately investi
gate and treat any malignant lesions
that do develop. We offer a screen
ing protocol for this purpose (Fig.
4), which includes monthly selfexamination and regular examina
tion of the breast and regional
lymph nodes by a physician or
experienced nurse clinician.
Preoperative and early postopera
tive mammography (at 3 to 6
months) would help delineate
changes occurring secondary to
surgery and rule out occult preop
erative lesions. Along with clinical
and self-examination of the breast,
mammography must be considered
in women more than 35 years old
or with risk factors for breast carci
noma. Further mammography
should be requested on the basis of
results and according to the recom
mendations of the American Cancer
Society (baseline mammography at
35 to 40 years of age, periodic
examinations between the ages of
40 and 50 years and annually after
the age of 50 years).6
Successive mammography in a
given patient should be carried out
CJS, VOL. 34. NO. 1, FEBRUARY 1991
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Patients Seeking Reduction Mammoplasty
>35 yr
risk factors
clinical lesion

<35 yr

no risk factors

NO MAMMOGRAPHY

MAMMO RAPHY

mammographic and clinical assess
ment of the breast after reduction.
The use of a consistent screening
protocol in women who either plan
to have or have had reduction mam
moplasty could lead to earlier detec
tion of malignant disease, thereby
reducing the overall morbidity and
mortality.
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Simplified Protocol for Banking Bone
From Surgical Donors Requiring a 90-Day
Quarantine and an HIV-1 Antibody Test
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The banking of femoral heads from patients who undergo total hip arthroplasty
provides a valuable resource for orthopedic surgery. Quality assurance of the
banked bone used in clinical procedures requires documented policies for screening,
procuring, storing and distributing.
Potential donors are screened at the time of donation for malignant disease,
possible communicable disease, sepsis and high-risk life-styles. After negative
culture results are confirmed and appropriate documentation has been completed,
the bone is frozen at -7 0 ° C . A quarantine period of 90 days follows. The donor is
followed up 90 days or more postoperatively. At that time written consent is
obtained for donation of the recovered tissue to the bone bank and for serology
testing for human immunodeficiency virus (HIV-1) antibody, hepatitis B surface
antigen (HBsAG), hepatitis B core antibody (HBcAb) and syphilis, and the donor is
rescreened for contraindications.
This protocol meets or exceeds all existing standards. The combination of
obtaining consent and serology testing at 90 days streamlines the logistics of
banking bone from surgical donors.

La conservation des tetes de femurs provenant des patients qui subissent une
arthroplastie complete de la hanche est la source d’un materiau d’une grande valeur
en chirurgie orthopedique. L’assurance de la qualite des os conserves pour les
interventions futures exige Tusage de politiques etablies pour effectuer la selection,
le prelevement, la conservation et la distribution.
Au moment d’effectuer leur don, les donneurs potentiels sont soumis a des
epreuves de depistage du cancer, des maladies transmissibles, des infections et des
modes de vie a risque eleve. Apres confirmation des resultats negatifs par culture et
apres obtention de la documentation appropriee, Tos est congele a -7 0 ° C . Une
periode de quarantaine de 90 jours suit. Le donneur fait l’objet d’une surveillance
postoperatoire d’au moins 90 jours. A ce moment, le donneur signe une formule de
consentement pour le don du tissu preleve et pour des epreuves de depistage
serologique des anticorps au virus immunodeficitaire humain (VIH-1), de l’antigene
de surface du virus de l’hepatite B (HBsAG), des anticorps a Tantigene nucleocapsidique de l’hepatite B (anti-HBc) et pour le test VDRL; le donneur fait aussi l’objet
d’un nouveau depistage des contre-indications.
Ce protocole rencontre ou depasse toutes les normes actuelles. L’obtention apres
90 jours du consentement ecrit, associee au epreuves de depistage serologique
rationalise la logistique de la banque d’os provenant de donneurs chirurgicaux.

From Victoria General Hospital, Halifax
*Bone-bank technologist, Victoria General Hospital, Halifax. Certified tissue bank specialist with
the American Association o f Tissue Banks
tAssistant professor o f surgery, Department o f Surgery, Division o f Orthopedics. Medical
director, Bone bank, Victoria General Hospital, Halifax
A ccep ted for publication Apr. 30, 1990
Reprint requests to: Mr. A. La Prairie, Bone bank, Rm. 6 -0 3 9 , Victoria General Hospital
Halifax, N S B 3 H 2 Y 9

emoral heads and other bones
from patients treated surgically
for such conditions as osteoarthritis
and hip fractures are an available
resource for orthopedic surgery.
Common uses o f allogeneic banked
bone are as follows: (a) re-establish
ing structural bone stock;*-3 (b)
enhancing bone fusion (spinal sur
gery);4-7 and (c) enhancing osseous
integration o f prostheses in arthroplastic surgery.8"10
Autogeneic bone is the graft o f
choice.1112 It has several advan
tages: there is no immune response
or possibility o f viable peripheral
osteoblast cells and no chance o f
disease transfer. However, lack o f
sufficient available bone, increased
surgical time, blood loss associated
with harvesting o f autogenous
grafts, pain at the donor site and
morbidity provide sufficient argu
ments for the use o f allogeneic
banked bone.2-613- 17
Quality assurance o f banked bone
requires documented standards for
donor selection, tissue recovery,
preservation techniques, storage,
record keeping and distribution.18
These allograft femoral heads must
be free o f potentially transmissible
diseases and sepsis. In 1988, the
first documented case o f human
immunodeficiency virus (HIV) trans
mitted from a femoral head trans
plant was reported.19 This motivat
ed a proposal at a recent Canadian
conference on allografts in orthope
dic surgery that a test for the HIV
antibody be done 90 days postoper
atively on all living bone donors.20
The American Association o f Tissue
Banks (AATB) issued a revision to

F
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its standards.21 As of January 1988,
the association advised that: (a)
an absolute quarantine be placed
on all tissues from living donors for
at least 90 days; (b) after 90 days
the donor be tested for the HIV
antibody; and (c) the tissue be re
leased for distribution only if the
results of the tests for the HIV-1
antibody are negative.
Protocols for banking bone from
surgical donors have been well established41516-22' 24 but do not include
the required quarantine and testing
of the donor at 90 days for HIV-1
serology.
In a recent survey of Canadian
hospitals25 it was concluded that
many inadequacies exist in the op
eration of bone banks, including
lack of consent from living donors
and testing for the HIV-1 antibody.
In light of the increased interest
in allograft bone transplantation,
the possibility of transmitted dis
ease and the medicolegal implica
tions, we believe that a review of
the practice of banking bone from
surgical donors is due. This review
must include reference to the new
standards in HIV testing and ad
dress the required patient consent
for both release of tissues and the
confidential serologic testing.
A protocol has been established
at the Victoria General Hospital in
Halifax (Fig. 1) that meets or ex
ceeds all documented standards of
the AATB, the Centers for Disease
Control in Atlanta and the US Food
and Drug Administration. The pro
tocol addresses the required written
consent for donation and serologic
testing and the 90-day quarantine
followed by HIV antibody testing.
We believe this protocol provides
necessary guidelines for Canadian
bone banks.

Methods
The osteoarthritic patient receiv
42
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ing a hip prosthesis is screened by
the surgeon for contraindications
(Table I). Biopsy specimens (2 X
bone nibbles, not swabs) are taken
from the femoral head for aerobic
and anaerobic cultures. The bone is
then soaked in a 10% Proviodine
solution, placed in a plastic dispos
able jar (500 mL), sterile-wrapped
sequentially with three freezer bags
and passed off to the circulating
nurse. An operating-room drape is
added for protection, and a patient
addressograph label is attached (in-

eluding name, identification number
and date of birth). The donor infor
mation form is filled out, including
the surgeon’s name, the donor’s
name, identification number, blood
type, Rh factor, confirmation of
screening, diagnosis and surgery
performed. The form is signed by
the surgeon and the circulating
nurse. The wrapped femoral head is
placed in a locked refrigerator
maintained at 5°C and equipped
with temperature monitor and
alarm. The bone bank is notified.
All documentation is sent to the
bone-bank office.
Initial aerobic and anaerobic cul
ture results are reported (by phone)
to the bone bank after 48 hours. If
they are negative, the bone is trans
ferred to a freezer maintained at
-7 0 °C and equipped with highl
and low-temperature alarms. A
technologist is on call at all times in
case the unit fails. Access to this
freezer is limited to the technologist
and the bone-bank director. A chart
recorder is in place to confirm main
tenance of temperature. Once a
week the freezer temperature moni
tors and alarm are checked (cali
brated if necessary) and the findings
documented.
A confidential donor file, com
plete with an assigned unique donor
number (e.g., 89-101) is main
tained at the bone bank. A final
report of the results of the cultures
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Table I. Contraindications to Donation of
Bone to the Bone Bank

FIG. 1. Flow chart of process required
to place acceptable donor femoral head
in bone bank.

Recurrent or chronic infections
Systemic viral infections
History of viral hepatitis
Malignant disease
Slow nerve viruses (Creutzfeldt—Jakob
disease, rabies) or history
Metabolic bone diseases (e.g., rheumatoid
arthritis)
Long-term steroid therapy
Disease of unknown etiology (systemic
lupus erythem atosus, A lzh e im e r’s
disease, rheumatoid arthritis)
High-risk life-style or history
Recipients of human derived growth factor
hormone

K
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is sent to the bone bank after 6
days. A report of positive culture
results is brought to the attention
of the bone-bank director for inter
pretation.
A bone-bank follow-up sticker
(Fig. 2) is sent to the medical
records department at the end of
the 90-day postoperative quaran
tine. This “flag” is placed on the
outer cover of the outpatient chart
to remind the surgeon to obtain
consent and samples for serologic
testing at the clinical follow-up, at
least 90 days after the tissue was
harvested.
At the clinic, the patient’s social
and medical history and postopera
tive recovery are reviewed against
any further possible contraindica
tions to donation. Written consent
is obtained for donation of bone and
for serologic testing to screen for
the HIV-1 antibody, hepatitis B sur
face antigen (HBsAG), hepatitis B
core antibody (HBcAb) and syphilis
(VDRL test). Test results are direct
ed in confidence to the bone-bank
medical director.

FIG. 2. Large sticker applied to patient
chart after 90-day quarantine period.
Sticker acts as “flag” to remind physi
cian to obtain written consent and
serologic testing.

If the patient refuses consent, the
refusal is noted in the bone-bank
file, and the bone is discarded.
Abnormal results for any of the
serologic tests mandates that the
femoral head be subjected to fur
ther clinical study and that it be
discarded if the test results are
positive. All abnormal results are
reported to the surgeon.
When the results of the serologic
tests, the consent forms and the
laboratory reports are complete, the
donor file is reviewed and signed by
the bone-bank medical director. The
tissue is labelled with the unique
donor number and is placed in the
available bone inventory section of
the bone-bank freezer, and the in
ventory list is updated.
The surgeon may request a femo
ral head from the bone bank. A
minimum of 24 hours’ notice is
required to confirm the availability
of Rh-compatible bone-graft materi
al and to deliver it to the operating
room on time. Every effort is made
to use bone-graft material that has
been donated by one of the sur
geon’s own patients.
The file for that femoral head is
then rechecked by the technologist,
its distribution is noted, and it is
delivered to the operating room,
complete with instructions and a
recipient form. The recipient form
includes the unique donor number,
donor blood type (ABO and Rh) and
name of the issuing technologist.
The circulating nurse confirms
that the donor number on the allo
graft package matches the recipient
form and relays information to the
surgeon about blood type, Rh fac
tor and use of Proviodine at the
time of procurement.
The outer plastic wrap is opened
by the circulating nurse and the
bone is transferred to the sterile
table. A small biopsy specimen is
taken for culture (results are sent to
bone bank). The bone is soaked in a
warm (40°C) antibiotic solution of

80 mg tobramycin, 1 g cefazolin
(Kefzol) and 50 000 U bacitracin
per 1000 mL of Ringer’s lactate
solution for at least 10 minutes
before use.
The completed recipient form in
cludes recipient’s name, identifica
tion number, diagnosis, surgeon’s
name, surgery performed and use of
allograft bone. A copy may be main
tained in the patient chart. If not,
the unique donor number is record
ed in the surgical report. The origi
nal recipient form is maintained in
confidence by the bone bank. The
bone bank also retains any reports
of adverse reactions or problems.
Only femoral heads that have not
been used and are promptly re
turned to the bone bank are consid
ered acceptable for reuse. Any bone
that has been exposed to the recipi
ent operating field but not used, or
has been used in part, is unaccept
able.
An unused, returned bone graft
is accompanied by a statement as to
the course of the graft and the
reason for return. Acceptance of
this graft is determined by the
bone-bank medical director.

Discussion
Donor Screening

Donors are typically patients who
undergo total joint replacement for
osteoarthritis or femoral-head frac
ture. They are otherwise healthy
individuals, free of malignant dis
ease (with the exception of primary
basal cell tumour of skin following
excision), absence of infection or
history of communicable disease
(Table I). Diseases of unknown eti
ology (rheumatoid arthritis, autoim
mune diseases, systemic lupus ery
thematosus) and life-styles consid
ered to be at high risk (intravenous
drug abuse, recipients of clotting
factor concentrate, sexual activity
CJS, VOL. 34. NO. 1, FEBRUARY 1991

43

LA PRAIRIE AND GROSS

at risk for AIDS) are also contrain
dications to donation.1826
Complete screening of social and
medical history cannot be overem
phasized. A small but definite rate
of false-negative results is possible
with serologic testing, indicating
that use of bone from patients in
high-risk groups is not acceptable
despite negative serologic results
for HIV-1 and hepatitis B.27 Sero
logic tests for many viruses that
slowly affect nerves are not avail
able; only a clinical observation of
rapid dementia may indicate the
presence of disease.28 Age does not
preclude the usefulness of the bonegraft material, but may make it
more difficult to obtain an accept
able medical history and rule out
disease-related dementia (e.g.,
Creutzfeldt-Jakob disease, Alz
heimer’s disease, rabies). No con
fused or demented patient should
be accepted as an organ, blood or
tissue donor.29
Currently there are no approved
serologic tests for screening blood
and tissue donors for non-A, non-B
hepatitis (NANB).30 Nonspecific
means of screening against NANB
include surrogate testing for
HBcAb and screening with respect
to the medical and social histo
ries.3031 The American Red Cross
now screens all blood donors for
human T-cell lymphotrophic virus
type I (HTLV-1).32 This is not cur
rent practice in Canada since
HTLV-1 has a lower prevalence in
the general population, so that
there is a greater chance of a
false-positive result; also, the speci
ficity of the test is low in Canadian
subjects. A summary of current
serologic tests and acceptable re
sults is presented in Table II.
Screening for contraindications
should be continued at the postop
erative follow-up examination. Any
clinical observations of swollen
lymph nodes, prolonged high body
temperature, infection or high leu44
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kocyte count should be noted.
These may not be absolute con
traindications but could be evidence
of potential disease or infection.

Cultures

Swabs for culture are of minimal
or no value.33 Biopsy or curettage
are better procedures. Specimens
are transferred to the microbiology
laboratory in dry sterile containers
with appropriately marked requisi
tions. They should not be placed
into liquid media. Specimens taken
at time of procurement are labelled
“Donor.” A second specimen ob
tained at the time of implantation is
labelled “Graft.”
The bone chips or soft-tissue bi
opsy specimens are cultured in
cooked meat broth at 37°C for 6
days. They are observed for growth
over the incubation period. If
growth is observed, or at day 6, the
specimen is subcultured onto blood
agar aerobically and BHI agar an
aerobically at 37°C for 48 hours.
All isolates from these specimens
are considered pathogens, including
diptheroids and coagulase-negative
staphylococci. If growth is from the
“ Donor” specimen, only identifica
tion is required. If the growth is
from the “Graft” specimen identifi
cation and susceptibility testing are
carried out on each isolate. Records
of culture results from all graft
specimens are maintained to help
provide a view to quality assurance
of the bone-bank program.

HIV shall tissue be released for
distribution.” This quarantine is
considered necessary in order to
accommodate the window of time
between exposure to the virus and
production of antibodies.3435 Most
published reports suggest that the
majority of cases show positive se
rologic results for the HIV-1 anti
body by 9 weeks.36"40 Cohen and
associates41 estimated the risk of
HIV-1 transmission by transfusion
at 0.003% (30 per million). Ward
and colleagues34 estimated the risk
of transmission of HIV-1 at 26 per
million transfusions. A recent re
port by the American Red Cross42
stated that the probability of expo
sure to the AIDS virus from the
screened blood supply in the United
States in 1987 was 1:156 000 (6 in
1 million). Our protocol calls for
rescreening of the social and medi
cal histories and review of the post
operative follow-up at the clinical
interview at least 90 days after
procurement of the femoral head.
By providing a quarantine of 12 or
more weeks before testing for the
HIV-1 antibody, it should be possi
ble to reduce the risk a further
99%.37 The risk by comparison
would be less than 30 in 100 mil
lion.
We believe that an increase of the
quarantine period from 12 weeks to
24 weeks as is the case for repro
ductive tissues19-26-43 is unwarranted
when a documented protocol for
screening of medical and social hisTable II. S u m m a ry o f A cce p ta b le R e su lts
o f S e ro lo g ic T e sts

Quarantine

The AATB standards18 state that
“tissues from all living donors shall
be held in quarantine for at least
90-days at which time the donor
shall be tested for human im
munodeficiency virus (HIV) anti
body. Only if tests are negative for

Test

Acceptable result

H IV-1 a n tib o d y (EIA
sc re e n )
H B sA g
H B cA b
V D R L (s y p h ilis )
Rh fa c to r
B lo o d ty p e

N egative
N egative
N egative
N o n -re a ctive
P o s itiv e /n e g a tiv e
A /B / A B / 0

EIA = E n z y m e -lin k e d im m u n o s o rb e n t a ssa y, H BsAG = h e p a titis B s u rfa c e a n tig e n ,
H B cA b = h e p a titis B co re a n tib o d y .
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tory accompanies HIV-1 antibody
testing more than 90 days after
surgical procurement. This ratio
nale is supported by the Federal
Centre for AIDS and the Working
Group on HIV Infection in Organ
and Tissue Transplantation, Health
and Welfare Canada (A.J. Clayton,
W. Schlech: Personal communica
tion 1990).

►

“Flag” Method

b

X-

Our experience has shown that
most surgeons forget to obtain
written consent for donation of har
vested bone before surgery. They
usually remember during the course
of the hip replacement. This prob
lem, combined with the 90-day
quarantine for postoperative HIV
testing, has led us to the protocol
of obtaining written consent and
doing all serologic testing at least
90 days postoperatively at the clini
cal follow-up.
A large red sticker or “flag” (Fig.
2) was designed to be attached to
the outer jacket of the patient file
or chart and serves to remind the
surgeon that the patient’s femoral
head has been stored in the freezer
and that consent for use and for
serologic testing must be obtained.
Each consent form is accompa
nied by stepwise instructions for the
review of the donor’s history and
clinical follow-up against possible
contraindications, by instructions to
obtain consent and details of sero
logic tests to be obtained and by a
note instructing the laboratory to
send the results to the bone bank.
We believe this method of flag
ging can also be applied to patients
followed in a private office or an
outside clinic, if staff notification
and instructions are appropriate.
Our own clinic is now adapting this
to the hospital computer system.
When the patient comes to the
clinic, the data sheet automatically

includes a flag to request donation
and perform screening.

Consent

Femoral head bone banks should
adhere strictly to established guide
lines for testing, reporting and con
fidentiality.44-45 There should be no
testing for the HIV antibody with
out informed, written consent.32-37-46
The patient should be apprised of
the nature of bone banking and the
need for screening and serologic
testing.
Consent must include permission
for donation of the bone for trans
plant and for serologic testing. It
must be obtained in writing and
must name all the tests to be per
formed (AIDS, hepatitis, syphilis). It
should also state that all results are
kept confidential and that any ab
normal results are forwarded to the
patient’s physician. It is the respon
sibility of the physician to interpret
the results of the test for the pa
tient.38
We have instituted a system of
obtaining consent after the 90-day
quarantine period. The patient usu
ally does not have to consent to the
removal of the femoral head, since
this is implicit in the surgical proce
dure. After the 90-day quarantine is
the most appropriate time for
screening for HIV-1 antibody, and
this test is pivotal to the use of the
femoral head for bone grafting.
Asking patients at this stage is
ethical because the treatment has
not changed as a result of taking
the femoral head and will not
change whether consent is given or
not. We find that few patients re
fuse consent at this stage.
The result of our protocol is a
one-step procedure providing the
90-day quarantine for AIDS testing
with written consent. There is no
potential complication of dilution
due to transfusion of blood pro

ducts during surgery.47 This proto
col has the advantage of providing
review of the medical history
against contraindications at two
stages and allowing a review of the
postoperative clinical course.

Packaging

Packaging of the femoral head in
a plastic container and three freezer
bags has a number of advantages:
an aseptic barrier is provided; water
loss due to cold storage is eliminat
ed; the disposable plastic container
allows easy handling and removal of
the frozen bone at implantation; the
bone may also be thawed in warm
antibiotics and damage to the outer
wrap from the sometimes sharp
bony edges of the graft is prevent
ed; at the time of use, the outer bag
is opened by the circulating nurse
and the bone, still packaged in the
two inner bags, is presented to the
scrub nurse. The extra inner bag
allows for the possibility of error in
opening the package.
The patient addressograph label
placed on the package at the time
of procurement contains all immedi
ate information required for bonebank processing. When the allo
graft is considered acceptable for
implantation (after all results are
reported) this label is removed and
the individual donor number is at
tached.
A label (or accompanying leaflet)
is also attached, stating that the
serologic results of graft specimens
were negative for HIV-1 antibody,
HBsAg, HBcAb and syphilis. It also
gives information about the blood
type and Rh factor and use of
Proviodine at time of procurement.

Bone-Graft Storage

Long-term storage of allograft
bone requires cold storage at tem-
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peratures below —60 °C. This cold
environment is below the eutectic
point of bone48 and is cold enough
to inhibit the degradative enzyme
activity of collagenases.49 The freez
er should be equipped with hightemperature alarm sensors and a
chart recorder to verify mainte
nance of environment.26 This sys
tem should be checked and the
temperature documented weekly
with a manual alcohol thermometer.
Access is limited to bone-bank per
sonnel to prevent loss of banked
bone and potential use of bone that
has not been released for trans
plant.
By providing a second smaller
refrigerator or freezer for tempo
rary storage, it is possible to main
tain limited access to the bone
freezer and allow bone to be stored
in a holding location until the re
sults of the initial 48-hour cultures
are known. This system helps re
duce the possibility of contamina
tion of the bone freezer and allows
retrieved femoral heads to be depos
ited by operating-room staff.
It is important to place accept
able bone grafts in a physically
separated part of the freezer and to
document the placement systemati
cally; this reduces the possibility of
removing a graft that has not been
approved and facilitates inventory
checks of available allograft bone.

Antibiotic Prophylaxis

The 10% Proviodine solution, in
which the bone is soaked at the
time of procurement, is used as an
antiseptic, because antibiotics re
quire an incubation period before
they are effective. The bone is
thawed with a solution of bacitracin
with an aminoglycoside (to
bramycin) and cephalosporin (Kefzol). It provides wide-spectrum anti
biotic prophylaxis50-53 against the
major aerobic and anaerobic patho
46
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gens. This protocol is similar to
that used with large, open, surgical
wound procedures54-56 and allograft
bone applications.57 Thawing of
bone before use provides an effec
tive incubation period for the antibi
otics and also allows the washing
out of the residual Proviodine from
the graft. The antibiotic solution
may be substituted for the initial
soaking in Proviodine, if desired.
The patient should also be main
tained on an appropriate antibiotic
prophylactic regimen, directed
against the common pathogens as
sociated with all orthopedic proce
dures.57 We currently use a thirdgeneration cephalosporin.

Rh Status o f Donor Bone

The Rh status of donor bone
must be documented and the recipi
ent’s surgeon made aware.58 This is
most important with allograft pro
cedures to Rh-negative women with
potential childbearing years remain
ing, although anti-Rh(D) immuno
globulin therapy is possible.59

Record Keeping

A surprisingly large number of
forms have to be completed to
maintain quality control of surgical
bone grafts (see Table III). Instruc
tions for screening, procurement,
consent, serologic testing and use
of graft are required to standardize
these procedures, especially when a

variety of medical and nursing staff
may be involved.
Documentation of screening, pro
curement, consent, culture and se
rology results are also necessary for
complete and accurate records (Ta
ble III).18-23-26 A section in the sero
logic and culture results form
should also include documented ap
proval for release of tissue by the
bone-bank director.
Also required is a recipient form.
This form may combine graft infor
mation (Rh factor, date of procure
ment, serologic tests) as well as a
section to be completed at the time
of grafting, documenting recipient
information, use of the graft, the
surgeon’s name and a notice stating
that any adverse reactions should
be reported to the bone bank.60 The
recipient form may be in duplicate,
one copy to remain in the patient’s
chart and the other returned to the
bone bank.
If the recipient form cannot be
included with the patient chart, the
unique donor number is recorded
on the operative report.
Use of a personal computer for
database, inventory and word pro
cessing is ideal61 to maintain accu
rate physical records, help with in
ventory, produce forms and tabu
late incomplete serology and micro
biology reports.

<
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Personnel

Daily operations, record keeping
and distribution of allografts may

Table III. Standardized F orm s o f In stru ctio n and D ocum entation Required fo r Banking Bone From
Surgical Donors
Form

Type

FH1
FH2

Instruction
Instruction

FH3
FH4
FH5
FH6
FH7

In stru ctio n
D ocum ent
D ocum ent
D ocum ent
D ocum ent

Description
Screening and procurem ent in stru ction s
9 0 -d a y postoperative screening, consent and se ro lo g ic
in s tru ctio n s
In stru ctio n s fo r clinical application
P rocurem ent and screening docum entation
W itnessed consent fo rm
Record o f testing and release signature
G raft statem ent, recipient data and adverse reaction fo rm
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be performed by a designated tech
nologist or operating-room staff
member. Overall operation of the
bone bank, release of acceptable
tissues and verification of docu
mented policies is the responsibility
of the bone-bank medical director.18
Protocols are written and updat
ed from recommendations made by
clinicians, operating-room nursing
staff and the departments of pathol
ogy and microbiology.

2.

3.

4.

5.

reconstructions assessed by roentgenog
raphy and scintigraphy. Clin Orthop
1988; 231: 103-109
S amuelson KM, F reeman MAR, L evack
B et al: Homograft bone in revision
acetabular arthroplasty. J Bone Joint
Surg [Br] 1988; 70: 367-372
T rancik TM, S tulberc BN, W ilde AH:
Allograft reconstruction of the acetabu
lum during revision total hip arthroplas
ty. J Bone Joint Surg [Am] 1986; 68:
527-533
K aufman HH, J ones E: The principles of
bone spinal fusion. Neurosurgery 1989;
24: 264-270
K napp DR jr , J ones ET: Use o f cortical
cancellous allograft for posterior spinal
fusion. Clin Orthop 1988; 229: 99-106

Conclusions
►

Standards for banking bone from
surgical donors now include a
90-day quarantine, at which time
the donor is tested for the HIV-1
antibody. This quarantine empha
sizes the need for dedicated equip
ment and documented standards in
donor selection, tissue recovery,
preservation techniques, storage,
record keeping and distribution.
The screening of medical and
social histories, and serologic test
ing for HIV-1 antibody, HBsAg,
HBcAb and syphilis after a 90-day
quarantine minimize the risks of
transmitting disease through the
graft. This is a safe and effective
program, which streamlines the pa
perwork and handling of banked
surgical bone. The methodology de
scribed meets or exceeds criteria set
by the Centers for Disease Control
in Atlanta, the US Food and Drug
Administration and the AATB.
The authors gratefully acknowledge the
operating-room nursing staff and the
staff in the Department of Microbiolo
gy, Department of Immunology and
Department of Orthopedics at the Victo
ria General Hospital, Halifax, for their
assistance and suggestions.
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Addendum
Effective Aug. 1, 1990, The Ameri
can Association of Tissue Banks
(AATB) (as stated in its newsletter
volume 13, number 3) requires that
all tissue donors be screened for the
antibody to the hepatitis C virus
(HCV). Although questions have
been raised as to the sensitivity and
specificity of current tests, they are
being applied in the screening of all
volunteer blood donors by the
American and Canadian Red Cross
societies. A positive result from an
HCV test would require that the

banked tissue be discarded. Absence
of a confirmatory antigen test ne
cessitates the counselling of living
donors about the possibility of
being positive for HCV.
Future test kits may be of better
benefit in screening HCV from
those in non-high-risk groups.
Meanwhile, this test will replace the
hepatitis B core antibody (HBcAb)
test described in our paper.
In a recent newsletter (volume
13, no. 4, 1990) the AATB stated
that, effective Apr. 1, 1991, an
increase in the quarantine will be
required for surgical bone donors,
from 90 to 180 days. After that
time the donor is to be screened for
human immunodeficiency (HIV-1)
and HCV antibodies.
This increase in the quarantine
appears to be in response to the
possibility of long-delayed serocon
version and brings surgical bone
donation in line with banking of
reproductive tissues from living do
nors. In our view, as described in
detail in our paper, this increase in
quarantine may not add any sub
stantial benefit in terms of reducing
the risk of HIV-1 transmission. It
may even make the banking of
surgical bone less feasible and re
sult in more orthopedic practices
opting for cadaveric bone banking,
for which there is no option for
quarantine and no way of account
ing for the window of time between
exposure and seroconversion.
In the banking of human tissue
for clinical transplantation there
will always be improvements to pro
tocols and screening criteria. The
value of these new applications
should be weighed with consider
ation given to the prevalence of
cases at risk in the donor popula
tion and the increased costs of
application.*

When choosing an antibiotic for nosocomial infections,

LOOK BEYOND
THE PRICE TAG.
Look at the
safety profile
and total cost
of treatment.

Significant biliary excretion of antibiotics can have a very disruptive effect on
intestinal flora, which may promote the emergence of resistant strains of bacteria and
cause diarrhea.12This can add substantially to the cost of treatment.3
CLAFORAN (cefotaxime sodium) has an excellent safety profile. With only 5% biliary
excretion, Claforan has little effect on intestinal flora, thus reducing the risk of
diarrhea and bacterial resistance.14 And Claforan provides excellent coverage of
major nosocomial pathogens.
Over a complete course of therapy, if one looks at the average cost per patient,
Claforan makes good sense.5
1. GuggenbichlerJP et al. J Antimicrob Chemother 1984;14(Suppl B):pg. 67-70.
2. Hooker KD, Dipiro JT. Clin Pharm 1988;Vol 7:pg. 878-888.
3. Gladen HE et al. Infect Surg 1986;5 (10) :559-572.
4. Alcock SR, Update in Intensive Care and Emergency Medicine 1989;7:102-108.
5. Bivens BA et al. Diag Microbiol Infect Dis 1989;12:113-118.
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Claforan
P R E S C R IB IN G IN F O R M A T IO N
Action
In vitro studies indicate that the bacterial action of Claforan (cefotaxime sodium) a semi-synthetic cephalosporin
antibiotic, results from inhibition of cell wall synthesis.
Indications and Clinical Uses
T reatm ent: Claforan (cefotaxime sodium) may be indicated for the treatment of infections caused by susceptible
strains of the designated micro organisms in the diseases listed below.
Lower resp ira to ry tract in fe c tio n s : pneumonia and lung abscess caused by Streptococcus pneumoniae
(formerly Diplococcus pneumoniae), other streptococci (excluding enterocci, e.g. S. faecalis), Straphylococcus
aureus (penicillinase and non-penicillinase producing), Escherichia coli, Hemophilus influenzae, (including
ampicillin resistant strains) and unspecified Klebsiella species.
Urinary tra c t infe c tio n s: caused by Escherichia coli, unspecified Klebsiella species (including K. pneumoniae),
Proteus mirabilis, indole positive Proteus, Serratia marcescens and Staphylococcus epidermidis. Also, uncomplicated
gonorrhea caused by N. gonorrhoeae including penicillin resistant strains.
Bacterem ia / S epticem ia: caused by Escherichia coli, unspecified Klebsiella strains and Serratia marcescens.
Skin in fe c tio n s : caused by Staphylococcus aureus (penicillinase and non-penicillinase producing, S. epidermidis,
Group A streptococci, Escherichia coli, Proteus mirabilis and indole positive Proteus.
Intra-abdom inal infections: caused by Escherichia coli, and unspecified Klebsiella species.
Gynecological infections: including pelvic inflammatory disease, endometritis and pelvic cellulitis caused by
E. coli, Group A streptococci and Staphylococcus epidermidis; anaerobic bacteria including unspecified Peptococcus
and Peptostreptococcus strains and some strains of Bacteroides fragilis. In several cases, although clinical cures
were achieved, bacteriological follow-up was not available.
Central nervous system in fe c tio n s : meningitis and ventriculitis caused by Haemophilus influenzae, Neisseria
meningitidis, Streptococcus pneumoniae, Klebsiella pneumoniae and Escherichia coli. Claforan is not active
against Listeria monocytogenes.
Clinical experience with Claforan in anaerobic infections is limited. Claforan has been used with some success in
wound and intra-abdominal infections against some strains of unidentified Bacteroides and anaerobic cocci.
Claforan has been shown to be active against some strains of Pseudomonas.
In the treatment of infections encountered in immunosuppressed and granulocytopenic patients, results of therapy
with Claforan have not been impressive.
Claforan should not be considered in the treatment of enterococcal infections, i.e. Streptococcus faecalis.
Specimens for bacteriologic culture should be obtained prior to therapy in order to isolate and identify the causative
organisms and to determine their susceptibilities to Claforan. Therapy may be instituted before results of susceptibility
studies are known; antibiotic treatment should be re evaluated once these results become available.
Prophylactic U s e : The administration of Claforan perioperatively (preoperatively. intraoperatively and postoperatively)
may reduce the incidence of certain infections in patients undergoing elective surgical procedures (e.g. abdominal
or vaginal hysterectomy, gastrointestinal and genitourinary tract surgery) that may be classified as contaminated or
potentially contaminated.
In patients undergoing caesarian section who are considered to be at increased risk of infection, intraoperative
(after clamping the umbilical cord) and postoperative use of Claforan may also reduce the incidence of certain
postoperative infections.
Effective use for elective surgery depends on the time of administration (see Dosage and Administration).
For patients undergoing gastrointestinal surgery, preoperative bowel preparation by mechanical cleansing as well as
with a non absorbable antibiotic (e.g. neomycin) is recommended.
If there are signs of infection, specimens for culture should be obtained for identification of the causative organism
so that appropriate therapy may be instituted.
Contraindications
Claforan is contraindicated in patients who have shown hypersensitivity to cefotaxime sodium, the cephalosporin
or the penicillin groups of antibiotics.
Warnings
Before therapy with Claforan is instituted, it must be carefully determined whether the patient has had previous
hypersensitivity reactions to cefotaxime, cephalosporins, penicillins or other drugs. Claforan should be given with
caution to patients with Type 1 hypersensitivity reactions to penicillin. Antibiotics, including Claforan should be
administered with caution to any patient who has demonstrated some form of allergy, particularly to drugs. If an
allergic reaction to Claforan occurs, the drug should be discontinued and the patient treated with the usual agents
(e.g. epinephrine, antihistamine, pressor-amines or corticosteroids).
P seu dom em branous colitis has been reported w ith the use of cephalosporins (and other broad spectrum
a ntib iotics); therefore, it is im po rtant to consider its diagnosis in patients who develop diarrhea during
the adm in istra tio n of Claforan. This colitis can range from m ild to life-threatening in severity.
Treatment with broad spectrum antibiotics, such as Claforan, alters the normal flora of the colon and may permit
overgrowth of Clostridium difficile or other Clostridia. It has been established that a toxin produced by Clostridium
difficile is one primary cause of antibiotic-associated colitis.
Mild cases of colitis may respond to discontinuation of Claforan and replacement with a suitable specific antibiotic.
Moderate to severe cases should be managed with fluid, electrolyte and protein supplemntation as indicated.
When the colitis is not relieved by discontinuance of Claforan administration or when it is severe, an antibiotic
specifically effective in antibiotic-associated pseudomembranous colitis (eg. vancomycin) or other suitable therapy
may be indicated. Other possible causes of colitis should also be considered (see Adverse Reactions).
Precautions
Claforan (cefotaxime sodium) should be prescribed with cauton in individuals with a history of lower gastro
intestinal disease, particularly colitis.
The safety of Claforan in pregnancy has not been established. Consequently, use of the drug in pregnant women
requires that the likely benefit from the drug be weighed against the possible risk to the mother and fetus.
Use of Claforan in women of child-bearing potential requires that the anticipated benefits be weighed against the
possible risks.
Cefotaxime is excreted in human milk in low concentrations. Caution should be exercised when the drug is
administered to nursing mothers.
Prolonged use of Claforan may result in the overgrowth of nonsusceptible organisms. Constant evaluation of the
patient’s condition is essential. If super-infection occurs, therapy should be discontinued and appropriate measures
taken.
Although Claforan rarely produces alterations in kidney function, evaluation of renal status is recommended,
especially in severely ill patients receiving high doses.
Patients with markedly impaired renal function should be placed on the special dosage schedule recommended
under Dosage and Administration, because normal dosage in these individuals is likely to produce excessive and
prolonged serum antibiotic concentrations.
Positive direct Coomb’s test is known to develop in individuals during treatment with the cephalosporin group of
antibiotics, including cefotaxime sodium.
In laboratory tests a fatso positive reaction to glucose may occur with reducing substances but not with the use
of specific glucose oxidase methods.
Adverse Reactions
The most frequent adverse reactions with their frequency of occurrence are:
H ype rsensitivity (1.8%): Rash, pruritus, fever. Local (5%): Injection site inflammation with intravenous
administration. Pain, induration and tenderness after intramuscular injection. Gastrointestinal (1.7%): Colitis,
diarrhea, nausea and vomiting. Symptoms of pseudomembranous colitis can appear during or after Claforan
treatment. H em ic and Lymphatic System ( < 1%): Mild, reversible leukopenia, granulocytopenia and thrombo
cytopenia have been reported. Some patients developed positive direct Coomb’s test during treatment with
Claforan. G en itourinary System ( < 1%): Moniliasis, vaginitis. Liver ( < 1%): Transient elevations in SGOT, SGFT,

serum LDH and serum alkaline phsphatase levels have been reported. Kidney ( < 1%): Increased serum creatinine
and BUN have occasionally been observed. Central Nervous System (0.2%): Headache.
Symptoms and Treatment of Overdosage
Since no case of overdosage has been reported to date with Claforan, no specific information on symptoms or
treatment is available. Treatment of overdosage should be symptomatic.
Dosage and Administration
Claforan (cefotaxime sodium) may be administered intramuscularly or intravenously after reconstitution (see Table
with recommended mode of reconstitution according to route of administration).
Adults
The dosage of Claforan should be determined by susceptibility of the causative organisms, severity of the infection
and condition of the patient.
Guidelines for Dosage of Claforan (cefotaxime sodium)

Type of Infection
Uncomplicated Gonorrhea
Uncomplicated infections
Moderately severe to severe infections
Very severe infections (e.g. septicemia, CNS)
Life-threatening infections

Daily Dose
(9)
1

Frequency and Route
1 g IM (single dose)

2

1 g every 12 hours IM or IV

3-6

1-2g every 8 hours IM or IV

6-8
up to 12

2g every 6-8 hours IV
2g every 4 hours IV

To prevent postoperative infection in contaminated or potentially contaminated surgery, recommended doses are
as follows.
(a) 1 g IM or IV administered 1/2 to 1-1/2 hours prior to the initial surgical incision to ensure that adequate
antibiotic levels are present in the serum and tissues at the start of surgery
(b) 1g IM or IV administered 1-1/2 to 2 hours following the first dose; for lengthy operative procedures, additional
intraoperative doses may be administered, if necessary, at appropriate intervals (1-1/2 to 2 hours) during surgery
(c) 1 g IM or IV administered within 2 hours following completion of surgery
The total cumulative prophylactic dose should not exceed 6 g in a 12 hour period.
Caesarian Section Patients
The first dose of 1 g is administered IV as soon as the umbilical cord is clamped. The second and third doses
should be given as 1 g IM or IV at 6 and 12 hours after the first dose.
Neonates, Infants, and Children
The following dosage schedule is recommended:
Neonates:
0-1 week of age
50 mg / kg IV q 12 h
1-4 weeks of age
50 mg / kg IV q 8 h
Infants and children (1 month to 12 years): For body weights less than 50 kg, the recommended daily dose is
50 to 100 mg / kg IM or IV of body weight divided into 4 to 6 equal doses, or up to 180 mg / kg / day for severe
infections (including central nervous system infections).
For body weights 50 kg or more, the usual adult dosage should be used.
The maximum daily dosage should not exceed 12 grams.
Administration of Claforan should be continued for a minimum of 48 to 72 hours after the patient defervesces or
after evidence of bacterial eradication has been obtained; a minimum of 10 days of treatment is recommended for
infections caused by Group A beta-hemolytic streptococci in order to guard against the risk of rheumatic fever or
glomerulonephritis; frequent bacteriologic and clinical appraisal is necessary during therapy of chronic urinary
tract infections and may be required for several months after therapy has been completed; persistent infections may
require prolonged treatment. Doses less than those recommended should not be employed.
Dosage for Patients with Impaired Renal Function
In patients with estimated creatinine clearance of less than 20 m L/m in / 1.73m2 the dose of Claforan should be
halved (see Precautions).
If serum creatinine values alone are available, the following formula (based on sex, weight, and age of the patient)
may be used to convert these values into creatinine clearance.
Males:
Weight (kg) x (140 - age)
72 x serum creatinine
Females:

0.85 x above value

Administration
Intram uscular: Claforan should be injected well within the body of a relatively large muscle such as the upper
outer quadrant of the buttock (i.e. gluteus maximus); aspiration is necessary to avoid inadvertent injection into a
blood vessel.
Intravenous: The intravenous route is preferable for patients with bacteremia, bacterial spticemia, or other severe
or life-threatening infections, or for patients who may be poor risks because of lowered resistance resulting from
such debilitating conditions as malnutrition, trauma, surgery, diabetes, heart failure, or malignancy, particularly if
shock is present or impending.
For bolus administration a solution containing 1 or 2 g of Claforan can be injected over a period of 3 to 5 minutes.
Using an infusion system, it may also be given over a longer period of time through the tubing system by which
the patient may be receiving other intravenous solutions. Butterfly* or scalp vein type needles are preferred for this
type of infusion. However, during infusion of the solution containing Claforan, it is advisable to discontinue
temporarily the administration of other solutions at the same site.
ADD-Vantage* Vial
When administering Claforan using the ADD-Vantage* Drug Delivery system, Claforan powder is added directly to a
single-dose flexible plastic ADD-Vantage* diluent container. Claforan 1 g or 2 g may be reconstituted in 50 mL or
100 mL of 5% Dextrose Injection USP or 0.9% Sodium Chloride Injection USP.
Stability
Solutions of Claforan reconstituted in 5% Dextrose Injection USP or 0.9% Sodium Chloride Injection USP in the
ADD-Vantage* flexible containers maintain satisfactory potency for 12 hours at room temperature.
Availability
Claforan (cefotaxime sodium) is supplied as a sterile, white to pale yellow powder, in vials containing 500 mg,
1.0 and 2.0 g of cefotaxime sodium and in ADD-Vantage* vials containing 1.0 and 2.0 g of cefotaxime sodium
(expressed as acid on a dry basis).
S torage; Claforan in the dry state should be stored at room temperature protected from light and heat.
Product monograph available on request.
‘ Reg'd TM of Abbott Laboratories.
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Comparison Between Patellar Resurfacing
With an Inset Plastic Button
and Patelloplasty
H.U. Cameron, MB, ChB, FRCSC*
Of 101 patients who underwent knee replacement with the Tricon P prosthesis and
were followed up for 2 or more years, 68 had patellar resurfacing with a recessed
press-fit plastic button and 43 patients had patelloplasty (shaving of the patella and
removal o f osteophytes). All patients were followed up for more than 2 years.
Three percent o f the patients who had patellar resurfacing, later had patellar
fractures; 4.6% o f the patients who had patelloplasty initially, subsequently required
patellar replacement. There were no instances o f loosening of the patellar
replacement.
Patellofemoral aching was experienced by 7.6% o f the patients who had patellar
resurfacing and by 17.6% of those who did not. O f the patients who had patellar
resurfacing, 61.5% could climb stairs without aids using the replaced side as the
lead leg compared with 37.2% of the patients who had patelloplasty. Overall ratings
of the surgical results were similar for the two groups.
The author concludes that patellar resurfacing improves the quality of the result
and that there are few drawbacks to the use of an inset patellar button.

Sur 101 patients qui re^urent une prothese du genou de type Tricon P et qui furent
suivis pendant 2 ans ou plus, 68 avaient eu une mise a neuf de la surface rotulienne
a l’aide d’un bouton de plastique appareille par pression alors que les 43 autres
avaient subi une plastie de la rotule (planage de la rotule et enlevement des
osteophytes).
Trois pourcent des patients qui avaient eu une remise a neuf de la surface
rotulienne, subirent plus tard une fracture; 4.6% des patients qui avaient eu une
plastie de la rotule necessiterent par la suite le remplacement de celle-ci. On n’a
constate aucun detachement de prothese.
Des douleurs rotulo-femorales ont ete rapportees par 7.6% des patients qui
avaient eu une remise a neuf de la surface et par 17.6% de ceux qui n’en avaient pas
eu. Des patients qui avaient eu une remise a neuf de la surface rotulienne, 61.5%
pouvaient monter un escalier sans aide en utilisant le cote opere comme jambe
d’appui, comparativement a 37.2% pour ceux qui avaient une plastie rotulienne.
L’evaluation globale des resultats chirurgicaux a ete la meme pour les deux
groupes.
L’auteur condu t que la remise a neuf de la surface rotulienne ameliore la qualite
des resultats et qu’il y a peu d’inconvenients a utiliser un bouton de plastique
incruste dans la rotule.
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roblems resulting from the use
o f metal-backed patellar prostheses12 have led to doubt about
the value o f patellar replacement. In
an attempt to define the advantages
and disadvantages o f patellar re
placement, I compared two groups
o f patients who received a Tricon P
knee replacement; one group had
patellar resurfacing, the other did
not.
The Tricon P knee prosthesis
(Richards Manufacturing Co., Mem
phis, Tenn.) was introduced in
1982. A refinement o f the RMC
knee prosthesis,3 it consisted o f a
cemented femoral component and
uncemented tibial and patellar com 
ponents. The tibial component was
held in place by ridged plastic pegs4
driven into undersized holes drilled
into the centre o f the medial and
lateral tibial plateaus. Although
these plastic pegs lasted reasonably
well,5 for long-term fixation, under
cut grooves were machined into the
undersurface o f the tibial com po
nent to allow for possible bone
upgrowth (Fig. 1).
The Tricon P patellar component
is a plastic button with a central
peg. It is inserted by reaming an
exact-sized hole into the centre o f
the patella and press-fitting the
component without cement (Fig. 2).
Recession o f this component allows
the shear loads on the patella to be
absorbed by the side walls o f the
component and not the central peg.
The component is load-sharing in
the sense that most o f the contact
between the patella and the metallic
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trochlear groove occurs on the plas
tic insert, but some bony contact
around the periphery is possible.
At first the advantages of a patel
lar component were not obvious
and it was seldom used. Later,
however, it was used universally.
All patellar components were insert
ed without cement.

Methods
One hundred and one patients

who underwent knee replacement
with the Tricon P prosthesis be
tween 1982 and 1987 at the Ortho
paedic and Arthritic Hospital in To
ronto, and who were followed up
for 2 or more years, were reviewed
prospectively according to the Hos
pital for Special Surgery rating sys
tem.6 Follow-up was at 3 months
and 6 months after placement and
annually thereafter. At each visit,
1-m standing anteroposterior, later
al and skyline x-ray films were
obtained.

FIG. 1. Tricon P replacement knee, showing grooves and flanges in two Freeman
pegs that hold implant in place. Undercut grooves have filled with bone and have
upside-down triangular shape, indicating that this bone is not produced by sinkage.
Patella has not been replaced in this case.

Technique
In all cases a midline skin inci
sion was made. Early in the series
the knee was opened with a lateral
parapatellar capsular incision to
avoid patellar avascular necrosis.7
Later a medial parapatellar capsular
incision was used if the patella was
located centrally, and a lateral ap
proach was used only if the patella
was in a laterally subluxed position
preoperatively.
The upper surface of the tibia
was cut off at right angles to the
floor using an extramedullary
guide, and holes were drilled in the
centre of the lateral and medial
tibial plateaus to receive the pegs.
Ligaments were balanced by means
of lamina spreaders. The distal fem
oral condyles were cut with an
intramedullary guide set at 7° of
valgus. The amount of distal femo
ral resection matched the thickness
of the metal component so as to
prevent proximal shift of the joint
line.3 The anterior and posterior
femoral condyles were resected, re
moving the same minimal amount
of bone from both posterior femoral
condyles to ensure that the knee
would be tight in flexion.8 Initially
the posterior cruciate ligament was
completely resected, but later in the
series it was simply left, or, if it was
tight, a midsubstance step cut was
made. Initially the patella was

FIG. 2. (Left) Patella is grasped in holder and central hole reamed out. (Middle) Close-up view shows outline of recessed patella
and fixation peg. Walls of plastic patella are surrounded by bone. (Right) Typical fibrous meniscus that surrounds and
overgrows patellar button.
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shaved and the osteophytes were
removed; later in the series routine
patellar replacement was carried out
using the press-fit patellar compo
nent already described.
All femoral components were ce
mented in place. Cement was used
to hold the tibial component in
place only if the bone was unusual
ly soft (if it could readily be indent
ed by finger pressure) or if substan
tial bone loss had occurred; these
conditions were more common in
patients who underwent revisions of
previous surgical procedures. Apart
from these indications, all tibial
components were inserted without
cement. Later in the series tibial
defects were repaired by bone graft
ing.9 Unless the tibial bone grafts
were large, all patients were allowed
immediate full weight bearing. The
patients considered in this study all
had noncemented tibial compo
nents.

Findings
Patellar Resurfacing

Sixty-eight patients (9 men 59
women, mean age 71 years) under
went patellar resurfacing. The fol
low-up ranged from 2 to 5 years
(mean 3.5 years). Three of these
patients underwent revision of pre
vious surgery and are considered
separately.
The results in 39 (60%) patients
were rated as excellent, in 23
(35.4%) as good and in 3 (4.6%) as
fair. Only five (7.6%) patients com
plained of aching in the patellofemoral joint during use. Forty (61.5%)
patients could climb stairs with no
aids using the operated leg as the
lead leg; 15 (24%) patients needed
the assistance of a handrail to use
the operated leg as the lead leg
when climbing stairs and 10 (15%)
used the other leg.
One of the three patients who

required revision of a previous sur
gical procedure experienced a su
pracondylar fracture 2 years after
operation. Open reduction and in
ternal fixation were carried out. The
femoral component subsequently
loosened and required revision. The
second patient had loosening of the
femoral component at 3 years. At
revision the tibial component was
found to be tight. The third patient
required a revision operation at 3
years to repair a sunken tibial com
ponent. The medial tibial plateau
had fractured before surgery and
had been inadequately reconstruct
ed.
One man continued to have patellofemoral pain. His patella was re
vised to a metal-backed patella at 1
year. He continued to have some
patellar aching, and his patella was
again revised, 4 years later, to a
custom-made patellar component
that covered the whole surface of
the patella. Currently he is doing
well. Two patients had neuroma of
the infrapatellar branch of the sa
phenous nerve, which took 18
months to settle, and three patients
had a minor wound dehiscence of
no particular significance. Two pa
tients (3%) had a patellar fracture.
One fracture occurred at 10 months
in a patient in whom a lateral
parapatellar approach had been
used. The fracture, which was
transverse with no separation,
healed with a fibrous nonunion.
The other, a longitudinal fracture at
18 months, occurred in a patient
who had had a medial incision with
no lateral release. Both patients
were treated simply by bracing for 4
weeks.
Patelloplasty

This group comprised 43 patients
(6 men 37 women, mean age 72
years). The follow-up ranged from 2
to 7 years (mean 4.5 years). Twen
ty-seven patients had the opposite

knee replaced with some other type
of prosthesis, and 5 patients had
other joints replaced.
In this group the results were
rated as excellent in 25 (58.1%)
patients, good in 15 (34.9%) pa
tients and fair in 3 (7%) patients.
Seven (16.2%) patients complained
of patellofemoral aching. Sixteen
(37.2%) patients could use the oper
ated leg as the lead leg when climb
ing stairs without using aids. Nine
patients (20.9%) could use the oper
ated leg as the lead leg if they used
the handrail and 18 (41.9%) pa
tients used the opposite leg as the
lead leg for stair-climbing.
None of the patients in this
group required surgical revision.
Two patients required patellar re
surfacing to relieve significant pa
tellofemoral pain, one at 14 months
and one at 19 months.

Discussion
In this study group the only
patellar problems potentially related
to patellar resurfacing were two
fractures (3%). Of those who did
not have their patellas resurfaced,
4.6% subsequently required resur
facing. Patellofemoral ache was
present in 16.2% of those with no
resurfacing and in 7.6% of those
who had resurfacing. When climb
ing stairs, 61.5% of the patients
who underwent patellar resurfacing
could ascend without aids, using
the leg with the replaced knee as
the lead leg, compared with 37.2%
of those who did not undergo resur
facing. There were minimal differ
ences in the ratings between the
two groups: the results of 95.4% of
the group with patellar resurfacing
were rated as good or excellent
compared with 93% of the group
with patelloplasty.
It is obvious therefore that resur
facing the patella seldom influences
the overall result but does affect the
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quality of the results. The knee
rating systems are coarse instru
ments at best and are not capable of
reflecting subtle differences, al
though stair-climbing ability dif
fered markedly between the two
groups.
The recessed plastic press-fit pa
tella has functioned well. The knees
that have been revised have general
ly shown wear only on a single
central facet, in spite of an average
range of motion greater than 100°.
The recession coupled with the de
velopment of a fibrous patellar me
niscus10 presumably protects the
components. No loosening and no
subsidence into the patella have
been noted, all components being
surrounded by a peri-implant bone
plate. There must be some concern
that, with time, there will be a
build-up of polyethylene debris from
this interface, possibly leading to
late bone resorption and loosen
ing,11 but this has yet to be seen.

Use of a lateral or medial parapatel
lar approach does not seem to influ
ence the result, and at our institu
tion we continue to use a medial
parapatellar incision when the patel
la is situated centrally before sur
gery and a lateral approach when it
is subluxed laterally.
The results of this study indicate
that the drawbacks to resurfacing
the patella are minimal and that the
improvement in “quality of life” for
patients who undergo this proce
dure is significant.
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Etiology of Prosthetic Anastomotic False
Aneurysms: Pathologic and Structural
Evaluation in 26 Cases
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To determine the etiology of anastomotic false aneurysms (AFAs), 26 textile graft
specimens, removed because of AFA, were studied morphologically, histologically
and by scanning electron microscopy. No cases of suture-related failures leading to
AFA were found. Nine cases of frayed grafts were documented but were not the
cause of AFA formation. In three cases, chemical degradation of the fibres, which
may have been secondary to lipid infiltration, may have contributed to AFA
formation. There were no cases of overt clinical infection, but the presence of
bacteria was documented by scanning electron microscopy in 20 cases. The role of
bacteria is not well defined, but they may be a factor in host arterial-wall
degeneration as a cause for AFA formation.
L’etiologie des faux anevrismes a ete etudiee a l’aide de 26 segments prothetiques
en polyester, explantes pour resection de faux anevrismes et analyses macroscopiquement, en microscopie optique et en microscopie electronique a balayage. Aucun
cas de rupture de suture n’a ete note. Neuf segments prothetiques presentaient un
effilochage a leur extremite, mais celui-ci n’etait pas responsable de la formation des
faux anevrismes. Cependant, parmi les defaillances prothetiques ayant pu contribuer
a la formation des faux anevrismes, nous avons observe trois cas de degradation
chimique des fibres vraisemblablement secondaire a une infiltration de lipides. Parmi
les specimens etudies, nous n’avions aucun cas d’infection clinique, cependant une
colonisation bacterienne a ete observee en microscopie electronique a balayage dans
20 cas. Le role des bacteries doit etre elucide et il pourrait agir comme facteur de
degenerescence de la paroi arterielle responsable de la formation de faux
anevrismes.
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nastomotic false aneurysms
(AFAs) at the junction of pros
thetic arterial anastomoses continue
to be a relatively common late com
plication of grafting.1 The etiology
of AFA is multifactorial. The recog
nized causes include suture dissolu
tion or fracture, overt infection at
the anastomosis, dilatation of the
graft, rupture of the prosthesis and
fraying of the prosthesis at the
suture line. Predisposing factors
considered to play a role are endar
terectomy near the anastomotic
site, compliance mismatch between
the prosthesis and the artery, inap
propriate graft-arterial diameter ra
tio, repeated mechanical traction at
the anastomosis and shortening of
the graft.2 The most common find
ing at the site of the anastomosis in
the noninfected false aneurysm is
an intact suture line in the prosthe
sis pulled out from the arterial wall,
usually at the toe of the graft.
Sometimes the graft is completely
separated from the artery. This
finding has been attributed to the
degeneration of the arterial wall at
the anastomotic site,3 but the cause
or nature of the arterial-wall degen
eration has not been elucidated. In
an attem pt to understand further
the etiology of AFAs, 26 grafts that
were resected at operation for AFA
were submitted for gross morpho
logic and histologic investigation
and scanning electron microscopy
(SEM).

A
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Patient Data and Methods
Twenty-six grafts, resected be
cause of AFA over an 8-year period
(1978 to 1986), were submitted for
pathological investigation. All were
removed by vascular surgeons in
Marseille, France. An accompanying
patient questionnaire, filled out by
the attending surgeon, provided the
relevant patient data. At the time of
graft implantation the 23 men and
3 women ranged in age from 28 to
74 years (average 56.2 years). Indi
cations for implantation were aortic
occlusive disease in 23 patients and
abdominal aortic aneurysm in 3
patients. The initial operative proce
dures performed are listed in Table
I. Twenty-four repeat operations
were performed because of a pulsa
tile mass in the groin (Table II) and
the remaining 2 because of throm
bosis of the graft. There was no
clinical evidence of graft infection.
At operation, a segment of graft
was removed, and a short interposi
tion graft was used to restore blood
flow. No recurrences or infections
were noted postoperatively at fol
low-up.
Processing o f Graft Specimens
After excision, the grafts were
opened longitudinally, carefully
rinsed with heparinized saline, fixed
in a buffered solution of 1.5% glutaraldehyde and shipped to the Bi
omaterials Institute at the St-Fran?ois d’Assise Hospital in Quebec.
As part of the ongoing graft
retrieval program, each specimen
was processed through a series of
pathological investigations. The
graft specimen, including suture,
was examined and photographed
with a Tessovar macrophotography
optical system (Carl Zeiss, Oberkochen, Germany). An appropriate rep
resentative segment was then se
lected for the pathological studies.
Each segment was divided into two.
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The first piece was post-fixed in
Perfix solution, dehydrated with
ethanol and clarified with toluene
before being mounted in paraffin.
Sections 4 p.m thick were then
stained for light microscopy using
Weigert’s, Masson’s trichrome and
Gram’s stains.
The second piece was post-fixed
in thiocarbohydrazide and osmium
tetroxide for examination by SEM.
Dehydration was obtained by im
mersion in a series of ethanol solu
tions of increasing concentrations,
culminating in pure ethanol, fol
lowed by critical-point drying with
liquid carbon dioxide as the transfer
medium. The specimen was then
coated with gold-palladium and ex
amined in a JSM 35CF scanning
electron microscope (Jeol [USA]
Inc., Peabody, Mass.) at 15 to 20
kV of accelerating voltage. The re
maining graft specimens were
cleaned for assessment of the textile
material through a series of 5%
sodium bicarbonate baths; this was
followed by rinsing with distilled
water.
Assessment Criteria
The sutures were assessed for
type and for evidence of fractures or
dissolution. The grafts were as
sessed for the following: type (macroscopically and by SEM), fraying
(macroscopically and by SEM), fibre
degradation (macroscopically and
by SEM), lipid infiltration (macro
scopically and by SEM), endothelialization (by SEM), integrity of the
inner capsule and fibrin deposition
(by SEM) and the presence of bacte
ria (histologically and by SEM).

Findings

between 5 and 10 years (Fig. 1).
The suture material used for the
anastomosis was identified in all but
four specimens. In 17 specimens,
monofilament suture (Prolene) had
been used, and in the remaining 5
specimens multifilament braided su
ture had been used. No suture
fractures or dissolution was identi
fied.
With respect to the types of
grafts recovered at reoperation (Ta
ble III), no clustering of a single
graft type within a given time peri
od was demonstrated.
Fraying, seen in nine grafts, was
most marked in the single woven
graft submitted (Fig. 2). The pres
ence of fraying did not seem to
contribute to the formation of AFA
in any case of this series.
Defects in the graft wall associat
ed with chemical fibre degradation
were seen in three grafts (Figs. 3 to
5). Lipid infiltration was seen in 17
grafts, the most marked being in a
patient with hyperlipidemia.
Only one specimen had some evi
dence of endothelial cell growth,
which was found near the anasto
mosis. In only 3 specimens was the
integrity of the inner capsule com
posed of packed fibrin found to be
T a b le 1. Types of Revascularization
Procedures Performed on 26 Patients Who
Had Grafts Removed Because of Aortic
False Aneurysms
N u m b er
ot patients

Procedure

14
6

Aortofemoral bypass
Unilateral aortofemoral or
ileofemoral bypass
Femoropopliteal bypass
Axillofemoral bypass
Patch grafts (1 aortic, 1
iliac)

3
1
2

T a b le II. Site of Aortic False Aneurysms in

26 Patients

The duration of implantation av
eraged 6.7 years (range from 1 to
10 years). Only five aneurysms were
diagnosed within 5 years of implan
tation; the remaining 21 appeared

Site

Femoral
Popliteal
Aortic
Iliac

N u m b e r of p atients

20
2
3
1

-A

-n -
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intact and confluent; in the remain
ing 23 specimens disrupted surfaces
were demonstrated with patchy (15)
or absent (8) internal capsules. Con
fluent and disrupted internal cap
sules are compared in Figs. 6 and 7
respectively.
In 18 specimens stained with
► >

Gram’s stain, bacteria were not
demonstrated; however, SEM dem
onstrated bacteria in 15 of these 18
specimens (Fig. 8). Overall, the
presence of a discrete bacteremic
colonization was demonstrated by
SEM in 20 of 26 patients. No
infection was detected clinically.

Discussion
The etiology of AFA is multifac
torial and can generally be classified
into three major groups: suture
fractures or dissolution, graft-relat
ed defects and factors related to the
host artery or arterial-prosthetic
junction.45
Currently, suture-related defects
account for only a small proportion
of all AFAs.1"3 With the elimination
of silk sutures and the more wide
spread use of nonabsorbable monoor multifilament suture, reports of
AFAs secondary to this group have
diminished but have not been com
pletely eliminated.2'36 There were
no suture-related failures leading to
AFA formation in our series, which
is consistent with this diminished
trend.4-5
Graft-related defects again ac
counted for a relatively minor pro
portion of recognized causes of
T a b le III. T y p e s o f G ra fts U sed

G ra ft ty p e

N um ber
of p a tie n ts

W e ft k n it f la t fib re
W e ft k n it te x tu riz e d fib re
W e ft k n it lig h tw e ig h t
W a rp k n it
W oven
D o u b le v e lo u r

7
9
3
5
1
1

►

r* -

FIG. 2. (A) Cleaned graft specimen demonstrating fraying at edges of woven graft. (B) Scanning electron micrograph of frayed
edges of graft (original magnification X 20).
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AFA.23-5 In this series, nine cases of
fraying and three cases of fibre
degradation were documented.
Fraying did not lead to AFA in any

case. However, the three cases of
fibre degradation are of particular
concern and likely contributed to
AFA formation in two instances.

Lipids may contribute to the degradative process, but the exact
mechanism and natural history of
this chemical degradative process is

A
w

1

S '

FIG. 3. (A) Marked lipid deposition in portion of graft removed from 73-year-old patient with femoral AFA that appeared 8 years
after implantation. (B) Cleaned graft specimen showing area of fibre degradation at site separate from anastomosis. (C) Scanning
electron micrograph demonstrating both fraying and rounded ends of trilobar fibres, reflecting chronic degradative process
(original magnification X 720).

A

FIG. 4. (A) Cleaned graft specimen from 58-year-old patient who required reoperation for aortic AFA 6 years and 4 months after
implantation. Note frayed edges on right and adjacent graft tear just proximal to bifurcation. (B) Scanning electron micrograph
of area of graft tear (original magnification X 20). (C) Scanning electron micrograph showing evidence of degradation at ends of
fibres (original magnification X 720).
*

'■ A

FIG. 5. (A) Cleaned graft specimen removed from 58-year-old patient who had aortobifemoral bypass performed 6 years earlier
and was found to have right femoral thrombosis. Linear tear was evident just proximal to intact suture line. (B) Scanning
electron micrograph demonstrating extensive residual lipid infiltration after cleansing in sodium bicarbonate baths (original
magnification X 20).
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not known.4-7 Furthermore, the rel
ative roles of lipids, bacteria and
macrophages are not well defined,
and further research needs to be
done in this area.
The remaining group of factors
related to the host artery or ar
terial-prosthetic junction accounted
for the majority of AFAs in most
recent series.2-3-8 Compliance mis
match, stress at the anastomosis,
adherence to the inguinal ligament
causing traction at the anastomosis,
associated hypertension or previous

endarterectomy are examples of
such factors and are the focus of
other reports.9-13 The most common
factor reported is that of degenera
tion of the arterial wall, but the
exact pathogenesis is not clear. The
arterial wall may undergo necrosis,
and subsequently fibrosis, during
the healing process. This fibrosed
wall gradually gives way to mechan
ical forces, enlarges and eventually
may be detected clinically or may
become symptomatic. Arterial ne
crosis may be secondary to suture

placement combined with repeated
mechanical stresses with or without
overt clinical infection. Although no
cases of overt infection were seen in
this series, the presence of bacteria
was documented by SEM in 20 of
the 26 patients. Gram’s staining
was negative in all 18 specimens so
stained, yet bacteria were seen in 15
of the specimens on SEM. This
high rate of bacterial invasion is
consistent with findings in the re
ports of Kaebnick and col
leagues,14-15 who obtained positive

FIG. 6. Graft removed from 74-year-old patient whose aortobifemoral bypass lasted 10 years before left AFA appeared. (A)
Scanning electron micrograph of internal capsule showing relatively smooth surface (original magnification X 200). (B) Note
the confluence of fibrin strands at higher magnification (original magnification X 2000).

FIG. 7. Graft removed from 65-year-old patient with right
femoral AFA in aortobifemoral bypass performed 6 years
previously. Internal capsule shows loose fibrin strands (com
pare with Fig. 6B) (original magnification X 200).

FIG. 8. Scanning electron micrograph of luminal surface of
graft removed from 79-year-old patient who had undergone
patch iliac angioplasty for iliac stenosis 1 year earlier. Note
presence of bacteria, often seen in clumps (arrows) (original
magnification X 2000).
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cultures in 90% of AFAs after ultrasonification of the specimens. Al
though samples were not taken for
culture in this series and the bacte
ria seen by SEM cannot be typed,
the most likely organism is Staphyloccoccus epidermidis, which
may reflect contamination at the
time of surgery.1617 The exact role
of these bacteria in the pathogene
sis of AFAs is unclear, and the lack
of case-control grafts removed ei
ther at autopsy or for reasons other
than AFA in this study makes it
difficult to associate the presence of
bacteria solely with AFAs. Recently,
however, Martin and colleagues18
produced anastomotic disruption in
9 (56%) of 16 dogs implanted with
a graft exposed to a biofilm-produc
ing strain of S. epidermidis. The
additional observation of an intact
and confluent internal capsule in
only 3 of our 26 specimens may
implicate a fibrinolytic process,
which could contribute to the even
tual breakdown of the fibrous wall
and dehiscence of the anastomosis
with formation of the AFA.

specimens and may play a role in
degeneration of the arterial wall
leading to necrosis. Chemical fibre
degradation, possibly secondary to
lipid infiltration, was seen in three
cases. There were no cases of su
ture-related failure leading to AFA
formation.
The authors are indebted to the operat
ing-room technicians and hospital at
tendants charged with the collection
and expedition of the specimens. The
technical assistance of Marielle Corriveau, Nicole Massicotte, Suzanne
Bourassa, Karen Horth, Richard Cou
ture and Gilles Mongrain is greatly
appreciated.
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Parathyroid Cyst: Diagnosis
and Treatment of an Unusual Surgical
Problem
B. Mitmaker, MD, PhD, FRCSC;* S. Lerman, MD, CSPQ;f E. Lamoureux, MD, FRCPCjf
L. Begin, MD, FRCPC$
A case of parathyroid cyst is reported in which the diagnosis was suggested when
watery, clear fluid was aspirated from a mass found in the anterior region of the
neck of a 34-year-old woman on routine medical examination. The diagnosis was
confirmed by measurement of the parathormone content in the cyst fluid and by
histologic examination of the cyst wall. Although rare, parathyroid cyst should be
considered in the differential diagnosis of cysts in the anterior compartment of the
neck.
Surgery has been the usual treatment of such cysts, but several reports have been
published in which repeated aspiration resulted in the disappearance of the cyst. If
conservative treatment of a parathyroid cyst is unsuccessful, the cyst should be
removed surgically.

preoperative diagnosis of these le
sions by determining the parathy
roid hormone (PTH) levels of the
cyst fluid.6-8
In this paper we describe a case
that illustrates the value of PTH
determination on the fluid aspirate
of an anterior neck mass.

Case Report
Un cas de kyste de la parathyroide est signale oil le diagnostique a ete suggere
lorsqu’un liquide aqueux, limpide a ete aspire d’une masse decouverte a la region
anterieure du cou d’une femme de 34 ans au cours d’un examen medical de routine.
Le diagnostique a ete confirme par la mesure de la teneur en parathormone du
liquide du kyste et a l’examen histologique de la paroi du kyste. Bien que rares, les
kystes de la parathyroide devraient etre consideres dans le diagnostique differentiel
des kystes du compartiment anterieur du cou.
La chirurgie a ete utilisee comme traitement habituel de ces kystes, mais
plusieurs rapports ont ete publies oil l’aspiration repetee a provoque la disparution
du kyste. Si le traitement conservateur du kyste de la parathyroide echoue, le kyste
devrait etre excise.

lthough microscopic cysts are
common in both normal and
abnormal parathyroid glands, a sin
gle parathyroid cyst, large enough
to assume clinical and surgical im
portance, is rare.1-4 Since the initial
case report by Goris in 1905,5 162
such cases have been published.

A

Despite this, the condition is hardly
mentioned in modern surgical text
books and is rarely considered in
the differential diagnosis of anterior
neck masses. However, awareness
of this condition is worthwhile,
since fine-needle aspiration of cystic
masses in the neck permits the
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An anterior neck mass was dis
covered during routine medical ex
amination of a 34-year-old woman.
There were no symptoms of thyroid
dysfunction or local compression.
There was no history of nephroli
thiasis, pancreatitis or peptic ulcer
disease. The family history was neg
ative for disorders of the thyroid
gland and for calcium homeostasis.
Physical examination revealed a 2
X 3-cm nodule in the region of the
left lobe of the thyroid gland. The
nodule was soft, mobile and non
tender, and there was no regional
lymphadenopathy. The clinical im
pression was consistent with a thy
roid nodule. The initial results of
tests of thyroid function were nor
mal. Thyroid scanning with io
dine-131 revealed a hypofunction
ing nodule, measuring 2 X 2 cm, in
the lower pole of the left lobe of the
thyroid, and ultrasonography dem
onstrated a 4.3 X 5-cm cystic struc
ture in the anterior compartment of
the neck (Fig. 1). Fine-needle aspi-
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ration biopsy yielded 10 mL of clear
watery fluid and resulted in com
plete disappearance of the mass.
Despite repeated fine-needle aspi
rations the cyst recurred. Each re
currence was heralded by pain and
discomfort on the left side of the
neck. The watery, clear appearance
of the fluid at the first aspiration
had prompted the treating physi
cian (S.L.) to measure the PTH
content of the cyst fluid (Table I).
The patient’s serum calcium and
PTH levels measured at the time of
the first recurrence were normal.
After the fifth recurrence of the
cyst surgical exploration of the
neck was carried out.
A cystic mass, 5 cm in diameter,
was found. It bulged anteriorly after
separation of the strap muscles
overlying the left lobe of the thyroid

FIG. 1. Ultrasonogram shows cystic
mass in left lobe of thyroid gland.

tiple sections of the cyst wall re
vealed a fibrous shell in which was
embedded in normally appearing
parathyroid tissue as well as some
thymic rests. The cyst wall was
lined by a continuous, single layer
of cuboidal wasserhelle and chief
cells, each with a prominent, dense
nucleus. The adjacent thyroid tissue
was histologically normal. The lin
ing epithelium of the cyst wall
showed a strong cytoplasmic reac
tion for PTH, using an immunoperoxidase technique for this
antigen (Dakopatts Corp., Missis
sauga, Ont.).

gland. The cyst was tense and had a
translucent opaque wall (Fig. 2).
Dissection of the cyst from the
inferior aspect of the atrophic left
thyroid lobe was impossible. Conse
quently the entire cyst, including
its attached thyroid lobe and isth
mus, was excised. The parathyroid
glands on the contralateral side
were essentially normal. The re
maining fourth parathyroid gland
on the side of the cyst was not
located and was assumed to be
present in the resected specimen.
The patient had a smooth recovery
and was able to leave the hospital
on postoperative day 4.
Gross examination of the speci
men revealed a cyst 5 cm in diame
ter, attached to an atrophic left
thyroid lobe. Aspiration of the cyst
yielded 5 mL of clear fluid. The
concentration of PTH in the aspi
rate was 10 000 ng/L.
Microscopic examination of mul-

Discussion
The presence of a clear, colour
less fluid obtained from an anterior
neck cyst should suggest the diag
nosis of a parathyroid cyst. The
performance of a PTH assay on the
cyst fluid not only has enhanced the
accuracy of the preoperative diag
nosis, but also has influenced the
treatment of 678 of these rare
cases. The PTH levels of the cyst
fluid reported in the literature7-910
were generally extremely elevated,
as in the present case. Although the
majority of these clinically palpable
parathyroid cysts are nonfunctional,
a small number have been associat
ed with hyperparathyroidism.1112
Pathologic changes in the walls of
these cysts or adenomas, such as
hemorrhage or necrosis, are be-

FIG. 2. Operative appearance of para
thyroid cyst occupying left lobe of
thyroid gland. Note translucent ap
pearance of cyst wall.
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lieved to be responsible for the
hyperparathyroid crisis reported in
some cases.2'1314
The pathogenesis of parathyroid
microcysts is uncertain. Several hy
potheses have been advanced. The
most common explanation for the
formation of microscopic cysts os
tensibly arising in normal parathy
roid glands is that they result from
degeneration or hemorrhage.1315
Other hypotheses include the reten
tion of parathyroid secretions with
in colloid vesicles, developmental
anomalies and the persistence of
Kursteiner canals, normally found
in fetal parathyroid glands.16
Ultimately the coalescence of
these microcysts or the progressive
enlargement of a single microcyst is
believed to give rise to a macroscop
ic cyst. Others1718 have suggested
that parathyroid cysts may be the
result of infarction of parathyroid
adenomas.
Clinically these rare lesions occur
most commonly in the fourth and
fifth decades of life. The female to
male ratio is 2.5:1. Less than 10%
of the cysts are associated with
hyperparathyroidism. For unknown
reasons, functioning parathyroid
cysts are 1.6 times more common in
men.111'1214'19 Most commonly the
inferior parathyroid glands are in
volved, predominantly on the left
side, as in this case. The mass is
generally related to the inferior
poles of the thyroid gland with
most patients complaining of mild
discomfort and pain in the cervical
region. A cystic mass in the lower
neck palpable on physical examina

tion is usually considered to be
thyroidal or branchial in ori
gin.2'3'8'2021 Given the ease of fineneedle aspiration of these lesions
for diagnostic purposes, the pres
ence of a clear watery fluid should
suggest this diagnosis, which can
be verified by PTH assay.67'910
At present the initial treatment of
these large parathyroid cysts is nee
dle aspiration, since some have been
known to disappear completely.2910
No reports in the literature have
described the use of sclerotherapy,
a method frequently used in the
treatment of large thyroid cysts.
Those parathyroid cysts that tend
to recur after repeated aspirations
are treated definitively by surgical
removal.

References
1. Black , BM, W atts CF: Cysts of para
thyroid origin. Surgery 1948; 25: 941945
2. Clark OH: Parathyroid cysts. Am J
Surg 1978; 135: 395-402
3. M cGoon DC, Cooley DA: Parathyroid
cyst: an unusual cervical tumor. Surgery
1951; 3: 725-727
4. W elti H: A propos des kystes parathyroidi'ens. Mem Acad Chir (Paris)
1946; 72: 33-35
5. Goris D: Extirpation de trois lobules
parathyroidiens kystiques. Ann Soc
Beige Chir 1905; 5: 394
6. C lark OH, O kerlund MD, Calavieri RR
et al: Diagnosis and treatment of thy
roid, parathyroid and thyroglossal duct
cysts. J Clin Endocrinol Metab 1979;
48: 983-987
7. Doppman JL, K rudy AG, Marx SJ et al:
Aspiration of enlarged parathyroid
glands for parathyroid hormone assay.
Radiology 1983; 148: 31-35
8. K atz AD, Dunkleman D: Needle aspira
tion of nonfunctioning parathyroid

cysts. Arch Surg 1984; 119: 307-308
9. Ginsberg J, Y oung JE, W alfish PC:
Parathyroid cysts: medical diagnosis and
management. JAMA 1978; 240: 15061507
10. P acini F, A ntonelli A, L ari R, et al:
Unsuspected parathyroid cysts diag
nosed by measurement of thyroglobulin
and parathyroid hormone concentration
in fluid aspirates. Ann Intern Med 1985;
102: 793-794
11. A lbertson DA, Marshall RB, Jaeinon
WT: Hypercalcemic crisis secondary to a
functioning parathyroid cyst. Arch In
tern Med (Chicago) 1965; 116: 416423
12. Calandra DB, S hah KH, P rinz RA et al:
Parathyroid cysts: a report of eleven
cases including two associated with hy
perparathyroid crisis. Surgery 1983; 94:
887-892
13. Castleman B: Tumors of the parathy
roid glands In (Atlas o f Tumor Patholo
gy, sec VI, fasc 15), Armed Forces
Institute of Pathology, Washington, DC,
1952: 1-74
14. Chodack P, A ttie JN, Groder MG:
Hypercalcemic crisis coicindental with
hemorrhage in parathyroid adenoma.
Arch Intern Med (Chicago) 1965; 116:
416-423
15. N orris EH: Primary hyperparathyroi
dism; report of 5 cases that exemplify
special features of this disease (infarc
tion of parathyroid adenoma; oxyphil
adenoma). Arch Pathol 1946; 42: 621624
16. Gilmour JR: The normal histology of
the parathyroid glands. J Pathol Bacteri0/1939; 48: 187-222
17. F ischer ER, Gruhn J: Parathyroid cysts.
Cancer 1957; 10: 57-64
18. H aid SP, M ethod HL, B eal JM: Para
thyroid cysts. Arch Surg (Chicago)
1967; 94: 421-425
19. H oehn JG, Beahrs OH, W oolner LB:
Unusual surgical lesions of the parathy
roid glands. Am J Surg 1969; 118:
770-776
20. Rosenbaum GR, Morad A: A review of
parathyroid cysts. W Va Med J 1963;
59: 300 -3 0 2

21. W anc CA, V ickery AL, M aloof F:
Large parathyroid cysts mimicking thy
roid nodules. Am Surg 1972: 175: 448454

r
\ L

x>

A

CJS, VOL. 34, NO. I, FEBRUARY 1991

61

The

Burning

Question

Does Your I nj ect abl e H 2 Ant agoni st Provide Prompt, Persi stent Gastric pH Control?

The on set o f a n tisecreto ry effect o f PEPCID® 20 m g I.V. was n oted as ea rly as on e hour a fter
adm in istration in a study of hypersecretor individuals.1 Mean gastric pH values were maintained above
4.0 for up to 12 hours. The convenient ql2h dosage of PEPCID® I.V. may mean significant cost savings
and a reduction in time needed to prepare medication. So for prompt, persistent pH control: PEPCID*.
For many patients with pathological hypersecretory conditions or intractable
___
ulcers, or for short term use in patients unable to take oral medication.
m sd
e j i
MERCK F0r Complete Prescribing Information Please See Page 84
nO H M F
Ca n a d a

©Trademark Merck & Co., Inc./Merck Frosst Canada Inc., R.U.
PCD-90-CDN-3103-JA

Pepcid uw
(famotidine injection)

A

i

i

•

A nswers th e b u rn in g q u estio n

v
v

ORIGINAL ARTICLES

Spinal Injuries in Ice Hockey Players,
1966-1987
Charles H. Tator, MD, PhD, FRCSC; Virginia E. Edmonds, RN, BA; Lillian Lapczak, BSc;
Ira B. Tator, BA, MSc
A registry, established by the Committee on Prevention of Spinal Cord Injuries Due
to Hockey, of major injuries to the spine or spinal cord sustained while playing ice
hockey contains 117 cases entered between January 1966 and March 1987; 112 of
these injuries were sustained in Canada. Between 1981 and 1986 up to 15 hockey
related major spinal injuries were reported in Canada each year. Most injuries
occurred in teenagers and players under 30 years of age who were playing in
supervised games. The most common cause of injury was a push or check from
behind, which caused the player to be catapulted head first into the boards.
The authors describe the programs currently being implemented to prevent the
occurrence of major spinal injuries. Unfortunately, these programs have not
decreased the number of injuries reported annually.

Un registre des blessures serieuses de la moelle epiniere subies par les joueurs de
hockey sur glace a ete etabli par le Comite pour la prevention des blessures de la
moelle epiniere dues au hockey. Celui-ci renferme maintenent 117 cas repertories
entre janvier 1966 et mars 1987; 112 de ces blessures ont ete subies au Canada. De
1981 a 1986, jusqu’a 15 blessures serieuses de la moelle ont ete associees au
hockey, chaque annee, au Canada. La plupart des lesions sont survenues chez des
adolescents ou chez des joueurs de moins de 30 ans qui evoluaient dans des circuits
organises. La cause de blessures la plus frequente etait une poussee ou un echec
venant de l’arriere qui avait pour effet de catapulter le joueur, tete premiere, dans la
bande.
Les auteurs decrivent les programmes actuellement mis en vigueur pour prevenir
les blessures serieuses de la moelle epiniere. Malheureusement, ces programmes
n’ont pas fait diminuer le nombre de lesions signalees annuellement.

round the world, participa
tion in sports and recreational
activities has resulted in acute
injury to the spinal cord,1 although
the types of activities leading to
these catastrophic injuries differ be-

A

tween countries. In Canada diving
has always been the leading cause
of spinal-cord injury in the sportsrecreation category;2-4 until recently
such injuries were rarely related to
hockey. In a review o f 55 patients
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who sustained acute spinal-cord in
juries while participating in sports
or recreational activities and were
treated in two Toronto hospitals
between 1948 and 1973, not a
single case was hockey related.2
The first report o f spinal-cord inju
ry associated with hockey in the
Canadian literature was published
in 1984.5 No spinal-cord injuries
were mentioned in reports o f h ock 
ey related injuries in the English
literature before 1984,6- n although
Feriencik7 in 1979 reported hockey
related injuries to the lumbar spine
in Czechoslovakia.
In 1981 the Committee on Pre
vention o f Spinal Cord Injuries Due
to Hockey was formed. Since then
it has conducted research into the
causes o f these injuries and has
developed preventive programs. The
committee conducted its first Cana
dian national survey in 1982 to
document the extent o f the prob
lem; since then, two additional sur
veys have been done. By March
1987, 117 hockey related spinal
injuries had been reported to the
registry. It should be noted that the
registry is strongly supported by
the Canadian Amateur Hockey As
sociation and the Canadian Paraple
gic Association.
This article provides demograph
ic details o f these 117 injuries,
discusses the possible causal mech
anisms and outlines the preventive
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programs introduced by the Canadi
an Sports Spine and Head Injuries
Research Centre to reduce the inci
dence of these tragic injuries. It is
the committee’s belief that collect
ing data on spinal injuries in hock
ey is an essential part of the effort
to eliminate these injuries.

Methods
The Committee on Prevention of
Spinal Cord Injuries Due to Hockey
conducted national surveys in
1982, 1984 and 1986. Question
naires, in English and French, were
sent to approximately 1000 neuro
surgeons, orthopedic surgeons and
physical medicine and rehabilitation
specialists practising in Canada,
asking them to report all major
spinal injuries seen in their prac
tices. Information was collected on
all patients with hockey related
major injuries to the spine, with or
without injuries to the nerve roots
or spinal cord. Excluded were minor
spinal injuries such as sprains,
strains, flexion-extension injuries
and whiplash. In addition, case re
ports published in the media were
collected to augment the cases re
ported by the physicians, although
virtually every case was eventually
reported by a physician. In approxi
mately half of the cases, the infor
mation provided by the physician
was augmented by information from
the players, coaches and league
officials. The data on the six cases
occurring in the United States were
submitted by physicians in the Unit
ed States who became aware of the
work of the committee.
For the purpose of this report,
the data from the first 42 cases
reported in 198412 have been added
to the more recent cases. Thus, the
present report spans the period
from 1966, when the first reported
case occurred, to March 1987, the
date of occurrence of the last case
64
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included in this report. The data
were accumulated at the Canadian
Sports Spine and Head Injuries Re
search Centre, Toronto Western
Hospital, University of Toronto,
which is the research facility of the
Committee on Prevention of Spinal
and Head Injuries Due to Hockey.
The March 1987 cut-off date was
based on a report made at that time
to the Canadian Amateur Hockey
Association, one of the sponsors of
the registry.

Results
Geographic Location

Except for the six injuries that
occurred in the United States and
were reported by US physicians, all
injuries reported to the Committee
occurred in Canada (Table I). Fiftyseven (49%) injuries occurred in
Ontario; only 12 injuries (10%) oc
curred in Quebec. The rest of the
Canadian cases were distributed
across the country in proportion to
the population.
Annual Incidence

The injuries occurred rarely in
the 1960s and 1970s (Table II).
Beginning in 1980, the number of
Table 1. Geographic Location of Hockey
Related Spinal Injuries Sustained by 117
Patients Between January 1966 and March
1987
Frequency, no.
Location
Ontario
Quebec
Alberta
British Columbia
Nova Scotia
Saskatchewan
Manitoba
Prince Edward Island
Yukon Territories
Newfoundland
New Brunswick
United States
Unknown

(% )

57 (49)
12 (10)
9(8)
9(8)
5(4)
5 ( 4)
4 ( 3)
3(3)
3(3)
2(2)
1 ( 0.5)
6(5)
1 ( 0.5)

major spinal injuries occurring an
nually increased markedly, and be
tween 1982 and 1986 they num
bered approximately 15/yr.
Sex and Age

Of the 117 injuries, 112 (96%)
occurred in boys and men and 5
(4%) occurred in girls and women.
Sixty-four percent of the players
were between 11 and 20 years of
age, and only 19% were between 21
and 30 years of age (Table III). The
youngest player to sustain a major
spinal injury was 11 years old and
the oldest 47 years (median 18
years, mean 21 years).
Level o f Injury

Almost 80% of the injuries inTable II. The Number of Spinal Injuries
Occurring Annually,* Reported to the
Committee on Prevention of Spinal and
Head Injuries Due to Hockey, From January
1966 to March 1987t
Year

Number ot injuries

1966
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987 (to March)

1
1
2
2
4
2
8
12
15
15
15
12
15
6

‘ The injuries are recorded for the year in
which they occurred rather than the year
when they were reported to the committee.
tData are missing for seven injuries.

Table III. Age of Injured Players*
Age, yr+

Frequency, no. (%)

1 1 -2 0
21 - 3 0
31 - 4 0
4 1 -5 0

75 (64)
22(19)
7 ( 6)
3 ( 3)

'Data are missing for 10 cases (8%).
tAge range 11 to 47 yr, mean 21 yr,
median 18 yr.

HOCKEY SPINAL INJURIES

volved the cervical spine (Table IV);
approximately 48% of the injuries
affected C4-5, C5 and C5-6. Tho
racic, thoracolumbar and lumbosa
cral injuries were relatively rare.
The most common site of injury
(15.6%) was C5-6.

which was cervical in all cases. Of
the 117 injured players, 5 were
known to have died as a result of
their injuries at the time of prepar
ing this report. Most deaths were
attributed to respiratory failure.
Type o f Athletic Event

Neurologic Deficit

As noted above, the registry ex
cluded minor injuries such as verte
bral strains, although fractures or
dislocations of the spine were in
cluded even if they did not cause
neurologic injuries. The spinal cord
was affected in 52.1% of the inju
ries, and damage to one or more
nerve roots occurred in 10.3% of
the injuries (Table V). Of those
whose spinal cord was injured, 29
patients sustained complete perma
nent spinal-cord injuries with no
preservation of motor or sensory
function below the level of injury,

T a b le IV. Vertebral Level of Spinal Injury*

The largest number of injuries
occurred in supervised, scheduled
games within an organized hockey
league (Table VI): 85 players (73%)
were known to have sustained their
injuries in organized games. Only a
small number of injuries occurred
during practices or unstructured or
unsupervised events (shinny).
Mechanism o f Injury

Axial loading was found to be the
most common mechanism causing
cervical-spine and cervical-cord in
jury. Axial loading was applied to
the head when the helmeted head
struck another object, especially the
boards. The event that precipitated
the injury was usually a push or

check from behind (31 injuries,
26.5%). In most instances the play
er was completely unsuspecting of
the impact and was hurled horizon
tally into the boards; the cervical
spine was crushed between the
abruptly halted, helmeted head and
the torso. In most instances the
axial loading was applied with the
head in neutral alignment with the
neck and torso or in slight flexion.
Major degrees of flexion or exten
sion were much less common. Im
pact with the boards accounted for
76 injuries (65%) (Table VII). Im
pact between players was the cause
of injury in 10.3%; injuries caused
by impact with the ice (2.6%) or
goal post (0.9%) occurred less fre
quently. In most cases the player
collided with the boards (Table
VIII). Other frequent causes of inju
ry were pushes and checks from the
front and from the sides, especially
into the boards. In many of these
injuries, impact with the boards
produced the spinal injury.

Frequency, no.

(% )

V e rte b ra l level

Cervical, C1 - C7, T1
Thoracic, T1 — T11
Thoracolumbar, T11/12 L1 /2
Lumbosacral, L2 - S5

93 (79.5)
3 ( 9.2)
7 ( 6.0)
6 ( 5.1)

’ Data are missing for 8 cases (6.8%).

T a b le V. Neurologic Type of Injury

(n = 73)*

T a b le V III. Mode of Injury*
T a b le V I. Type of Hockey Played When

Spinal Injury Occurred*
Frequency, no.
T yp e of p la y

Organized games
Practices
Unstructured play (shinny)
Unknown

(% )
85 (73)
4 ( 3)
1 ( 1)
27 (23)

Frequency, no.
T y p e of injury

Spinal cord injury
Complete m otor and
complete sensory loss
Complete m otor and
incomplete sensory
loss
Incomplete motor loss
and incomplete
sensory loss
Incomplete sensory loss
Root injury only

(°/»)

T a b le V II. Type of Collision*
Frequency, no.

29 (24.8)

9 ( 7.7)
21 (17.9)
2 ( 1.7)
12(10.3)

*No neurologic injury in 28 cases (23.9%).
Data were missing or incomplete in 16
cases (13.7%).

T yp e of collision

Boards
Other players
Ice
Goal post
Boards and playerst
Players and ic e t
Players and goal p o s tt
Boards and ic e t

(% )

70 (59.8)
12(10.3)
3 ( 2.6)
1 ( 0.9)
5 ( 4.3)
1 ( 0.9)
1 ( 0.9)
1 ( 0.9)

*Data were incomplete or missing in 23
cases (19.7%).
tM o re than one type of collision.

F re q u e n c y , no.
M o d e of in ju ry

Single mechanisms
Pushed or checked from
behind
Pushed or checked
Slide
Tripped on ice
Trip or fall
Tripped by player
Slide w ith player
Lost balance
Missed check
M ultiple mechanisms
Tripped on ice + slide
Tripped on ice + slide
w ith player
Trip + fall
Slide + pushed or
checked
Slide + pushed or
checked from behind
Trip or fall + pushed or
checked
Slide + tripped by player

(% )

26 (22.2)
1 5 (1 2 .8 )
6 ( 5.1)
10 ( 8.5)
3 ( 2.6)
3 ( 2.6)
1 ( 0.9)
2 ( 17)
2 ( 1.7)
3 ( 2.6)
1 ( 0.9)
1 ( 0.9)
2 ( 1.7)
5 ( 4.3)
1 ( 0.9)
1 ( 0.9)

*Data incomplete or missing in 35 cases
(29.9%).
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O ther Features

Burst fractures and fracture-dis
locations were the most frequent
types of vertebral injuries. There
was one case of a ruptured cervical
disc that caused an incomplete spi
nal-cord injury. Cases were reported
of hockey players who had cervicalspine stenosis with neurapraxia and
transient traumatic quadriparesis,
which was described in football
players by Torg, Pavlov and Genuario.1314 However, spinal stenosis
in hockey players was not accurate
ly documented in this study.
Almost all the players in this
series were wearing helmets, and
more than two-thirds were wearing
face masks. Only three cases of
serious hockey related head injury
were reported to the Committee
between 1981 and 1987.

Discussion
Unfortunately, hockey related
spinal-cord injuries have not de
clined during the interval since
1984 when we reported the results
of the first national survey. From
1966 to March 1987, we recorded
117 cases of hockey related spinal
injury, including five deaths. The
Committee received reports of 12 to
15 such injuries occurring each
year in Canada between 1981 and
1986. In 1985 the Canadian Ama
teur Hockey Association instituted
a rule prohibiting pushing or check
ing from behind. Either the rule has
not been enforced as vigorously as
it should be, or the time required
for the referees, coaches and play
ers to adjust their behaviour has
not been sufficient. A push or
check, causing the top of the helmeted head to strike the boards was
the most common mechanism.
Young men in their teens and early
20s playing organized hockey were
at greatest risk of spinal injury;
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nearly three-quarters of the injuries
occurred during organized games.
Only 4% of the known cases in
volved injuries incurred during
practice or shinny. This finding is
fundamental in terms of injury pre
vention. It also is reflected in some
of the recent American literature.
For example, Gerberich and col
leagues15 also found that the major
ity of injuries occurred during orga
nized games, and in their study
from Minnesota,15 82.3% of all
hockey injuries ’occurred during
games.
Efforts to prevent spinal-cord in
jury in hockey must address the
rudimentary problem of aggression
during the game. In the Minnesota
study, players were asked to rank
their reasons for playing the game.
Extraordinarily, those players who
noted in their first or second rank
ing that playing hockey was a
means of ridding tension and ag
gression ran a fourfold risk of con
cussion.15 Recognition of this atti
tude may be important in isolating
the causes and developing preven
tive strategies.
As in the initial analysis of the
first 42 cases,12 there was a sharp
contrast between the numbers of
reported cases from Quebec and
Ontario — 10% versus 49% (Table
I). Although Ontario has more
hockey players than Quebec, the
number of injuries exceeds an ex
planation on this basis. Indeed, the
authors believe that differences in
organization and player attitude
may account for this major dispari
ty. The correlation between meth
ods of coaching and refereeing and
the incidence of injuries needs to be
carefully scrutinized.
From an epidemiologic viewpoint
it is worthwhile to review some of
the conclusions drawn from the
literature on American football. Al
though the incidence of head inju
ries was markedly reduced during
the 1960s and 1970s due to the use

of helmets, the incidence of spinalcord injuries may have increased,16
according to the results of excellent
epidemiologic studies of injuries
documented by two athletic injury
reporting systems.1617 It was con
cluded that the helmeted head was
being used as an offensive weapon
to spear the opponent. Head-first
tackling and blocking were disal
lowed, and since then there has
been a marked reduction in the
incidence of spinal-cord injuries in
football.18 In the late 1970s and
early 1980s, the annual number of
cases of quadriplegia in football
players decreased from about 30 to
10.17 There are approximately four
cases of quadriplegia a year in Can
ada due to hockey. Thus, on a per
capita basis, hockey in Canada
causes approximately three times as
many cases of quadriplegia annually
as does football in the United
States. In terms of the risk of
spinal-cord injury, participation in
hockey appears to be much riskier
than participation in football, espe
cially in Ontario, although we have
not been able to obtain exact data
on the numbers of participants.
Analysis o f Etiologic Factors

Hockey related spinal injury is a
recent phenomenon; the Canadian
Sports Spine and Head Injuries Re
search Centre has identified several
causal factors. In our opinion, no
single factor is responsible for these
tragic accidents, but rather the ori
gin is multifactorial.
It should be noted that hockey
has also been associated with a
high incidence of non-spinal inju
ries. For example, a survey in 1986
found that hockey caused the high
est number of major injuries of all
types in sports or recreational activ
ities in the Province of Ontario.
Indeed, 79 of the 530 major inju
ries sustained while participating in
all types of sports and recreational
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activities during 1986 were hockey
related; the next most frequent
causes of injury were water and
motor sports.19
Head injuries, including face,
scalp and brain injuries comprised
40% to 50% of all injuries in ice
hockey before the introduction of
helmets and face masks.20-23 But,
even with the use of helmets, head
injuries still constitute about onequarter of hockey injuries.24 Most
of the remaining injuries are to the
limbs, especially the lower limbs.25
The following factors appear to
be significant to the current high
incidence of spinal-cord injuries in
ice hockey:
• Physical factors related to cur
rent players. Hockey players are
now taller and heavier and skate
faster than players in former years.
The increased weight and speed
raise the forces generated by colli
sions.
• Social and psychologic factors
among

■A

A

young

hockey

players.

There is an increased willingness to
take risks as youthful players try to
emulate the violence and aggression
of professional players. Unfortu
nately, most of these young players
have neither the physical fitness nor
the conditioning of professionals.
There is a feeling of invincibility
among young players, most likely
related to the large amount of pro
tective equipment worn. Indeed,
many of the victims interviewed
were completely unaware of the
possibility of spinal injury in hock
ey.
• Rules and refereeing. Fre
quently the rules were not enforced.
Many of the victims were injured
during illegal play, especially push
ing or checking from behind.
• Coaching. There was insuffi
cient emphasis on physical condi
tioning, especially of the neck mus
cles. The players did not receive
sufficient instruction about the
risks of hockey and the methods of

protecting the spine from injury.
Some coaches overemphasized body
contact and underemphasized pro
tective manoeuvres, especially
avoiding impact with the boards
and strategies for impacting safely.
The marked disparity in the inci
dence of these injuries between On
tario and Quebec suggests that atti
tude and coaching techniques were
extremely important etiologic fac
tors. It is of major importance that
there have been no recent reports of
hockey related spinal injuries from
Europe, where hockey is played
extensively in several northern
countries.
• Hockey rinks and equipment.
Small rinks have been considered a
possible factor because collisions
may be more frequent in smaller
rinks. The lack of shock absorption
of the boards in most rinks has
been questioned as a possible etio
logic factor. The use of helmets
became widespread in Canadian
hockey in the 1970s and preceded
by several years the marked in
crease in neck injuries. However,
biomechanical studies have not sup
ported the notion that the helmet is
an important factor.26 It should be
noted that helmets have been ex
tremely effective in reducing the
incidence of brain injuries in hockey
players. Before the widespread use
of helmets approved by the Canadi
an Standards Association, fatal
brain injuries were not uncommon
in hockey.27-28 We registered only
three cases of severe brain injury
between 1981 and 1987. Neverthe
less, we would encourage further
research into helmet design. Sim
and Simonet25 have recently com
mented with respect to head and
neck injuries in hockey that “Hel
met design has been improved, but
few researchers have specifically
studied how well newer helmets
absorb impact and prevent injury.”
We do not know if poorly fitting
helmets contributed to any of the

injuries in this series, but we do not
believe this was a significant factor.
There is little evidence that a neck
protector such as a roll-type collar
will prevent any of these injuries
and will not substitute for the ex
tensive neck conditioning exercises
we have called for. Face masks have
produced a remarkable reduction of
eye and dental injuries in hock
ey.29-30 We found no evidence that
face masks are related to the in
crease in spinal-cord injuries, as has
been suggested.31

Prevention Programs

The Committee on Prevention of
Spinal and Head Injuries Due to
Hockey has developed several spe
cific preventive programs to reduce
the incidence of these tragic spinal
injuries.
Player education and condition
ing. Canadian hockey leagues and

organizations have accepted the re
sponsibility for reducing the inci
dence of these injuries by improving
player awareness and coaching
techniques, and by changing and
enforcing rules. Players are being
made aware of the risks of certain
aspects of play, especially going
into the boards face first and
“blindly.” Several defensive tactics
for avoiding spinal injuries are
being taught, especially avoiding
impact of the helmeted head with
the boards, the ice surface or other
players. A videotape entitled “Smart
Hockey” was produced in 1988 by
the Committee, and is being distrib
uted widely to leagues and schools.
Coaches and league officials are
encouraging players to perform spe
cific exercises to strengthen the
neck muscles; these are detailed in
a brochure Neck and Spine Condi
tioning fo r Hockey Players, which
has been distributed to all hockey
players since 1984 and is also in
cluded with the videotape.
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Rules and refereeing. The hockey
leagues have taken a leading role in
encouraging positive attitudes to
ward injury reduction and safe
hockey. In 1985 the Canadian Ama
teur Hockey Association introduced
specific rules against pushing or
checking from behind, and the as
sociation has resolved to reduce
violence in the game by enforcing
the rules.
Equipment manufacturers and
rink contractors. Further research
is required to improve the safety of
hockey equipment. Although some
excellent research has been
done,26-32 further research on hel
mets must be done on shape, fric
tion and shock absorption. Re
search into the shock absorption of
the boards should be conducted.
Placement of unyielding backing,
such as concrete blocks, behind the
boards should be discouraged. The
leagues have adopted other safety
measures, including the use of mag
netic goalposts, and are promoting
increasing the size of rinks to inter
national standards. Perhaps lowinterest federal or provincial loans
could be made available to ease the
burden of changing to the larger,
European-size rinks.
Sports medicine experts. Special
ists in sports medicine and other
recreation researchers should be en
couraged to continue research into
spinal injuries. It is essential to
continue an organized reporting
system to assess the effectiveness of
the preventive programs.33 Further
epidemiologic and biomechanical re
search should be strongly encour
aged and supported by the hockey
associations and by provincial, state
and federal governments.
We hope that hockey will follow
the excellent example set by the US
football program, which reduced
the incidence of major spinal-cord
injuries by improving awareness
and attitude and by effecting rule
changes.16' 1834
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Summary
Major spinal injuries have been
recognized as a common problem in
Canadian ice hockey only during
the 1980s. The causes of these
injuries have been found to be mul
tifactorial. The increased weight,
height, speed and aggressiveness of
hockey players are important fac
tors. Lack of awareness of the haz
ards of small rinks and of certain
high-risk manoeuvres such as
checking or pushing from behind
are also important factors. Until
1985 there were no specific rules
against checking or pushing from
behind. Lack of neck-muscle
strengthening and the player’s feel
ing of invincibility when outfitted in
modern equipment have set the
stage for these tragic injuries. After
these factors were identified, specif
ic measures were taken to correct
them, and a reporting system was
established in Canada so that the
effects of the preventive programs
could be monitored. Greater aware
ness of the risk factors by players,
coaches, leagues officials, referees
and parents promises to be an effec
tive prophylactic measure. The cur
rent, specific preventive programs
involve the hockey associations,
players, equipment manufacturers,
health care professionals, research
ers and governments.
The Canadian Sports Spine and Head
Injuries Research Centre is grateful to
the Ontario Ministry of Tourism and
Recreation, the Canadian Amateur
Hockey Association, the National Hock
ey League Players Association, the Ca
nadian Paraplegic Association, Mr. Jack
Cooper and Cooper Canada for funds to
carry on this research. The technical
assistance of Maria Vespa and Bev
Woods is gratefully acknowledged.
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Item 145
The incidence of pneumococcal sepsis is higher among patients who have had splenectomy than in the general
population. Patients with otherwise normal reticuloendothelial systems are largely able to compensate for the
loss of their spleen. In otherwise normal patients, the incidence of overwhelming sepsis after splenectomy varies
in several large series from approximately 1.5% (with a 50% mortality) to 3% (with a 30% mortality). Thus, the
risk of dying from overwhelming sepsis in otherwise normal patients after splenectomy approximates 1%. The
probability of sepsis rises significantly (to 20% to 30%) in patients with certain hematologic diseases such as
thalassemia and other abnormalities of the reticuloendothelial system. Polyvalent pneumococcal vaccines can
reduce this risk somewhat. Because these vaccines do not protect against all serotypes of pneumococci,
however, and because sepsis can be produced by other organisms, the protection is approximately 30%.
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^PRIMAXIN®
(imipenem and cilastatin sodium
for injection)
Antibiotic

•
•
•
•
•
•

Morganella morganii
Neisseria
Proteus (indole positive and indole negative
strains)
Providencia
Pseudomonas aeruginosa
Serratia marcescens

Gram-positive Anaerobes

CNS adverse experiences such as myoclonic
activity, confusional states, or seizures have
been reported with PRIMAXIN® especially when
recommended dosages based on renal function
and body weight were exceeded. These expe
riences have occurred most commonly in patients
with CNS disorders (e.g., brain lesions or
history of seizures) and/or who have compro
mised renal function. However, there were rare
reports in which there was no recognized or
documented underlying CNS disorder. Close
adherence to recommended dosage schedules
is urged, especially in patients with known
factors that predispose to seizures.

•
•
•

Clostridium (excluding C. difficile)
Peptococcus
Peptostreptoccus

Gram-negative Anaerobes

•
•

Bacteroides fragilis
Bacteroides (non-fragilis)

CONTRAINDICATIONS
PRIMAXIN® (imipenem and cilastatin sodium for
injection) is contraindicated in patients who have
shown hypersensitivity to either component of this
product.

ACTION

WARNINGS

Imipenem exerts a bactericidal action by inhibiting
cell wall synthesis in aerobic and anaerobic gram
positive and gram-negative bacteria.

PRIMAXIN® (imipenem and cilastatin sodium for
in je c tio n ) SHOULD BE ADMINISTERED WITH
CAUTION TO ANY PATIENT WHO HAS DEMONS
TRATED SOME FORM OF ALLERGY, PARTICULARLY
TO STRUCTURALLY-RELATED DRUGS. IF AN
ALLERGIC REACTION TO PRIMAXIN® OCCURS,
DISCONTINUE THE DRUG. SERIOUS HYPER
S E N S IT IV IT Y R EAC TIO N S MAY REQUIRE
EPINEPH R IN E AND OTHER EMERGENCY
MEASURES.

PR IM A XIN ® c o n s is ts o f tw o c o m p o n e n ts :
(1) im ipenem , a derivative o f thienam ycin, a
carbapenem antibiotic; and (2) cilastatin sodium, a
specific inhibitor of dehydropeptidase-l a renal
enzym e w hich m etabolizes and in a c tiv a te s
imipenem. Cilastatin blocks the metabolism of
imipenem in the kidney, so that concom itant
administration of imipenem and cilastatin allows
antibacterial levels of imipenem to be attained in the
urine.
Inhibition of cell-wall synthesis is achieved in gram
negative bacteria by the binding of imipenem to
penicillin binding proteins (PBPs). In the case of
E s c h e r ic h ia c o li and s e le c te d s tra in s o f
Pseudomonas aeruginosa, imipenem has been
shown to have highest affinity for PBP-2, PBP-1a
and PBP-1 b, with lower activity against PBP-3. The
preferential binding of imipenem on PBP-2 and
PBP-1 b leads to direct conversion of the individual
cell to a spheroplast resulting in rapid lysis and cell
death without filament formation. When imipenem
is removed p rio r to com plete k illing of gram
negative species, the remaining viable cells show a
measurable lag, termed a "post-antibiotic effect"
(PAE), prior to resumption of new growth.

INDICATIONS AND CLINICAL USE
PRIMAXIN® (imipenem and cilastatin sodium for
injection) may be indicated in the treatment of
serious infections when caused by sensitive strains
of bacteria. Where considered necessary, therapy
may be initiated on the basis of clinical judgment
before results of sensitivity testings are available.
Continuation of therapy should be reevaluated on
the basis of bacteriological findings and of the
patient’s clinical condition.
Imipenem is active in vitro against a wide range of
gram -positive and gram -negative aerobic and
anaerobic bacteria, including most strains which
are beta-lactamase producin g. Patients have
responded while under treatment with PRIMAXIN®
for single or mixed infections of the following body
systems, when they were associated with a number
of pathogenic species and strains of the genera
listed:
1.
2.
3.
4.
5.
6.
7.
8.

Lower Respiratory Tract Infections
Urinary Tract Infections
Intra-Abdominal Infections
Gynecological Infections
Septicemia
E ndocarditis caused by S taphylococcus
aureus
Bone and Joint Infections
Skin Structure Infections

Gram-positive Aerobes

•
•
•
•

Listeria monocytogenes
Nocardia asteroides
Staphylococcus (excluding many strains
which are methicillin resistant)
Streptococcus (excluding S. faecium)

Gram-negative Aerobes

•
•
•
•
•
•
•

Acinetobacter
Citrobacter
Enterobacter
Escherichia coli
Haemophilus influenzae
Haemophilus parainfluenzae
Klebsiella

emesis, inappetence, body weight loss, diarrhea
and death) at doses equivalent to the average
human dose in pregnant rabbits and cynomolgus
monkeys that is not seen in non-pregnant animals in
theseorother species. In other studies, PRIMAXIN®
was well tolerated in equivalent or higher doses (up
to 11 times the average human dose) in pregnant
rats and mice (see REPRODUCTION STUDIES
under TOXICOLOGY in the complete monograph).
Nursing Mothers

It is not known whether PRIMAXIN® is excreted in
milk. If the use of PRIMAXIN® is deemed essential,
the patient should stop nursing.
Pediatric Use

Efficacy and tolerability in infants under the age of
3 months have not yet been established; therefore,
PRIMAXIN® is not recommended in the pediatric
age group below the age of 3 months.
Drug Interactions

Concomitant administration of PRIMAXIN® and
probenecid results in only minimal increases in
plasma levels of imipenem and plasma half-life. It is
not recommended that probenecid be given with
PRIMAXIN®.
PRIMAXIN® should not be mixed with or physically
added to other antibiotics. PRIMAXIN® has been
administered concomitantly with some antibiotics,
such as aminoglycosides.
There is no evidence to suggest that association of
PRIMAXIN® with any other beta-lactam antibiotics
has any therapeutic advantage.

Pseudomembranous colitis

ADVERSE REACTIONS

Pseudomembranous colitis has been reported with
the use of PRIMAXIN®. Therefore it is important to
consider this diagnosis in patients who develop
diarrhea during or after therapy. This colitis may
range from mild to life threatening in severity.

PRIMAXIN® (imipenem and cilastatin sodium for
injection) is generally well tolerated. The following
adverse reactions were reported on 1,723 patients
treated in clinical trials. Many of these patients were
severely ill and had multiple background diseases
and physiological impairments, making it difficult to
determine causal relationship of adverse ex
periences to therapy with PRIMAXIN®.

Mild cases of pseudomembranous colitis may
respond to drug discontinuance alone. In more
s e v e re case s, m a n a g e m e n t m ay in c lu d e
s igm o idosco py, a p p ro p ria te b a c te rio lo g ic a l
studies, fluid, electrolyte and protein supple
mentation, and the use of a drug such as oral
vancomycin, as indicated. Other causes of colitis
should also be considered.

Local Adverse Reactions

Adverse local clinical reactions that were reported
as possibly, probably or definitely related to therapy
with PRIMAXIN® were:

PRECAUTIONS
General

Prolonged use of PRIMAXIN® (imipenem and
cilastatin sodium for injectio n) may result in
overgrowth of resistant organism s. Repeated
evaluation of the patient's condition is essential. If
superinfection occurs during therapy, appropriate
measures should be taken.
CNS adverse experiences such as m yoclonic
activity, confusional states, or seizures have been
reported with PRIMAXIN® especially when recom
mended dosages based on renal function and body
weight were exceeded. These experiences have
occurred most commonly in patients with CNS
disorders (e.g., brain lesions or history of seizures)
and/or who have compromised renal function.
However, there were rare reports in which there was
no recognized or documented underlying CNS
disorder. Close adherence to recommended dosage
schedules is urged especially in patients with
known factors that predispose to seizures (see
DOSAGE A N D A D M IN IS T R A T IO N ). A n ti
convulsant therapy should be continued in patients
with a known seizure disorder. If focal tremors,
myoclonus, or seizures occur, patients should be
evaluated neurolo gically and placed on anti
convulsant therapy if not already instituted. If CNS
symptoms continue, the dosage of PRIMAXIN®
should be decreased or discontinued.
Use in Patients with Impaired Renal Function

Dosage in patients with impaired renal function is
based on the severity of infection but the maximum
daily dose varies with the degree of renal functional
im pa irm e nt (see DOSAGE AND A D M IN IS 
TRATION - Dosage in P atients w ith Renal
Insufficiency).
Use in Pregnancy

The use of PRIMAXIN® in pregnant women has not
been studied, therefore, PRIMAXIN® should be
used during pregnancy only if clearly needed. Use
of this drug in women of childbearing potential
requires that the anticipated benefits be weighed
against possible hazards.
Reproduction studies with bolus I.V. doses suggest
an apparent intolerance to PRIMAXIN® (including

Incidence (%)

Phlebitis/thrombophlebitis
Infused vein pain
Vein induration
Infused vein infection

1.7
0.6
0.2
0.1

Systemic Adverse Reactions

Adverse clinical reactions that were reported as
p o ssib ly, pro b a b ly, or d e fin ite ly related to
PRIMAXIN® were:
Incidence (%)
Gastrointestinal

nausea
diarrhea
vomiting
tongue papillar hypertrophy
pseudomembranous colitis
(see WARNINGS)
hemorrhagic colitis
gastroenteritis
abdominal pain
glossitis
heartburn
pharyngeal pain
increased salivation

2.0
1.7
1.6
0.2
0.1
<0.1
<0.1
<0.1
<01
<0.1
<0.1
<0.1

CNS

fever
dizziness
seizures
(see PRECAUTIONS)
somnolence
confusion
myoclonus
vertigo
headache
encephalopathy
paresthesia

0.4
0.3
0.2
0.2
0.2
0.1
0.1
0.1
<0.1
<0.1

Special Senses

transient hearing loss in
patients with impaired hearing
tinnitus

<0.1
<0.1

Respiratory

dyspnea
hyperventilation
thoracic spine pain

0.1
<0.1
<0.1

Cardiovascular
hypotension
palpitations
tachycardia

0.4
0.1
< 0.1

Renal
oliguria/anuria
polyuria

<0.1
< 0.1

Skin
rash
pruritus
urticaria
skin texture changes
candidiasis
erythema multiforme
facial edema
flushing
cyanosis
hyperhidrosis
pruritus vulvae

0.9
0.3
0.2
0.1
0.1
<0.1
< 0.1
< 0.1
< 0.1
< 0.1
<0.1

Body as a whole
polyarthralgia
asthenia/weakness

<0.1
<0.1

Adverse Laboratory Changes
Adverse laboratory changes, without regard to drug
relationship, that were reported during clinical trials
were:
Hepatic: IncreasedSGPT.SGOT,alkalinephosphatase, bilirubin and LDH.
Hemic: Increased eosinophils, positive Coombs
test, decreased WBC and neutrophils, increased
WBC, increased platelets, decreased platelets,
decreased hemoglobin and hematocrit, increased
monocytes, abnormal prothrombin time, increased
lymphocytes, increased basophils.
Electrolytes: Decreased serum sodium, indreased
potassium, increased chloride.
Renal: Increased BUN, creatinine.
Urinalysis: Presence of urine protein, urine red
blood cells, urine white blood cells, urine casts,
urine bilirubin, and urine urobilinogen.

TREATMENT OF OVERDOSAGE
There are no data available on overdosage.
PRIMAXIN® (imipenem and cilastatin sodium for
injection) is cleared by hemodialysis.

DOSAGE AND ADMINISTRATION
The dosage recommendations for PRIMAXIN®
(imipenem and cilastatin sodium for injection)
represent the quantity of imipenem to be ad
ministered by I.V. infusion only. An equivalent
amount of cilastatin is also present in the solution.
The dosage of PRIMAXIN® should be determined
by the severity of the infection, renal function, body
weight, the antibiotic susceptibility of the causative
organism(s) and the condition of the patient. Doses
cited are based on body weight of 70 kilos.

The maximum daily dose should not exceed 4 g or
50 mg/kg, which ever is less.
Dosage in Elderly Patients
The recommended dosage of PRIMAXIN® in elderly
patients with normal renal function is the same as
given for adults above. Renal status of elderly
patients may not be accurately portrayed by
measurement of BUN or creatinine alone. Deter
mination of creatinine clearance is suggested to
provide guidance for dosing in such patients.
Dosage in Patients with Renal Insufficiency
P a tie n ts w ith c r e a tin in e c le a r a n c e s o f
< 5 mL/min/1.73m2 (=S0.08 mL/s/1.73m2) should
not receive PRIMAXIN® unless hemodialysis is
instituted within 48 hours. Both imipenem and
cilastatin are cleared from the circulation during
h e m o d ia ly s is . The p a tie n t s h o u ld re ce ive
PRIMAXIN® after hemodialysis and at 12 hour
intervals timed from the end of that hemodialysis
session. Dialysis patients, especially those with
background CNS disease, should be carefully
m o n ito re d ; fo r p a tie n ts on h e m o d ia ly s is ,
PRIMAXIN® is recommended only when the benefit
outw eighs the potential risk of seizures (see
PRECAUTIONS). Currently, there are inadequate
data to recommend the use of PRIMAXIN® in
patients undergoing peritoneal dialysis.
TABLE 2
MAXIMUM DOSAGE OF PRIMAXIN®
IN RELATION TO RENAL FUNCTION

RENAL
FU N C TIO N

C R EA TIN IN E
CLEARANCE
m L/m in/1.7 3 m2
(m L /s/1.7 3 m 2)

M ild
im pairm ent

M oderate
im p airm e nt

Severe*
im p airm e nt

DOSE

(g)

DOSAGE
INTERVAL

(h)

M A X IM U M
TOTAL
D A IL Y
D O SA G E

(g)

0.5

2 1 -3 0
(0.35 - 0.50)

0.5

8 -1 2

1 - 1 .5

0 .2 5 -0 .5

12

0 .5 -1 .0 * *

0 -2 0
(0 - 0 .3 3 )

6 -8

1 .5 -2

x P a tie n ts w ith c r e a tin in e c le a ra n c e o f 6 to
20 m L /m in /1 .73 m2 (0.1 - 0.3 m L /s /1 .73 m2) should
be treated w ith 250 mg (or 3.5 m g/kg w h ic h e v e r is
ow erl every 12 hours fo r m ost pathogens. When
the 500 mg dose is used in these patients, th e re may
be an increased risk o f seizures.
x * T h e h ig h e s t d o s e is o n ly re c o m m e n d e d fo r
in fe c tio n s due to less s u s c e p tib le o rg a n is m s
prim arily some strains of Ps. aeruginosa.

When only the serum creatinine level is available,
the following formula (based on sex, weight, and
age of the patient) may be used to convert this value
into creatinine clearance (mL/min). The serum
creatinine should represent a steady state of renal
function.
Males:

Weight (kg) x (140 - age)
72 x serum creatinine (mg/100 mL)

Females:

Dosage in Adults
The recommended daily dose is 1 to 2 g adminis
tered in equally divided doses every 6 to 8 hours
(see Table 1).

and in females the estimated creatinine clearance
(mL/s) is:

Severity
of infection

(lean body weight, kg) x (140 - age, years) x 1.2526
(72) x (serum creatinine concentration, pm ol/L)

Dose
(mg of imipenem)

Dosage
Interval

Daily
Dose

250 mg

6h

1.0 g

Moderate

500 mg

8h

1.5 g

Severe (fully
susceptible)

500 mg

6h

2.0 g

1000 mg
1000 mg

8h
6h

3.0 g
4.0 g

PRIMAXIN® is cleared by hemodialysis. After each
dialysis session the dosage schedule should be
restarted.
Dosage In Infants and Children

Mild

Severe* infections
due to less
susceptible
organisms
or life threatening
conditions

* Prim arily some strains o f Ps. aeruginosa.

Repeat, using 10 mL of the diluted suspension, to
ensure complete transfer of the contents of the vial
to the infusion solution.
CAUTION: CONTENTS OF VIALS NOT FOR
DIRECT INFUSION.

COMPATIBILITY AND STABILITY
List of diluents
0.9% Sodium Chloride Injection
5% or 10% Dextrose Injection
5% Dextrose Inje ctio n w ith 0.02% sodium
bicarbonate solution
5% D extrose and 0.9% S odium C h lo rid e
Injection
5% Dextrose Injection with 0.225% or 0.45%
saline solution
NORMOSOL-M in D5-W
5% Dextrose Injection with 0.15% potassium
chloride solution
Mannitol 2.5%, 5% and 10%
Solutions of PRIMAXIN® range from colourless to
yellow. Variations of colour within this range do not
affect the potency of the product.
PRIMAXIN®, as supplied in vials and reconstituted
as above maintains satisfactory potency for four
hours at room temperature and for 24 hours under
refrigeration (4°C). PRIMAXIN® has been found to
be stable in 0.9% Sodium Chloride Injection for
10 hours at room temperature and 48 hours under
refrigeration.

DOSAGE FORMS
PRIMAXIN® is supplied as a sterile powder mixture
in vials con taining im ipenem an hydrous and
cilastatin sodium as follows:
3514Ca - 250m gim ipenem equivalentand250m g
cilastatin equivalent in vials.
3516 Ca - 500 mg imipenem equivalent and 500 mg
cilastatin equivalent in vials.
STORAGE
The dry powder should be stored at a temperature
below 30° C.

0.85 x above value.

(lean body weight, kg) x (140 - age, years) x 1.4736
(72) x (serum creatinine concentration, pm ol/L)

I.V. Administration

A suggested procedure is to transfer approximately
10 mL from the 100 mL of the appropriate infusion
solution to the vial (see list of diluents under
COMPATIBILITY AND STABILITY). Shake well.
Return the resulting 10 mL of suspension to the
remaining 90 mL of the infusion solution.

AVAILABILITY

When using the International System of units (SI),
the estimated creatinine clearance (mL/s) in males
can be calculated as follows:

ADULT DOSAGE OF PRIMAXIN®

RECONSTITUTION
Contents of the vials must be suspended and
transferred to 100 mL of an appropriate infusion
solution.

Reconstituted solutions
3 1 -7 0
(0 .5 2 -1 .1 7 )

The median duration of treatment with PRIMAXIN®
in clinical trials for infections of the various body
systems ranged from 6 to 10 days except for
endocarditis and bone and joint infections for which
the median duration of treatment was 4 weeks.

TABLE 1

Each reconstituted 250 mg or 500 mg dose should
be given by intravenous infusion over twenty to
th irty minutes. Each 1000 mg dose should be
infused over 40 to 60 minutes. In patients who
develop nausea during the infusion, the rate of
infusion may be slowed.

The re com m e nde d to ta l d a ily d o sa g e of
PRIMAXIN® in children and infants 3 months of age
and older is 60 to 100 mg/kg of body weight divided
into 4 equal doses given at six hour intervals. The
higher dosages should be used for infants and
young children. The total daily dosage should not
exceed 2 grams. Clinical data are insufficient to
recommend an optimum dose for infants and
children with impaired renal function.
Administration
CAUTION: CONTENTS OF VIALS NOT FOR
DIRECT INFUSION.
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PRESCRIBING INFORMATION

Rocephin;
CEFTRIAXONE I SODIUM

Sterile Ceftriaxone Sodium
For Injection
Therapeutic Classification
Antibiotic
INDICATIONS AND CLINICAL USES The treatment of the following infections when caused by susceptible strains of the
designated micro-organisms: Lower respiratory tract inlections caused by £ coli, H. influenzae, K. pneumoniae and species,
Staph, aureus, Strep, pneumoniae and species (excluding enterococci). Urinary tract inlections (complicated and
uncomplicated) caused by £. coli. Klebsiella species, P, mirabilis and P. vulgaris. Bacterial septicemia caused by £ coli,
H. influenzae. K. pneumoniae. Staph, aureus and Strep, pneumoniae (excluding enterococci). Skin and skin structure
inlections caused by K. pneumoniae and species, P mirabilis, Staph aureus, Staph, epidermidis and Streptococcus
species (excluding enterococci). Bone and joint infections caused by Staph, aureus, Strep, pneumoniaeani Streptococcus
species (excluding enterococci). Meningitis caused by H. influenzae, N. meningitidis, and Strep, pneumoniae. Rocephin1,
should not be used tor the treatment of meningitis caused by L. monocytogenes. Uncomplicated gonorrhea (cervical/
urethral and rectal) caused by H. gonorrhoeae (penicillinase and nonpenicillinase producing strains).
Prophylaxis: The preoperative administration of a single 1 g dose of Rocephin® (sterile ceftriaxone sodium) may reduce
the incidence of postoperative infections in patients undergoing vaginal or abdominal hysterectomy, coronary artery
bypass surgery, or in patients at risk of infection undergoing biliary tract surgery. If signs of post surgical infection should
appear, specimens fo r culture should be obtained for identification of the causative organism(s) so that the appropriate
therapy may be instituted. CONTRAINDICATIONS Rocephin® (sterile ceftriaxone sodium) is contraindicated in patients
with known allergy to ceftriaxone, other cephalosporins or penicillins. WARNINGS Before therapy with Rocephin® (sterile
ceftriaxone sodium) is instituted, careful inquiry should be made concerning previous hypersensitivity reactions to
ceftriaxone, other cephalosporins, penicillins or other allergens. Rocephin® should only be administered with caution to
any patient who has demonstrated any form of allergy particularly to drugs. Serious, and occasionally fatal hypersensitivity
(anaphylactoid) reactions have been reported in patients receiving cephalosporins. The reactions are more likely to occur
in persons with a history of sensitivity to multiple allergens. Rocephin® should be administered with caution to patients
with type I hypersensitivity reaction to penicillin. If an allergic reaction occurs, the administration of Rocephin® should be
discontinued and appropriate therapy instituted. Pseudomembranous colitis has been reported with the use of Rocephin®,
(and with broad-spectrum and other antibiotics). Therefore, it is important to consider its diagnosis in patients
administered Rocephin- who dev^opdiarrhea. Treatment with broad-spectrum antibiotics, including Rocephin®, alters
the normal flora of ttie colon and may permltovergrowth of Clostridia. Studies indicate that a toxin produced by C/osfr/rf/um
difficile is one primary cause of antibiotic-associated colitis. Mild cases of colitis may respond to drug discontinuation
alone. Moderate to severe cases should be managed with fluid, electrolyte, and protein supplementation as indicated.
When the colitis is not relieved by discontinuation of Rocephin® administration or when it is severe, consideration shouid
be given to the administration of vancomycin or other suitable therapy. Other possible pauses ot the colitis should also
be considered, Rocephin® therapy shouid be discontinued in patients who develop signs or symptoms suggestive of

gallbladderdiseaseandconservativemanagementcorisidered.Theeffectofpre-existinggallbladderdiseaseisnot known.
In a few patients administered Rocephin®, shadows suggesting “sludge" have been -detected by sonograms of the
gallbladder in those who remained asymptomatic andin those who became symptomatic. This condition appeared to be
reversible on discontinuation ot RocepWn®therapy. inafew symptomatic patients receivmgdgof Ftapf*Y»W ho underwent
cholecystectomy, "sludge” containing traces of ceftriaxone was recovered from surgical specimens. Concretions
consisting o( the predipitated calcium salt ot ceftriaxone have been found in the gallbladder bile bf dogs and baboons
treated with high doses of ceftriaxone. PRECAUTIONS General Hypoprothrombinemia and alterations in prothrombin time
have occurred rarely in patients treated with Rocephin® (sterile ceftriaxone sodium) (see ADVERSE REACTIONS). Patients
with impaired vitamin K synthesis or low vitamin K stores (e.g. chronic hepatic disease and malnutrition) may require
monitoring ol hematology and coagulation parameters during Rocephin* treatment. Vitamin K administration (10 mg
weekly) may be necessary it the prothrombin time is prolonged before or during treatment. Prolonged treatment with
Rocephin* may result in overgrowth of non-susceptible organisms and organisms initially sensitive to the drug. If
superinfection ox^turs, appropriate measures should be taken. Rocephin® should be administered with caution to individuals
with a history of gastrointestinal disease, particularly colitis. Renal and Hepatic Impairment Although transient elevations
of BUN and serum creatinine have been observed in clinical studies, there is no other evidence that Rocephin®, when
administered alone, is nephrotoxic. In severe renal impairment (creatinine clearance of less than 10 mL/min), periodic
monitoring of serum ceftriaxone concentrations is recommended. The maximum daily dose should not exceed 2 g. In
severe renal impairment associated with clinically significant hepatic impairment, close monitoring of serum ceftriaxone
concentrations, at regular intervals, is recommended. If there is evidence of accumulation, dosage should be decreased
accordingly. Interactions Interactions between Rocephin® and other drugs have not been fully evaluated. Pregnancy The
safety of Rocephin® in the treatment of infections during pregnancy has not been established. Rocephin® should only be
used during pregnancy it the likely benefit outweighs the potential risk to the fetus and/or the mother. Ceftriaxone has been
detected in the umbilical cord blood, amniotic fluid and placenta. Nursing Mothers Ceftriaxone is excreted in human milk
at low concentrations. The clinical significance of this is unknown; therefore, caution should be exercised when Rocephin®
is administered to a nursing mother. Neonates The safety of Rocephin* in neonates (birth to one month of age) has not
been established. In vitro studies have shown that ceftriaxone can displace bilirubin from serum albumin. Caution should
be exercised when considering Rocephin®treatmentforhyperbilirubinemic neonates especially if premature. Elderly Patients
The elimination of ceftriaxone may be reduced in elderly patients possibly due to impairment of both renal and hepatic
function. Drug-Laboratory Test Interactions Ceftriaxone may interfere with urine glucose determinations utilizing the
copper-reduction test (CLINITEST), but not utilizing the glucose-oxidase test (DIASTtX or TES-TAPE) ADVERSE REACTIONS
During clinical trials with Rocephin® (sterile ceftriaxone sodium) the following adverse reactions have been observed:
Clinical Adverse Experiences: Dermatological: Rash (1.3%); exanthema, allergic dermatitis and pruritis (0.1 -1.0%).
Hematological: Anemia (0.1-1.0% ); auto-immune hemolytic anemia and serum sickness (<0.1%). Hepatic: Jaundice,
reports (in asymptomatic and symptomatic patients) of ultrasonographic shadows suggesting precipitations in the
gallbladder and reports of gallbladder sludge (<0.1 %) Urogenital: Moniliasis and vaginitis (0.1 -1.0%). Gastrointestinal:
Diarrhea (3.3%); nausea, vomiting, dysgeusiaand gastric pain (0.1-1.0%); abdominal pain, colitis, flatulence, dyspepsia,
pseudomembranous colitis and stomatitis (<0.1%). Neurological: Dizziness and headache (0.1 -1.0% ); ataxia and
paresthesia (<0.1%). Miscellaneous: Fever, chills, diaphoresis, malaise, burning tongue, flushing, edema and anaphylactic
shock (0.1 -1.0% ); bronchospasm, palpitations and epistaxis (<0.1%) Local Reactions al Injection Site: Pain (9.4%),
induration and tenderness (1 -2%); phlebitic reactions (0.1-1.0%); thrombophlebitis (<0.1 %). Laboratory Abnormalities:
Hematologic: Eosinophilia (4.6%), thrombocytosis (5.1%), leukopenia (2.0%); neutropenia, lymphophenia,
thrombocytopenia, increase or decrease in hematocrit, prolongation of prothrombin time and decrease in hemoglobin (0.1
-1.0%); leukocytosis, lymphocytosis, monocytosis, basophiliaand decrease in prothrombin time (<0.1%). Hepatic: Increase
in AST (SGOT) (4.0%)*, ALT (SGPT) (4.8%)', increase in alkaline phosphatase (1.0%); increase in bilirubin (0.1 -1.0%).
Urinary: Increase in BUN (1.1 %)‘ ; increase in creatinine, erythrocyturia, proteinuria and presence of casts in urine (0.1
-1.0% ); glycosuria (<0.1 % ).1 Incidence is more frequent in patients less than one year old.1 Incidence is more frequent
in patients less than oneyear old and over 50 years old. SYMPTOMS AND TREATMENTOFOVERDOSAGE Ultrasonographic
shadows suggesting precipitations in the kidneys accompanied by calcium ceftriaxone precipitate in the urine was
observed in one patient dosed with Rocephin® (sterile ceftriaxone sodium) at 10 g/day (2.5times the maximum recommended
dose). No other case of overdosage has been reported to date with Rocephin®. No specific information on symptoms or
treatment is available. Excessive serum concentration ot ceftriaxone cannot be reduced by hemodialysis or peritoneal
dialysis. Treatment should be symptomatic. DOSAGE AND ADMINISTRATION Rocephin® (sterile ceftriaxone sodium) may
be administered intravenously or intramuscularly after reconstitution. Dosage and route of administration should be
determined by the severity of intection, susceptibility of the causative organisms, and condition of the patient. The
intravenous route is preferable tor patients with septicemia or other severe or life-threatening infections. DOSAGE Adults:
Moderate and Severe Intentions: Total daily I.M. or I.V dose 1 or 2 g daily. The daily dose may be given as 0.5 or 1 g q12h,
or 1 or 2 g q24h. There is limited experience with daily doses of 3-4 g administered as a single dose or two equally divided
doses. The total daily dose should not exceed 4 o. Uncomplicated Gonorrhea: Single dose of 250 mg I.M. IntantsaM
Children (one month to 12 years of age) Serious Miscellaneous Inlections: Total daily I.M. or I.V. dose 50 or 75 mg/kg
administered as 25 or 37.5 mg/kg g12h. The total daily dose should not exceed 2 g. If body weight is 50 kg or more the
adult dose should be used Meninnitis: Total daily I.M. or I.V. dose -100 mg/kg administered as 50 mg/kg* q12h. * With
or without a loading dose of 75 mg/kg. The total daily dose should not exceed 4 g. With the exception of gonorrhea, which
is treated with a single dose, the administration ot Rocephin® should be continued for a minimum ot 48 to 72 hours after
the patient defervesces or after evidence of bacterial eradication has been obtained, usually 4 to 14 days. In bone and joint

infections the average duration of treatment during clinical trials was 6 weeks, with a range of 1 to 13 weeks, depending
on the severity of the infection. When treating infections caused by beta-hemolytic Streptococcus, it is recommended that
therapy be continued for at least 10 days. The average duration of therapy for infections associated with beta-hemolytic
Streptococcus during clinical trials was 2 weeks, with a range of 1 to 5 weeks, depending on the site and severity ot the
infection. Prophylaxis (Vaginal or Abdominal Hysterectomy, Coronary Artery Bypass Surgery, Biliary Tract Surgery):
For preoperative use as prophylaxis before vaginal or abdominal hysterectomy, coronary artery bypass surgery, or biliary
tractsurgery in patients at risk of infection, asingle dose of 1 g administered 1/2 to2 hours before surgery is recommended.
Impairment ot Renal and/or Hepatic Function In patients with mild to moderate renal impairment, changes in the dosage
regimen are not required, provided liver function is intact. In cases of preterminal renal failure (creatinine clearance less
than 10 mUmin), periodic monitoring of serum ceftriaxone concentrations is recommended. The daily dosage should be
limited to 2 g or less. In patients with liver damage, there is no need for the dosage to be reduced provided renal function
is intact. In cases of coexistent renal and clinically significant hepatic insufficiency, close monitoring ol serum ceftriaxone
concentrations, at regular intervals, is recommended. If there is evidence of accumulation, dosage should be decreased
accordingly. ADMINISTRATION Intramuscular: The reconstituted solution of Rocephin®should be administered by deep
intragluteai injection. It is recommended that not more than 1 g beinjected ata single site. Pain on intramuscular injection
is usually mild and less frequent when Rocephin® is administered in sterile 1% Lidocaine solution. Intravenous (bolus)
Injection: The reconstituted solution should be administered over approximately 5 minutes. Short Intravenous Infusion:
The further diluted intravenous solution should be given over a period of 10 to 15 minutes in infants and children and 20
to 30 minutes in adults. NOTE: Rocephin® solution should not be physically mixed with aminoglycoside antibiotics nor
administered at the same site because of possible chemical incompatibility.
PHARMACEUTICAL INFORMATION
Reconstitution
For Intramuscular Use
Reconstitute Rocephin® powder with the appropriate diluent:
• Sterile Water for Injection
• Bacteriostatic Water for Injection
• 0.9% Sodium Chloride Injection
• 1% Lidocaine Solution
• 5% Dextrose Injection
Reconstitute as follows:
Reconstitution Table (IM)
Vial
Size

Volume to be
added to vial
mL

0.25 g

0.9

0.5 g

14 ;

10 g

3.6

Approximate available
volume
mL

m

;

Approximate average
concentration
g/mL

1
2 mm

0.25

4

0.25

0.25

0.25
7.2
■ ■
8 I
200
b-akeweii until dissolved.
W
H W
W
NOTE- SOLUTIONS"PREPARED FOR INTRAMUSCULAR USEiOR ANY SOLUTION.CONTAINING LIDOCAINE OR
BACTERIOSTATIC WATER FOR INJECTION SHOULO NEVER BE ADMINISTERED INTRAVENOUSLY.
.-h-,;/:
For Intravenous Use
Reconstitute only with Sterile Water for Injection.
Reconstitute aS
W m fR
Reconstitution Table (IV)
Volume to be
added to vial
mL

Approximate available
volume
mL

Approximate average
concentration
g/mL

0.25 g

2.4

2.5

0.1

0.5 g

4.8

5.0

0.1

1.0 g

9.6

10.0

0.1

Vial
Size

0.1
20.0
19.2
2.0 g
Shake well until dissolved. The prepared solution may be further diluted to the desired volume with any of the “ Solutions
for IV Infusion” listed below.
Solutions for IV Infusion
0.9% Sodium Chloride Injection
5% Dextrose Injection
Dextrose and Sodium Chloride Injection
0.9% Sodium Chloride Injection in ADD-VANTAGE (Abbott) flexible diluent container, 50 mL and 100 mL
5% Dextrose Injection in ADD-VANTAGE (Abbott) flexible diluent container, 50 mL and 100 mL.
Pharmacy Bulk Package Reconstitution for Preparation of Intravenous Infusion Solutions
The closure of the pharmacy bulk vial shall be penetrated only one time after reconstitution, using a suitable sterile transfer
device or dispensing set which allows measured dispensing for the contents.

Vial
size

Volume to be
added to vial
mL

Approximate
available volume
mL

Approximate
average concentration
g/mL

10 g

95

100.0

0.1

Shake well until dissolved. Withdraw the required amount and dilute with one of the “Solutions for IV Infusion” . Any
unused solution remaining within a period of 8 hours should be discarded.
Stability of Solutions - Storage
For complete stability and storage information, consult the Product Monograph.
Incompatibility:
Rocephin® should not be physically mixed with other antimicrobial agents.
Rocephin® should not be added to blood products, protein hydrolysates or amino acids.
Rocephin® should not be added to solutions containing calcium.
DOSAGE FORM
Availability:
1.Rocephin® Vials containing sterile powder equivalent to 0.25 g, 1 g and 2 g of ceftriaxone.
2. Rocephin® Vials containing sterile powder equivalent to 1 g and 2 g of ceftriaxone for use only with Abbott Laboratories
Limited ADD-VANTAGE (Abbott) 0.9% Sodium Chloride Injection U.S.P. or 5% Dextrose Injection U.S.P. in 50 mL and
100 mL containers.
3. Rocephin® Pharmacy Bulk Vials containing sterile powder equivalent to 10 g ceftriaxone (not for direct administration).
The availability of the pharmacy bulk vial is restricted to hospitals with a recognized intravenous admixture programme.
Storage:
Rocephin® sterile powder should be stored at a controlled room temperature (between 15°and 30°C) and protected from
light.
Product Monograph available on request.
References:
1. Hell K. Chemotherapy 1989;35:228-235.2. Rocephin® Product Monograph.
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ORIGINAL ARTICLES

A.

Bilateral Central Dislocation of the Hip:
a Case Report
Patrick Kinnard, MD, FRCSC; Richard Lirette, MD, FRCSC
Bilateral central dislocation of the hip occurs rarely. The authors report a case in
which the patient was treated successfully by one-stage, bilateral, total hip
arthroplasty.
Une dislocation centrale simultanee des deux hanches est rare. Les auteurs
presentent un cas traite par prothese de hanches bilaterale en une seance
chirurgicale avec un excellent resultat.

imultaneous bilateral central
dislocation of the hip, which
occurs rarely, may be caused by
electric or convulsive therapy,1-4
epileptic seizures, convulsions sec
ondary to hyponatremia or low
magnesium and calcium levels after

S

parathyroidectomy5-7 and
brovascular accident.8

cere

Case Report
A 70-year-old woman was admit
ted to the Centre Hospitalier de

l’Universite Laval with pain in both
legs following severe convulsions
that occurred 2 weeks after she
underwent a hysterectomy. The
convulsions were caused by hypona
tremia, which was induced by inap
propriate secretion of the antidiu
retic hormone.
Radiography demonstrated bilat
eral, central, hip dislocation. The
pelvic rings were intact on the right
side and disrupted on the left.
The severity of the pain, despite
bilateral traction, necessitated a
one-stage, bilateral, total hip ar
throplasty under general anesthe
sia. After reduction and fixation of
the left pelvic ring, a screw-ring
acetabular prosthesis and a stan
dard cemented femoral stem were
inserted on each side (Fig. 1).
During the 3.5-hour operation
blood loss was 850 mL. There were
no postoperative complications, and
the patient was allowed to walk
with crutches, with no weight bear
ing on the left side for 6 weeks.
Eighteen months after surgery,
the patient was able to walk with
out pain or limp; she occasionally
used a cane when she experienced
discomfort but had resumed all her
preoperative activities.

Discussion

y

FIG. 1. Pelvis 1 year postoperatively.
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The mechanism of injury in bilat
eral central hip dislocation is both
complex and controversial.57 It
seems likely that the uncontrolled,
simultaneous, violent contraction of
the pelvitrochanteric muscles gener
ates sufficient force to fracture the
acetabular floor and dislocate the
femoral head centrally.57 The symC JS, V O L . 34, N O . 1, F E B R U A R Y 1991
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ANTIBIOTIC
metric nature of the contractions
may account for the bilaterality of
the injury.
All patients with this injury re
ported in the literature were treated
by traction and bed rest2' 7 to
achieve bone union, which ensued
successfully in most cases. If posttraumatic arthritis developed, elec
tive total hip replacement was per
formed.
In patients with subacute or
chronic fracture-dislocation of the
hip, a two-stage operation may be
preferable, first creating an ade
quate acetabulum .9
For our patient, a one-stage, bi
lateral, total hip arthroplasty was
indicated because she was in severe
pain. The one-stage procedure alle
viated much of her pain, allowing a
more comfortable recovery without
complications.

A C T IO N
In vitro studies demonstrate that the bactericidal
action of cefoxitin, a cephamycin derived from
cephamycin C, results from the inhibition of
bacterial cell wall synthesis. Evidence suggests
that the methoxy group in the la position is
responsible for the resistance of cefoxitin to
degradation by bacterial beta-lactamases.
IN D IC A T IO N S A ND C L IN IC A L USES
TREATMENT

The treatment of the following infections when
due to susceptible organisms:
1 - Intra-abdominal infections such as peritonitis
and intra-abdominal abscess
2 - Gynecological infections such as endo
metritis and pelvic cellulitis
3 - Septicemia
4 - Urinary tract infections (including those
caused by Serratia marcescens and Serratia
spp.)
5 - Lower respiratory tract infections
6 - Bone and jo in t in fe ctio n s caused by
Staphylococcus aureus
7 - Soft tissue infections such as cellulitis,
abscesses and wound infections
Appropriate culture and susceptibility studies
should be performed to determine the susceptib ilit y o f the c a u s a tiv e o rg a n is m (s ) to
MEFOXIN®. Therapy may be started while
awaiting the results of these tests, however,
modification of the treatment may be required
once these results become available.
Organisms particularly appropriate for therapy
with MEFOXIN® are:
Gram positive
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Staphylococci, penicillinase producing and
non-producing
Streptococci excluding enterococci

Gram negative (beta-lactamase producing and
non-producing strains)

Escherichia coli
Klebsiella species (including K. pneumoniae)
Proteus, indole positive and negative
Haemophilus influenzae
Providencia species
Anaerobes

Bacteroides fragilis
MEFOXIN® may also be appropriate for the
treatment of infections involving susceptible
strains of both aerobic and anaerobic bacteria.
MEFOXIN® is not active against Pseudomonas
spp., most strains of enterococci, many strains
of Enterobacter cloacae, and m eth icillin r e s is ta n t s ta p h y lo c o c c i and L i s t e r i a
monocytogenes.
C linical experience has demonstrated that
MEFOXIN® can be administered to patients who
are also receiving carbenicillin, gentamicin,
tobramycin, or amikacin (see PRECAUTIONS
and ADMINISTRATION).
PROPHYLACTIC USE

MEFOXIN® may be administered perioperatively (preoperatively, intraoperatively and postoperatively) to patients undergoing vaginal or
abdominal hysterectomy and abdominal surgery
when there is a significant risk of postoperative
infection or where the occurrence of post
operative infection is considered to be especially
serious.
In patients undergoing cesarean section, intra
operative (after clamping the umbilical cord)
and postoperative use of MEFOXIN® may
reduce the incidence of surgery related post
operative infections.

®Trademark Merck & Co., Inc.
Merck Frosst Canada Inc., R.U.

Effective prophylactic use depends on the time
of administration. MEFOXIN® usually should be
given one-half to one hour before the operation.
Prophylactic administration should usually be
stopped within 12 hours. It has been generally
reported that continuing administration of any
antibiotic beyond 24 hours following surgery
increases the possibility of adverse reactions
but, in the majority of surgical procedures, does
not reduce the incidence of subsequent
infection.
If signs of postsurgical infection should appear,
specimens for culture should be obtained for
identification of the causative organism(s) so
that appropriate treatment may be instituted.
C O N T R A IN D IC A T IO N S
MEFOXIN® is contraindicated in persons who
have shown hypersensitivity to cefoxitin or to
the cephalosporin group of antibiotics.
W ARNING S
Before therapy with MEFOXIN® is instituted,
careful inquiry should Be made to determine
whether the patient has had previous hyper
sensitivity reactions to MEFOXIN®, cepha
losporins, penicillins or otherdrugs. MEFOXIN®
should be given with caution to penicillinsensitive patients.
There is some clinical and laboratory evidence
of partial cross-allergenicity between cephamycins and the other beta-lactam antibiotics,
penicillins and cephalosporins. Severe reactions
(including anaphylaxis) have been reported
with most beta-lactam antibiotics.
Pseudomembranous colitis has been reported
w ith v ir tu a lly all a n tib io tic s in c lu d in g
MEFOXIN®. This colitis can range from mild to
life threatening in severity. Antibiotics should
therefore be prescribed with caution in indi
viduals with a historyof gastrointestinal disease,
particularly colitis. It is important to consider a
diagnosis of pseudomembranous colitis in
patients who develop diarrhea in association
with antibiotic use. While studies indicate that a
toxin produced by Clostridium difliciie is one
primary cause of antibiotic-associated colitis,
other causes should also be considered.
Any patient who has demonstrated some form of
allergy, particularly to drugs, should receive
antibiotics including MEFOXIN® with caution.
If an allergic reaction to MEFOXIN® occurs,
adm inistration of the drug should be dis
continued. Serious hypersensitivity reactions
may require treatment with epinephrine and
other emergency measures.
P R E C A U TIO N S
The total daily dosage should be reduced when
MEFOXIN® is administered to patients with
transient or persistent reduction of urinary
output due to renal insufficiency (see DOSAGE
AND ADMINISTRATION) because high and
prolonged serum antibiotic concentrations can
occur from usual doses.
In patients treated with MEFOXIN® a false
positive reaction to glucose in the urine may
occur with Benedict’s or Fehling's solutions but
not with the use of specific glucose oxidase
methods.
Using the Jaffe Method, falsely high creatinine
values in serum may occur if serum concen
trations of cefoxitin exceed 100 pg/mL. Serum
samples from patients treated with MEFOXIN®
should not be analyzed for creatinine if with
drawn within two hours of drug administration.
High concentrations of cefoxitin in the urine
may interfere with measurement of urinary 17hydroxy-corticosteroids by the Porter-Silber
reaction, and produce false increases of modest
degree in the levels reported.
Increased nephrotoxicity has been reported
fo llo w in g co n co m ita n t a d m in istra tio n of
cephalosporins and aminoglycoside antibiotics.
Prolonged use of MEFOXIN® may result in the
overgrowth of non-susceptible organisms.
Repeated evaluation of the patient's condition is
essential and if super-infection occurs during
therapy, appropriate measures should be taken.
Should an organism become resistant during
antibiotic therapy, another antibiotic should be
substituted.

Use in Pregnancy
The safety of MEFOXIN® in the treatment of
infections during pregnancy has not been
established. If the administration of MEFOXIN®
during pregnancy is considered necessary, its
use requires that the anticipated benefits be
weighed against possible hazards to the fetus.
Reproductive and teratogenic studies have been
performed in mice and rats and have revealed no
evidence of impaired fertility or harm to the fetus
due to MEFOXIN®.
There are no controlled studies in pregnant
women.
Nursing Mothers
Cefoxitin is excreted in human milk. Caution
should be exercised if use is indicated.
Children
In children 3 months of age or older, higher
doses of MEFOXIN® (100 m g /kg /d a y and
above) have been associated with an increased
incidence of eosinophilia and elevated SGOT.

ADVERSE REACTIONS
MEFOXIN® is generally well tolerated. Adverse
reactions rarely required cessation of treatment
and usually have been mild and transient.
Local Reactions
Throm bophlebitis has occurred with intra
venous administration. Some degree of pain and
tenderness is usually experienced after intra
muscular injections using water. Induration has
occasionally been reported.
Allergic
M a cu lo p a p u la r rash, u rtic a ria , p ru ritu s ,
eosinophilia, fever and other allergic reactions
including anaphylaxis have been noted.
Gastrointestinal
Symptoms of pseudomembranous colitis can
appear during or after antibiotic treatment.
Nausea and vomiting have been reported rarely.
Blood
Eosinophilia, leukopenia, neutropenia, hemo
lytic anemia, and thrombocytopenia and bone
marrow depression have been reported. Some
individuals, particularly those with azotemia,
may develop positive direct Coombs tests
during therapy with MEFOXIN®.
Liver Function
Transient elevations in SGOT, SGPT, serum
LDH, and serum alkaline phosphatase and
jaundice have been reported.
Cardiovascular Function
Flypotension.
Renal Function
Elevations in serum creatinine and/or blood
urea nitrogen levels have been observed. As
with the cephalosporins, acute renal failure has
been reported rarely. The role of MEFOXIN® in
changes in renal function tests is difficult to
assess, since factors predisposing to prerenal
azotemia or to impaired renal function have
often been present.

TREATMENT OF OVERDOSE
Other than general supportive treatment, no
specific antidote is known. MEFOXIN® can be
eliminated by dialysis in patients with renal
insufficiency.

DOSAGE AND ADMINISTRATION
MEFOXIN® may be administered intravenously
or intramuscularly as required. (See complete
m on o g ra ph on A D M IN IS T R A T IO N and
RECONSTITUTION.)
Intravenous Administration
The intravenous route is preferable for patients
with bacteremia, bacterial septicemia, or other
severe or life-threatening infections, or for
patients who may be poor risks because of
lowered resistance resulting from such debili
tating conditions as m alnutrition, trauma,
surgery, diabetes, heart failure, or malignancy,
particularly if shock is present or impending.
TREATMENT DOSAGE
Adults
The usual a d u lt dosage is 1 g or 2 g of
MEFOXIN® every 6 to 8 hours. Dosage and
route of administration should be determined by

severity of infection, su sce p tibility of the
causative organisms, and condition of the
patient. The usual adult dosages are shown in
the Table below.
Usual Adult Dosage
Type of
infection

Daily
Dosage

Frequency
and Route

Uncomplicated
forms* of infections such as
pneumonia,
urinary tract
infection, soft
tissue infection

3-4 g

1 g every 6-8 h
I.V. or I.M.

Moderately
severe or severe
infections

6-8 g

1 g every 4 h
or
2 g every 6-8 h I.V.

Infections
commonly
needing antibiotics in higher
dosage (e.g. gas
gangrene)

12 g

2 g every 4 h
or
3ge ve
h I.V.

'Including patients in whom bacteremia is absent or
unlikely

Therapy may be started while awaiting the
results of susceptibility testing.
Antibiotic therapy for group A beta-hemolytic
streptococcal infections should be maintained
for at least 10 days to guard against the risk of
rheum atic fever or glom erulonephritis. In
staphylococcal and other infections involving a
collection of pus, surgical drainage should be
carried out where indicated.
Adults with Impaired Renal Function
MEFOXIN® may be used in patients w ith
reduced renal function but a reduced dosage
should be employed and it is advisable to
monitor serum levels in patients with severe
impairment.
In adults with renal insufficiency, an initial
loading dose of 1 g to 2 g should be given. After
a loading dose, the following recommendations
for maintenance dosage may be used as a guide:
MAINTENANCE DOSAGE OF
MEFOXIN® IN ADULTS
WITH REDUCED RENAL FUNCTION
RENAL
FUNCTION

DOSE

FREQ UENCY

50-30

1-2 g

every 8-12 h

29-10

1-2 g

every 12-24 h

Severe
impairment
Essentially
no function

A t p re se n t th e re is in s u ffic ie n t data to
recommend a specific dosage for children with
impaired renal function. However, if the adminis
tration of MEFOXIN® is deemed to be essential
the dosage should be m odified consistent with
the recommendations fo r adults (see Table
above).
PROPHYLACTIC USE
For prophylactic use, a three-dose regimen of
MEFOXIN® is recommended as follows:
Vaginal or abdominal hysterectom y and
abdominal surgery
2 g adm inistered in tra m u scu la rly or in tra 
venously just prior to surgery (approximately
one-half to one hour before initial incision).
The second and third 2 g doses should be
administered at 2-6 hour intervals after the
initial dose.
Cesarean Section
The first dose of 2 g should be administered
intravenously as soon as the umbilical cord has
been clamped. The second and third 2 g doses
should be given intravenously or intram us
cularly four hours and eight hours after the first
dose.

AVAILABILITY
MEFOXIN® is supplied as sterile powder in
boxes of 10 vials:
3356 Ca - 1 g cefoxitin as sodium salt
3357 Ca - 2 g cefoxitin as sodium salt
3548 Ca - 1 g c e fo xitin as sodium salt in
ADD-Vantage® vial
3549 Ca - 2 g ce fo xitin as sodium salt in
ADD-Vantage® vial
For full details on preparation and adminis
tration with ADD-Vantage® vials - please
consult Product monograph.
Storage
MEFOXIN® in the dry state should be stored
below 30°C . The d ry m ate ria l as w ell as
solutions tends to darken, depending on storage
conditions; product potency, however, is not
adversely affected.

PRODUCT MONOGRAPH AVAILABLE
ON REQUEST

CREATININE
CLEARANCE
mL/min

Mild
impairment
Moderate
impairment

In severe infections, the total daily dosage in
infants and children may be increased to
200 mg/kg, but not to exceed 12 g per day.
MEFOXIN® is not recommended for the therapy
of meningitis. If meningitis is suspected, an
appropriate antibiotic should be used.

9-5

0.5-1 g

every 12-24 h

<5

0.5-1 g

every 24-48 h

(342-a,11,90)

MSP
MERCK
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In patients undergoing hem odialysis, the
loading dose of 1 -2 g should be given after each
hemodialysis, and the maintenance dose should
be given as indicated in the Table above.
Neonates (Including Premature Infants), Infants
and Children (See WARNINGS for Neonates
under ADMINISTRATION in the com plete
monograph.)
Premature Infants
with Body Weights
Above 1500 g

20-40 mg/kg every 12 h I.V.

Neonates

01 week of age 20-40 mg/kg every 12 h I.V.
1- 4 weeks of age
20-40 mg/kg every 8 h I.V.
Infants

1 month to 2 years
of age

20-40 mg/kg every 6 h or
every 8 h I.M. or I.V.

Children

20-40 mg/kg every 6 h or
every 8 h I.M. or I.V.
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Lymphatic Fistula After Vascular
Reconstruction: a Case-Control Study
John L. Murphy, MD, FRCSC; C. William Cole, MD, FRCSC; Prudy M. White, RN;
Graeme G. Barber, MD, FRCSC; Adrien G. Bouchard, MD, FRCSC; Neil V. McPhail, MD, FRCSC;
Walter G. Waddell, MD, FRCSC, FACS; James L. Wellington, MD, FRCSC, FACS

A retrospective case-control study was carried out to assess the importance of
lymphatic fistulas that develop after vascular reconstruction and to determine the
risk factors associated with them. The authors compared 35 patients who had
lymphatic fistula after vascular reconstruction with 70 control patients, taken from
the same database. They found a significant difference between the two groups only
in age and indication for surgery: lymphatic fistulas were more likely to develop in
older patients and in patients who underwent aortobifemoral bypass for limb salvage
rather than for claudication (p < 0.05).
Une etude cas-temoins retrospective a ete menee pour etablir l’importance des
fistules lymphatiques qui surviennent a la suite de reconstructions vasculaires et
pour calculer les facteurs de risques qui en decoulent. Les auteurs ont compare 35
patients avec fistules lymphatiques suite a une reconstruction vasculaire avec 70
patients temoins, issus d’une meme banque de donnees. Ils n’ont trouve de
difference significative entre les deux groupes que par rapport a l’age et l’indication
pour la chirurgie: les fistules lymphatiques etaient plus frequentes chez les patients
plus ages et ceux qui ont subi un contournement aortobifemoral pour recuperation
d’un membre plutot que pour claudication (p < 0.05).

ymphatic fistula is an uncom
mon complication of surgery in
the groin but may be of importance
in certain circumstances, such as
after vascular reconstruction, par
ticularly when prosthetic material is
used. Lymphatic fistulas in this sit
uation have been said to heighten
the risk of graft infection,1 but, to
our knowledge, this hypothesis has
not been tested. The purpose of our
study was to assess the importance

L

of lymphatic fistulas occurring after
vascular reconstruction and to de
termine the risk factors associated
with them.

Methods
Review of a computerized data
base of vascular surgery patients
treated at the Ottawa Civic and
Ottawa General hospitals between

From the Division o f Vascular Surgery, Department o f Surgery, Ottawa Civic Hospital, Ottawa
Accepted fo r publication Dec. 27, 1989
Reprint requests to: Dr. C. William Cole, Division o f Vascular Surgery, Ottawa Civic Hospital,
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1982 and 1987 was used to identify
those with lymphatic fistula, de
fined in this study as clear, watery
drainage from a groin wound that
was present 7 or more days postoperatively. A control group was se
lected from the same database by
taking the nearest numbered record
of a patient with a groin wound
before and after each case of lym
phatic fistula. The majority of study
subjects were interviewed and ex
amined by one of us (J.L.M.), and
additional information was obtained
by a review of the hospital records.
Data were analysed by comparison
of the two groups using the x 2 test
with Yates’ correction and Stu
dent’s t-test when required.

Findings
Thirty-five patients satisfied the
criteria for inclusion in the study.
The demographic characteristics of
the two groups were comparable.
Patients with a lymphatic fistula
differed from control patients in two
important variables: age and indica
tion for surgery. Those with a lym
phatic fistula were older (Table I)
and had undergone surgery more
often for limb salvage than for
claudication (Table II).
Throughout the follow-up there
were no graft infections or pseudo-

LYMPHATIC FISTULA

aneurysms in either group (Table
III). During that time two graft
occlusions occurred in the fistula
group and six among the controls.
The causes of death in the fistula
group included myocardial infarc
tion (four patients), carcinoma
(four), stroke (three) and others
(three); no death was attributed to a
graft complication. Other factors
that may have influenced wound
healing and perhaps contributed to
the development of a lymphatic fis
tula were diabetes (seven patients),
renal failure (two), steroid therapy

(two) and repeat surgery that in
volved a previous groin incision
(six).
Cultures of the lymphatic drain
age were positive in 8 of the 35
patients with a lymphatic fistula
(Table IV). However, only two had
clinically apparent superficial
wound infections; one infection de
veloped after a lymphocele was as
pirated. These infections resolved
with intravenous antibiotic therapy,
and there were no long-term seque
lae.
Drainage from the fistula persist

Table 1. Demographic Characteristics of 35 Patients With Lymphatic Fistula and 70 Control
Patients
Group
Patients

Fistula

Mean age, yr
Sex, M:F
Smokers, no.
Diabetics, no.

69.9
31:4
31
7 (all men)

Control

p value

63.4
51:19
57
14

< 0.05*
NS
NS
NS

*Two-tailed Student’s f-test.
Table II. Indication for Operation and Type of Reconstruction
Group
Indication/procedure
Aneurysm
Aortobifemoral bypass
Occlusive disease
Claudication
Aortobifemoral bypass
Limb salvaget
Aortobifemoral bypass
Femorofemoral bypass
Femoropopliteal bypass
Femorotibial bypass
Axillofemoral bypass
Other

Fistula

Control

13

14

p value
NS
< 0 .0 1 *

2

24

4
1
8
2
5
1

32
—
—
—
—

—

* x 2 with Yates’ correction.
tOne patient had aortobifemoral and femoropopliteal bypass.

ed for an average of 28 days and
resulted in prolonged hospital stay
in most cases, but no other prob
lems arose over a follow-up that
averaged more than 3 years. The
management of all cases consisted
of bed rest and scrupulous wound
care together with continuous anti
biotic therapy; none had surgical
exploration.

Discussion
The findings from this study
show that lymphatic fistulas compli
cating vascular reconstructive sur
gery in the groin do not frequently
lead to graft infection. The impor
tance of a postoperative lymphatic
fistula in this group of patients may
therefore depend upon other fac
tors. It has been suggested that
distal foot lesions may allow micro
organisms to be transported to the
groin by way of lymph channels,
with resultant local contamination
and infection in a prosthetic graft.2
Graft infection was not seen in this
series, but the significance of distal
foot lesions can be appreciated
when 20 of the 22 patients with
occlusive disease had limb-threaten
ing ischemia compared with 32 of
the 56 control patients with occlu
sive disease (p < 0.01). The type of
reconstruction may also be a factor
in the development of a lymphatic
fistula: none of the control patients
in this study had popliteal or tibial
incisions compared with 10 patients

Table III. Outcome Over 5 Years
Group
Outcome

Fistula

Control

Follow-up, mo
Mean
Range
Positive culture, no.
Superficial infection, no.
Graft infection, no.
Anastomotic aneurysm, no.
Graft occlusion, no.
Death, no.
Lost to follow-up, no.

42.7
6-84
8
2
0
0
2
14
5

41.5
12-84
1
2
0
0
6
10
14

Table IV. Microorganisms Isolated From
the Groin of Eight Patients With Lymphatic
Fistula
Organism isolated
Staphylococcus
epidermidis
Pseudomonas aeruginosa
Enterococcus
Staphylococcus aureus
Escherichia coli
Mixed organisms

Number of
isolates
4
2
3
2
2
3
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with lymphatic fistula (Table II).
When taken together, these data
suggest that distal procedures asso
ciated with severe ischemic changes
are more likely to result in a lym
phatic fistula at the groin than
bypasses to the femoral artery for
proximal occlusive disease.
The incidence of lymphatic fistula
reported in the literature is incon
sistent and often not accompanied
by a clear definition of what is
meant by the term. In many groin
wounds lymph drainage occurs for
a short time and is not always
reported. In a recent multicentre,
prospective study of aneurysm sur
gery only three lymphatic fistulas
were noted in 367 groin anastomo
ses.3 This may represent under
reporting since another report of
423 groin wounds identified 27
cases of lymphatic fistula.4 In that
report, only 9 of 22 patients had
lymph drainage for more than 5
days.4 There is no widely accepted
definition of a lymphatic fistula and
little more agreement regarding its
importance. When clear lymph
drainage is abundant or when drain
age persists beyond the usual time
for a patient to be discharged from
hospital, most would agree that a
lymphatic fistula exists. The pres
ent study included only fistulas that
were present 7 or more days postoperatively, to distinguish them
from minor wound drainage that
may moisten a groin dressing in the
early postoperative period.
The management of lymphatic
fistula is the subject of considerable
controversy. All patients in this
series were treated nonoperatively,
but others have recommended a
more aggressive, surgical approach.
Kwaan, Bernstein and Connolly5
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compared operative and nonopera
tive management in a small series.
On the basis of one graft infection
in seven nonoperative cases com
pared with none in five managed
surgically, they concluded that op
erative treatment reduced hospital
stay and the risk of graft infection.
The present series is larger and the
follow-up longer. Our findings sup
port a contrary position: that non
operative therapy has a low inci
dence of infectious complications
and most fistulas will respond with
out operative intervention. Surgery
may be required for fistulas drain
ing very large volumes of lymph or
those that fail to respond to nonop
erative management. The nature of
the microorganisms present in a
groin wound infection largely deter
mines the consequences. Arteries
infected with Staphylococcus au
reus or gram-negative organisms,
or both, more often result in disrup
tion than arteries infected with Sta
phylococcus epidermidis.6 The or
ganisms cultured from the draining
lymph in the cases reported here
were more often S. epidermidis than
any other. It is possible that greater
contamination with a more virulent
organism such as Pseudomonas sp.
would have resulted in a much
different outcome. No correlation
was noted between culture results
and the presence of open or infected
foot lesions. However, the observa
tion that a lymphatic fistula oc
curred more often in patients oper
ated upon for limb salvage may be
of more than passing importance.
Many patients with severe ischemia
present with edema in the affected
part, which is due mainly to two
causes: first, with severe ischemia
patients keep the limb in a position

of dependency, even at rest, which
results in clinically apparent edema;
second, ischemic tissues lose the
integrity of cell membranes and
leak fluid into the interstitium.
Postoperatively, this results in a
greater volume of lymph flow
through channels in the groin that
have a reduced capacity as a result
of the surgical procedure.
Important risk factors predispos
ing to the development of a lym
phatic fistula in the groin were
advanced age and surgery for limb
salvage. A consequence of this com
plication was prolonged hospital
stay, but the clinical course and
outcome were not otherwise influ
enced.
We thank David Moher, Department of
Research, for statistical support and
assistance with study design, and Lise
Fournier for follow-up of patients.
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Directives aux auteurs
Le Journal canadien de chirurgie prendra en consideration les manuscrits d’articles originaux consacres a la
recherche clinique, a la technique chirurgicale ou a l’histoire de la chirurgie, des revues generates, un nombre
restreint d’observations cliniques, des editoriaux et des lettres. Les manuscrits, en frangais ou en anglais, doivent
etre adresses, en triple exemplaire, aux redacteurs scientifiques, Journal canadien de chirurgie, CP 8650,
Ottawa, ON K1G 0G8.
Dans la lettre d’accompagnement, l’auteur doit declarer que le manuscrit n’a pas ete publie auparavant et qu’il
n’a ete soumis a la consideration d’aucun autre journal. Les auteurs doivent y joindre une autorisation signee
par les personnes citees sous la rubrique des remerciements ou dans le materiel d’illustration. Les auteurs
doivent devoiler tout interet commercial qu’ils pourraient avoir en rapport avec le sujet de l’etude, ainsi que
l’origine de tout appui materiel ou commercial.

Organisation du manuscrit
Le style doit se conformer aux «Recommandations aux auteurs pour des manuscrits devant etre soumis a des
revues biomedicales# (Can Med Assoc J 1991 Mar 15; 144(6), Br Med J 1991 Feb 9; 302(6772) et N Engl J Med
1991; 324 : 424-428).
Les noms des auteurs doivent apparaitre sur la page de titre, de meme qu’a l’endos de chaque jeu
d’illustrations. Les remerciements sont portes sur un feuillet separe, non pagine, a la suite de la bibliographic.
Pour faciliter la correction et la revision sur support electronique, toutes les pages (page de titre, resume,
texte, remerciements, bibliographic, figures, legendes et tableaux) doivent etre dactylographies en double
interligne, en caracteres de 10 points de qualite lettre, sans justification de la marge de droite ou espacement
proportionnel. Les manuscrits ne doivent pas etre imprimes en mode brouillon d’une imprimante a matrice.
Pour tout manuscrit, les auteurs doivent soumettre un original et deux photocopies de bonne qualite, ou deux
impressions supplementaires du texte et des tableaux, et trois copies pretes a la reproduction photographique
des figures.
Pour les observations cliniques, il n’est pas necessaire de rapporter une anamnese detaillee avec les resultats
de l’examen physique courant. Les resultats negatifs ou normaux ne doivent etre mentionnes que s’ils sont
essentiels a l’exclusion d’un diagnostic possible. II suffit d’etablir les raisons qui ont contribue au diagnostic ou
au traitement. L’evolution clinique doit etre decrite succinctement et les observations ou evenements importants
doivent etre rapportes avec suffisamment de details pour en etablir la credibilite. La bibliographie doit se limiter
au soutien du point que l’on veut faire ressortir quant a l’evenement ou a l’observation.
Des resumes sont exiges pour les articles de revue, ceux sur l’histoire, ainsi que pour les observations
cliniques; ils ne sont pas requis pour les articles sur les techniques chirurgicales ou pour les editoriaux. Les
resumes doivent etre brefs mais, neanmoins, detailles (de 60 a 150 mots).
La bibliographie doit etre etablie numeriquement, selon l’ordre d’apparition dans le texte. Les references citees
dans les tableaux sont numerotees d’apres l’ordre de la premiere mention du tableau dans le texte. Le style
adopte pour la bibliographie est celui qui est utilise dans ce numero du Journal.
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Les figures en couleur sont a la charge de l’auteur. II lui faudra fournir une diapositive et deux cliches couleur
de chacune des figures.
Si le manuscrit est fourni sur disquette, en plus de la copie dactylographiee, veuillez preciser l’appareil de
traitement de texte et le logiciel utilises. Nous revisons les textes a l’aide d’un appareil a traitement de texte
compatible avec le systeme IBM (WordPerfect 5.1, 5.0 ou 4.2) et nous ne pouvons corriger des disquettes qui ne
sont pas compatibles.
Le processus de prise en charge du manuscrit, la revue critique et la decision redactionelle prennent environ 8
semaines. L’original d’un manuscrit non retenu sera retourne aux auteurs; les copies seront detruites.
Les manuscrits retenus pour publication recevront les corrections necessaires pour les rendre conformes au
style du JCC, ainsi que pour la grammaire, la syntaxe et la ponctuation, de meme que toute correction
qu’exigerait la comprehension du texte. L’auteur designe recevra une copie de la version revisee ou une epreuve
d’imprimerie; il aura la responsabilite d’obtenir l’assentiment de ses co-auteurs pour les changements.
On s’attend a ce que les auteurs signent un document cedant leurs droits au JCC. Les manuscrits retenus
deviennent la propriete permanente de l’AMC et ne peuvent etre publies ailleurs, en tout ou en partie, sans
l’autorisation ecrite de l’editeur. Les tires a part sont disponibles sur commande et peuvent etre distribues selon
les desirs de l’auteur.B
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Lactose free

5-aminosalicylic acid

5-Aminosalicylic Acid
lEnteric Coated Tablets
^PHARMACOLOGICAL CLASSIFICATION
Lower Gastrointestinal Anti-inflammatory
v ACTIONS AND
. CLINICAL PHARMACOLOGY
5-aminosalicylic acid (5-ASA) is considered
''t o be the active component of sulfasalazine.
►
Although its mode of action has not been
. definitely elucidated, 5-ASA is thought to
have a topical anti-inflammatory effect which
is produced by inhibition of prostaglandin
and/or leukotriene synthesis.
Mesasal™ tablets have an acrylic based resin
coating which is specifically designed to
‘ release 5-ASA in the terminal ileum and
- colon. Urinary recovery studies have shown
_ that 35% of the 5-ASA is absorbed. The
absorbed 5-ASA is rapidly acetylated and
excreted mainly by the kidney.
Detectable plasma levels of 5-ASA were
. seen 4 hours after a single oral dose of
tablets (2 x 250 mg). Peak plasma levels
of 5-ASA and l\l-acetyl-5-ASA were 1.2
•and 1.9 pg/mL, respectively, and occurred
,6.5 - 7 hours post-dosing. Mean steadystate plasma levels of 5-ASA and
N-acetyl-5-ASA using a 500 mg t.i.d.
- dosage schedule are 0.7 and 1.2 pg/mL,
^respectively.
Except for a delay of 1.5 - 3 hours in time to
peak of 5-ASA and N-acetyl-5-ASA plasma
levels, Mesasal™ pharmacokinetics are
^essentially the same in fasted and fed
subjects.
INDICATIONS
. Mesasal™ (5-aminosalicylic acid) tablets are
indicated in the management of acute
ulcerative colitis, and for the prevention of
relapse of active ulcerative colitis.

CONTRAINDICATIONS
Mesasal™ (5-aminosalicylic acid) is
contraindicated where there is a history of
hypersensitivity to salicylates.
Mesasal™ is contraindicated in cases of
hemorrhagic diathesis.
Mesasal™ is contraindicated in patients with
existing gastric and duodenal ulcers.
Mesasal™ is contraindicated in patients with
urinary tract obstruction.
WARNINGS
In cases of severe liver and kidney disorders,
caution should be exercised.
U se in P regnancy:

In the first three months of pregnancy,
treatment is recommended only if potential
benefits outweigh the possible risks.
P e d iatric Use:

There is no experience with respect to the
use of this drug in children; potential
benefits should be weighed against possible
risks.
PRECAUTIONS
D rug Interaction s:

The blood-sugar reducing effect of sulfonyl
ureas may be enhanced. Interactions with
coumarins, methotrexate, probenecid,
sulfinpyrazone, spironolactone, furosemide
and rifampicin cannot be excluded.
Potentiation of undesirable glucocorticoid
effects on the stomach is possible.
In long term therapy, periodic urinalysis
should be conducted. Caution should be
exercised when therapy is first initiated in
patients known to be allergic to
sulfasalazine.
ADVERSE REACTIONS
In controlled clinical trials in 395 patients
who received 5-ASA, the following adverse
reactions were reported: headache (3.04%),

BECAUSE IN 5-ASA
THERAPY, THE DIFFERENCE
IS THE DELIVERY MECHANISM
nausea (2.03%), abdominal pain (1.52%),
and diarrhea (1.52%). Other adverse effects
common to salicylates, including
hypersensitivity reactions, may be expected
to occur rarely. There have been a few
spontaneous reports of pancreatitis, acute
and chronic interstitial nephritis and
pericarditis, associated with 5-ASA therapy.
SYMPTOMS AND
TREATMENT OF OVERDOSAGE
There is no specific antidote. Gastric lavage
should be employed, followed by promotion
of diuresis by the intravenous infusion of an
electrolytic solution.
DOSAGE AND ADMINISTRATION
During the acute inflammatory stage and in
long-term maintenance therapy, Mesasal™
(5-aminosalicylic acid) must be taken
reliably and consistently by the patient in
order to ensure therapeutic success.
Although symptomatic relief may be seen as
early as three to twenty-one days, therapy
should be continued depending on clinical
findings.
The following dosage regimens are
recommended:
A d u lts

Tablets: For the management of acute
ulcerative colitis: 1.5 g to 3 g daily in
divided doses. For prevention of relapses
of acute ulcerative colitis: 1.5 g daily in
divided doses.
AVAILABILITY AND STORAGE
T ab le ts

Mesasal™ enteric coated tablets, 250 mg
and 500 mg, are available in amber glass
bottles of 100 tablets. Mesasal™ tablets
should be swallowed whole before meals
with plenty of fluid.

BOOK REVIEWS

ATLAS OF ORTHOPAEDIC PA
THOLOGY. Lester E. Wold, Richard
A. McLeod, Franklin H. Sim et al.
Atlases in Diagnostic Surgical Pathol
ogy series; editor, Gerald M. Bordin.
276 pp. Illust. W.B. Saunders Compa
ny, London/Harcourt Brace Jovanovich, Inc., Philadelphia; HBJ-HoltSaunders Distribution Services, To
ronto. 1990. Price not stated. ISBN 0 7 2 1 6 -2 9 1 1 -3

This atlas is one of a proposed series
relating to specific, well-defined areas of
specialty pathology. It has been pre
pared by four staff members of the
Mayo Clinic — two pathologists, a
radiologist and an orthopedic surgeon
who has a specific interest in orthopedic
oncology.
The book is well organized into
seven sections, each section being clear
ly defined by the common factor of the
cell or origin of the lesions to be
discussed. Thus, section one is on os
teoid-forming lesions, section two on
cartilage-forming lesions, section three
on fibrous lesions, and so on. This
allows for a speedy reference to lesions
of similar origin. Each tumour or tumour-like condition within each section
is given a short chapter, which begins
with a brief discussion of the incidence
of the lesion, signs and symptoms,
major radiographic features, differential
diagnosis and the histology. The intro
duction is followed by lavishly illustrat
ed examples of the gross and micro
scopic appearances, including radio
graphs and some clinical photographs.
The illustrations are superb.
This textbook sets out admirably to
accomplish its goal. For the practising
surgeon, it is an excellent reference for
the pathologic features of malignant
and benign musculoskeletal tumours.
Unfortunately, it is restricted in its
scope to tumour pathology, so that
many important pathological conditions
affecting the musculoskeletal system
are ignored. The text therefore is mis
named — it is not an atlas of orthope
dic pathology but an atlas of tumours
and tumour-like conditions of bone and
connective tissue.
Despite this shortcoming it remains
an excellent reference text for practis
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ing surgeons and surgical trainees. It
will prove invaluable for orthopedic sur
geons in training in improving their
understanding and knowledge of these
relatively uncommon conditions and
will greatly assist them in formulating
differential diagnoses based upon the
clinical and radiographic presentation of
these lesions.
James P. Waddell, MD, FRCSC
Surgeon-in-chief
Division of Orthopedics
St. Michael’s Hospital
Toronto, ON
M5B 1W8

METABOLIC BONE DISEASE AND
CLINICALLY RELATED DISOR
DERS. 2nd ed. Edited by Louis V.
Avioli and Stephen M. Krane. 912 pp.
Illust. W.B. Saunders Co./Harcourt
Brace Jovanovich, Inc. Philadelphia.
1990. $240. ISBN 0 -7 2 1 6 -2 7 6 6 -8

Readers should first be aware that the
reviewer of this book is an orthopedic
surgeon: this review is therefore from
the point of view of an orthopedic
surgeon, and a senior one at that.
This text first appeared in two vol
umes in 1977 and 1979. This second
edition, now one volume, attempts “to
present a correlated view of metabolic
bone disease and related topics, stress
ing the relationship between genetics,
molecular biology, biochemistry, pa
thology, and clinical syndromes, in a
single volume.” The editors appear to
have accomplished their goals by pro
ducing a relatively compact book of just
under 1000 pages which, nevertheless,
covers a frequently poorly understood
group of bone diseases, including os
teopetrosis, osteogenesis imperfecta,
Gaucher’s disease and sarcoidosis, as
well as female osteoporosis syndrome,
osteomalacia, renal osteodystrophy and
hyperparathyroidism. A chapter on met
abolic bone disorders in children is a
welcome addition, and one on tumours
of bone is perhaps justified, at least on
the basis of differential diagnosis.
The editors are professors of medi
cine, in St. Louis and Boston respec

tively, and they have put together con
tributions from 40 authors, almost ex
clusively North American. Interestingly,
the only “foreign” authors are from
Melbourne, Australia, and they have
contributed the chapter on a Canadian
discovery, calcitonin.
Two features are immediately evi
dent: the relative paucity of illustrations
(which presages a large amount of solid
reading) and the very extensive refer
ence lists for each chapter. A quick
check for the least number of refer
ences revealed the chapter on hypercal
cemia of malignant disease (a useful one
for orthopedic surgeons) with 87; sever
al chapters contain over 500 references.
The index was put to the test on a
number of occasions and responded
consistently and with ease. Subjects
dear to the hearts of orthopedic sur
geons (alkaline phosphatase, myositis
ossificans, fractures in Paget’s disease)
were easily traced.
As a clinician, I found it difficult to
adjust to the scientific terminology
(dare I say jargon?), but after a chapter
or two it came with greater ease. As a
reader of English, I also had occasional
difficulty with words. “Solubilization”
tied my silent tongue, but it is in
Webster’s dictionary.
The book, therefore, is judged to be
an extensive compilation of current
knowledge in its field, and as such
should be a useful reference for those
physicians and surgeons clinically active
in the area of skeletal diseases and
injuries. Its subtitle “and Clinically Re
lated Disorders” is significant. It is not
simply a large tome on osteoporosis
with a number of exotic but rare diseas
es added. It includes conditions encoun
tered daily in orthopedic practice and is
broadened by inclusion of a wide group
of conditions as differential diagnoses.
At the list price of $240 it is unlikely
to grace the shelves of many personal
libraries but should be an essential
addition to all group-practice and medi
cal-centre libraries.
Kenneth S. Morton, MD, CM, FRCSC
Department of Orthopedics
3rd Floor
910 W 10th Ave.
Vancouver, BC
V5Z 4E3

BOOK REVIEWS

SHOULDER R EC O N ST R U C T IO N .
Charles S. Neer II. Illustrated by Rob
ert J. Demarest. 551 pp. Illust. W.B.
Saunders Company, London/Harcourt
Brace Jovanovich, Inc., Philadelphia;
HBJ-Holt-Saunders Distribution Ser
vices, Toronto. 1990. $165. ISBN 0 7 2 1 6 -2 8 3 2 -X

Shoulder surgery has attracted the in
terest of many orthopedic surgeons and
allied health professionals in the last
decade. Before then, this joint was
rarely the focus of any major discus
sion, and surgical treatment was offered
by only a few who had special interest
in that area. Dr. Neer became interested
in this joint early in his career. Stimu
lated by his teacher, Dr. Harrison
McLaughlin, Neer makes his vast expe
rience available to the reader in this
extensive book. In it he combines an
underlying pathologic condition with a

0Anaprox® DS 550 mg
^Anaprox® 275 mg
(naproxen sodium)
Indications:
Relief of mild to moderately severe pain, accompanied by
inflammation such as musculoskeletal trauma, post
dental extraction, relief of post-partum cramping and
dysmenorrhea.
Contraindications:
Anaprox and Anaprox DS (naproxen sodium) are contrain
dicated in patients, with active ulcers or active inflam
matory diseases of the gastrointestinal tract. They are
also contraindicated in patients who have shown hyper
sensitivity to it or to naproxen. Since cross-sensitivity
has been demonstrated, Anaprox or Anaprox DS should
not be given to patients in whom ASA or other non
steroidal anti-inflammatory drugs induce the syndrome
of asthma, rhinitis, or uticaria. Sometimes severe and
occasionally fatal anaphylactic reactions have occurred
in such individuals.
Warnings:
Peptic ulceration, perforation and gastrointestinal bleed
ing, sometimes severe and occasionally fatal, have been
reported during therapy with non-steroidal anti-inflam
matory drugs (NSAID's) including Anaprox and Anaprox
DS. Anaprox and Anaprox DS should be given under
close medical supervision to patients prone to gastroin
testinal tract irritation particularly those with a history of
peptic ulcer, diverticulosis or other inflammatory dis
eases of the gastrointestinal tract.
Patients taking any NSAID including this drug should
be instructed to contact a physician immediately if they
experience symptoms or signs suggestive of peptic ulcer
ation or gastrointestinal bleeding. These reactions can
occur without warning at any time during the treatment.
Elderly, frail and debilitated patients appear to be at
higher risk from a variety of adverse reactions from
NSAIDs. For such patients, consideration should be

clear indication for a procedure and
details the potential pitfalls.
The figures by Robert J. Demarest
are of high quality and vividly illustrate
Neer’s concepts from his earlier, wellknown articles. The figures are accom
panied by detailed anatomic drawings
and radiographs, outlining the individu
al pathologic conditions.
The anatomy of the shoulder region
and related conditions are described in
detail. A chapter on shoulder rehabilita
tion will be of interest to the orthopedic
surgeon and to all personnel involved in
restoring shoulder-girdle function.
The remaining five chapters focus on
all the common shoulder disorders. Cuff
lesions and impingements as well as
glenohumeral arthroplasty are covered,
reflecting the author’s long-time inter
ests. The chapter on fractures of the
shoulder clearly outlines the pathologic
concept and eventual outcome of any

fracture and its treatment. Neer de
serves the credit for creating a classifi
cation that has become the common
knowledge base for the treatment of
shoulder fractures.
An extensive collection of references
reflects the volume of Neer’s work and
will direct orthopedic surgeons to addi
tional topics of interest.
This book is a pleasure to read and a
necessity for any orthopedic surgeon
working in this field. Its clear concept
and excellent illustrations make it very
attractive for professionals in related
specialties such as rheumatology and
physical medicine.

given to a starting dose lower than usual. The safety
of Anaprox and Anaprox DS in pregnancy and lactation
has not been established and its use is therefore not
recommended.

for patients on chronic therapy. Caution should be exer
cised by patients whose activities require alertness if
they experience drowsiness, dizziness, vertigo or depres
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ing sites and may lead to drug interactions or interfere
with certain laboratory tests. See product monograph for
specific examples. The safety and efficacy of this drug in
children has not been established and its use in children
is therefore not recommended.
Adverse reactions:
Adverse reactions which occur in > 1 % of patients
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G.I.: heartburn, constipation, abdominal pain, nausea,
diarrhea, dyspepsia, stom atitis and diverticulitis.
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Special Senses: tinnitus and hearing disturbances.
Others: thirst.
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Precautions:
Anaprox or Anaprox DS (naproxen sodium) should not
be used concomitantly with the related drug Naprosyn®
(naproxen) since they circulate in plasma as the
naproxen anion.
G.l. system: If peptic ulceration is suspected or con
firmed, or if gastrointestinal bleeding or perforation occurs
Anaprox or Anaprox DS should be discontinued, and
appropriate treatment instituted. Renal effects: Patients
with impaired renal function, extracellular volume deple
tion, sodium restrictions, heart failure, liver dysfunction,
those taking diuretics, and the elderly, are at greater risk
of developing overt renal decompensation. Assessment
of renal function in these patients before and during
therapy is recommended. Naproxen sodium and its metab
olites are eliminated primarily by the kidneys, and there
fore, a reduction in daily dosage should be anticipated to
avoid the possibility of drug accumulation in patients
with significantly impaired renal function. Naproxen
sodium should not be used chronically in patients having
baseline creatinine clearance less than 20m l/m inute.
Peripheral edema has been observed, consequently,
patients with compromised cardiac function should be
kept under observation when taking Anaprox or Anaprox
DS. Each Anaprox tablet contains approximately 25 mg
of sodium and each Anaprox DS tablet contains approxi
mately 50 mg of sodium. This should be considered in
patients whose overall intake of sodium must be mark
edly restricted. As with other drugs used in the elderly or
those with impaired liver function it is prudent to use the
lowest effective dose. Severe hepatic reactions includ
ing jaundice and cases of fatal hepatitis have been
reported with NSAIDs. The prescriber should be alert to
the fact that the anti-inflammatory, analgesic and antipy
retic effects of Anaprox or Anaprox DS (naproxen sodium)
may mask the usual signs of infection. Periodic liver
function tests and ophthalmic studies are recommended

Joachim F. Lohr, MD, FRCSC
Assistant professor of surgery,
University of Ottawa,
Ottawa General Hospital,
Ottawa, ON
K1H 8L6
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NOTICES

Nursing Mothers

4

Studies performed in lactating rats have shown that
PEPCID® is secreted in breast milk. It is not known
whether this drug is secreted in human milk.
Nursing mothers should either stop this drug or
should stop nursing.

V

Pediatric Use

Safety and effectiveness in children have not been
established.
Use In Elderly Patients

No dosage adjustment is required based on age (see
HUMAN PHARMACOLOGY, Pharmacokinetics).

Congres annuel de l’Association
des chirurgiens genereux du Que
bec

L’Association des chirurgiens genereux
du Quebec tiendra son congres
annuel les jeudi et vendredi, 2 et 3 mai
1991 chez le Chateau Frontenac, Que
bec. Pour renseignements s’adresser au
secretariat de l’Association: (514) 3939179.

ADVERSE REACTIONS

Histamine H2 Receptor Antagonist
ACTIONS AND
CLINICAL PHARMACOLOGY
PEPCID* (famotidine) is a competitive inhibitor of
histamine Hr receptors. The primary clinically
important pharmacologic activity of PEPCID® is
inhibition of gastric ju ice secretion. PEPCID®
reduces the acid and pepsin content, as well as the
volume, of basal, nocturnal, and stimulated gastric
secretion.

INDICATIONS AND CLINICAL USE

Laparoscopic Cholecystectomy

The Department of Surgery, University
of Toronto, will be holding postgradu
ate courses in laparoscopic cholecystec
tomy for general surgeons, at the
Mount Sinai Hospital, Toronto, on the
following dates: Mar. 20 and 21, 1991;
Apr. 3 and 4, 1991; Apr. 17 and 18,
1991; May 1 and 2, 1991; May 15 and
16, 1991: May 29 and 30, 1991 and
June 26 and 27, 1991. (These dates
may be subject to change.) For further
information please contact: Dr. S.M.
Strasberg, Course director, Mount Sinai
Hospital, Rm. 1225, 600 University
Ave., Toronto, ON M5G 1X5; phone:
(416) 586-8420; fax: (416) 586-8392.

Gastrointestinal Surgery for Se
vere Obesity

A National Institutes of Health Consen
sus Development Conference on gas
trointestinal surgery for severe obesity
will be held from Mar. 25 to 27, 1991
in the Masur Auditorium, The Warren
Grant Magnuson Clinical Center, Na
tional Institutes of Health, Bethesda,
Md. For further information contact:
Conference registrar, Prospect Associ
ates, 1801 Rockville Pike, Ste. 500,
Rockville, MD 20852: phone: (301)
468-MEET; fax: (301) 770-5164.
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PEPCID® (famotidine) is indicated in the treatment
of the following conditions where a controlled
reduction of gastric secretion is required for ulcer
healing:
1. Treatment of acute duodenal ulcer;
2. Prophylactic use in duodenal ulcer;
3. Treatment of acute benign gastric ulcer;
4. Treatment of pathological hypersecretory
conditions (e.g., Zollinger-Ellison syndrome).
PEPCID® I V. is indicated in some hospitalized
patients with pathological hypersecretory con
ditions or intractable ulcers, or as an alternative to
the oral dosage forms for short-term use in patients
who are unable to take oral medication.

CONTRAINDICATIONS
H y p e rs e n s itiv ity to any com pone nt of this
medication.

PEPCID® (famotidine) is usually well tolerated;
most adverse reactions have been m ild and
transient. The adverse reactions listed below have
been reported during clinical trials in 2333 patients.
In those controlled clinical trials in which PEPCID®
was compared to placebo, the overall incidence of
adverse experiences in the group which received
PEPCID®, 40 mg at bedtime, was similar to the
placebo group. No antiandrogenic or other adverse
hormonal effects have been observed.
The following adverse reactions have been reported
at a rate of greater than 1% in patients on therapy
with PEPCID® in controlled clinical trials, and may
be causally related to the drug: headache (4.6%),
dizziness (1.2%), constipation (1.2%) and diarrhea

Gastrointestinal

8.0%

Nausea
Vomiting
Anorexia
Abdominal discomfort
Dry mouth

1.6%
0.9%
0.5%
0.3%
0.2%

Nervous System/Psychlatrlc

7.3%

Insomnia
Somnolence
Anxiety
Paresthesia
Depression
Libido decreased

0.6%
0.4%
0.3%
0.3%
0.2%
0.1%

Respiratory

Bronchospasm

4.4%

3.0%

Fatigue
Asthenia
Fever

0.6%
0.3%
0.2%

Musculoskeletal

1.7%

Musculoskeletal pain
Arthralgia

0.1%
0.1%

Drug Interactions

Skin

1.7%

Studies with famotidine in man, in animal models,
and in vitro have shown no significant interference
with the disposition of compounds metabolized by
the hepatic microsomal enzymes, e.g., cytochrome
P450 system. Compounds tested in man have
inclu d e d w a rfa rin , th e o p h y llin e , phenytoin,
diazepam, am inopyrine and antipyrine. Indo
cyanine green as an index of hepatic blood flow
and/or hepatic drug extraction has been tested and
no significant effects have been found.

Pruritus
Rash
Alopecia
Flushing
Acne
Dry skin

0.4%
0.3%
0.2%
0.2%
0.1%
0.1%

Use in Pregnancy

Reproductive studies have been performed in rats
and rabbits at oral doses of up to 2000 and
500 mg/kg/day, respectively (approximately 2500
and 625 times the maximum recommended human
dose, respectively), and have revealed no evidence
of impaired fertility or harm to the fetus due to
PEPCID®. There are, however, no adequate or wellcontrolled studies in pregnant women.
Since the safe use of PEPCID® in pregnant women
has not been established, the benefits of treatment
with PEPCID® should be weighed against potential
risks.

-r

<0.1%

Body as a Whole

Gastric malignancy should be excluded prior to
initiation of therapy of gastric ulcer with PEPCID®.
Symptomatic response of gastric ulcer to PEPCID®
therapy does not preclude the presence of gastric
malignancy.

V

( 1. 6% ) .

PRECAUTIONS

Use in Gastric Ulcer

-

Other reactions have been reported in clinical trials
but occurred under circumstances where a causal
relationship could not be established. However, in
these rarely reported events, that possibility cannot
be excluded. Therefore, these observations are
listed to serve as alerting information to physicians.

Patients with Severe Renal Insufficiency

Dosing intervals may need to be prolonged in
p a tie n ts w ith advanced renal in s u ffic ie n c y
(creatinine clearance <10 mL/min.) to adjust for the
longer elim ination half-life of famotidine. (See
CLINICAL PHARMACOLOGY and DOSAGE AND
ADMINISTRATION.)

4

Cardiovascular

1.0%

Palpitations

0.2%

Special Senses

0.9%

Taste disorder
Tinnitus
Orbital Edema

0.1%
0.1%
<0.1%

Urogenital

0.9%

The adverse reactions reported for PEPCID®
Tablets may also occur with PEPCID® I.V. In
addition, transient irritation at the injection site has
been observed with PEPCID® I.V.
Laboratory Abnormalities

Laboratory parameters may be affected during
treatment with PEPCID®, but the changes are
u su ally no t con sid ere d serious. Among the
laboratory changes that were reported during
clinical trials were increases in AST, ALT, BUN, and
serum creatinine. These changes were rarely of
clinical significance.

■s-
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Only three patients had to be discontinued from
therapy because of laboratory adverse experiences,
however laboratory abnormalities were present at
baseline.

Parenteral Products
Dilution of PEPCID® I.V.
for Infusion

SYMPTOMS AND TREATMENT
OF OVERDOSAGE
There is no experience to date with deliberate
overdosage. Doses of up to 640 mg/day have been
employed in patients with pathological hyper
secretory con d itio n s with no serious adverse
effects. In the event of overdosage, treatment
should be sym p tom a tic and supportive. U n
absorbed material should be removed from the
g a s tro in te s tin a l tra c t, the patient should be
m onitored, and supportive therapy should be
employed.
The oral LD50 of famotidine in male and female rats
and mice was >5000 mg/kg.

DOSAGE AND ADMINISTRATION
DUODENAL ULCER
Acute Therapy
The recommended adult oral dosage of PEPCID®
(famotidine) for acute duodenal ulcer is 40 mg once
a day at bedtime. Treatment should be given for
4-8 weeks, but the duration of treatment may be
shortened if healing can be documented. Healing
occurs within 4 weeks in most cases of duodenal
ulcer.
Maintenance Therapy
For the prevention of recurrence of duodenal ulcer,
it is recommended that therapy with PEPCID® be
continued with a dose of 20 mg once a day at
bedtime, for a duration of up to 6-12 months
depending on the severity of the condition.
BENIGN GASTRIC ULCER
Acute Therapy
The recommended adult oral dosage for acute
benign gastric ulcer is 40 mg once a day at bedtime.
Treatment should be given for 4 to 8 weeks, but the
duration of treatment may be shortened if healing
can be documented.
PATHOLOGICAL HYPERSECRETORY C O N 
D ITIO N S (SUCH AS ZOLLINGER-ELLISON
SYNDROME)
The do sage o f PEPCID® in p a tie n ts w ith
pathological hypersecretory conditions varies with
the individual patient. The recommended adult oral
starting dose fo r pathological hypersecretory
conditions is 20 mg q6h. In some patients, a higher
starting dose may be required.
Doses should be adjusted to individual patient
needs and should continue as long as clinically
indicated. Doses up to 160 mg q6h have been
ad m inistered to som e pa tie n ts w ith severe
Zollinger-Ellison syndrome.
Intravenous Administration
In some hospitalized patients with pathological
hypersecretory conditions or intractable ulcers, or
in patients who are unable to take oral medication,
PEPCID® I V. may be administered. The recom
mended dosage is 20 mg every 12 hours.
Intravenous injection therapy should be changed to
oral treatment as soon as the acute situation is
under control.
Concomitant Use with Antacids
Antacids may be given concomitantly if needed.
Dosage Adjustment for Patients with Severe Renal
Insufficiency
In patients with advanced renal insufficiency, i.e.,
with a creatinine clearance less than 10 mL/min.,
the elimination half-life of PEPCID® may exceed
12 hours reaching approximately 24 hours in anuric
patients.
To avoid excess accumulation of the drug, the
dosing interval of PEPCID® may be prolonged to
36-48 hours as indicated by the patient's clinical
response.

PHARMACEUTICAL INFORMATION
COMPOSITION
Tablets
Each tablet for oral administration contains either
20 mg or 40 mg of famotidine.
Injection
Each mL of the solution for intravenous injection
contains 10 mg of famotidine and the following
in a c tiv e in g re d ie n ts : L -a s p a rtic acid 4 mg,
mannitol 20 mg, and Water for Injection, q.s., 1 mL.
The multidose injectio n also contains benzyl
alcohol 0.9% added as preservative.

emptying and exocrine pancreatic function are not
affected by PEPCID®.

RECONSTITUTION

PEPCID® I.V.
Solution

V0I....3 ot
Compatible
I.V. Solution

Final
Volume

Final
Concentration

Rate of
Infusion

2 mL

3 mL

5 mL

4 m g /m L

N o t le s s t h a n

2 mL

8 mL

10 m L

2 m g /m L

N o t le s s th a n

2m L

100 m L

102 m L

0 .1 9 6 m g / m L

1 5 - 3 0 m in u t e s

2 m in u t e s

2 m in u t e s

PEPCID® I.V. Solutions are compatible with:
Water for Injection
0.9% Sodium Chloride Injection
5% Dextrose Injection
10% Dextrose Injection
Lactated Ringer's Injection
Sodium Bicarbonate Injection 5%
STABILITY AND STORAGE
RECOMMENDATIONS
PEPCID® I.V. Solution
Store at 2 - 8°C. Protect from light. If solution
freezes, bring the solution to room temperature;
a llo w s u ffic ie n t tim e to s o lu b iliz e a ll the
components.
Diluted PEPCID® I.V. Solutions should be used
within 24 hours due to the possibility of microbial
contamination during preparation.
NOTE: P are nteral d ru g p ro d u c ts sh o u ld be
inspected visually for particulate matter and
d is c o lo u ra tio n p rio r to a d m inistra tion
whenever solution and container permit.

DOSAGE FORMS AND AVAILABILITY
T a b le ts PEPCID® (fa m o tid in e ta b le ts ) are
D-shaped, film-coated tablets supplied as follows:
N o. Ca 8102 - 20 mg b e ig e c o lo u re d ,
coded 963. Available in bottles of 100 tablets.
No. Ca 8103 - 40 mg light brownish orange,
coded 964. Available in bottles of 100 tablets.
No. Ca 3539 - PEPCID® I.V., 10 mg per 1 mL, is a
clear, colourless solution and is available as a nonpreserved unit dose containing 2 mL of injectable
solution. Available in 10 x 2 mL vials.
No. Ca 3541 - PEPCID® I.V., 10 mg per 1 mL, is a
clear, colourless solution and is available as a
preserved m u ltip le dose c o n ta in in g 4 mL of
injectable solution. Available in 4 mL vials.

HUMAN PHARMACOLOGY
In both normal volunteers and hypersecretors,
PEPCID® inhibited basal nocturnal and daytime
gastric secretion, as well as secretion stimulated by
a variety of stimuli, such as pentagastrin and food.
After oral administration, the onset of the antisecretory effect occurred within one hour; the
maximum effect was dose-dependent, occurring
within one to three hours. Duration of inhibition of
secretion was 10 to 12 hours. After intravenous
administration, the maximum effect was achieved
within 30 minutes. Single intravenous doses of 10
and 20 mg inhibited basal nocturnal secretion fora
period of 10-12 hours. The 20 mg dose was
associated with the longest duration of action in
most subjects. Single oral doses of 20 and 40 mg
inhibited basal nocturnal acid secretion in all
subjects; mean gastric acid secretion was inhibited
by 86% and 94%, respectively, for a period of at least
10 hours. S im ilar doses given in the morning
suppressed food-stimulated acid secretion in all
subjects, with mean suppression of 76% and 84%,
respectively, 3 to 5 hours after drug, and of 25% and
30%, re spectively, 8 to 10 hours a fte r drug;
however, in some subjects who received the 20 mg
dose, the antisecretory effect was dissipated earlier,
within 6-8 hours. There was no cumulative effect
with repeated doses. The basal nocturnal intragastric pH was raised by evening doses of 20 and
40 mg of PEPCID® to mean values of 5.0 and 6.4,
respectively. When PEPCID® was given in the
morning, the basal daytime interdigestive pH at 3
and 8 hours after 20 or 40 mg of PEPCID® was
raised to about 5.0.
Fasting and postprandial serum gastrin levels may
be s lig h tly elevated d u rin g periods o f drug
antisecretory effect, and with chronic therapy an
increase in gastric bacterial flora may occur. Gastric

Other effects
Systemic pharmacologic effects of PEPCID® in the
CNS, cardiovascular, respiratory or endocrine
systems have not been found to date. Serum
prolactin levels do not rise after intravenous bolus
doses of 20 mg PEPCID® and no antiandrogenic
effects have been detected.
Pharmacokinetics
PEPCID® is incompletely absorbed. The bioavaila
bility of oral doses is 40-45%. Bioavailability may be
slightly increased by food, or slightly decreased by
acntacids; however, these effects are of no clinical
consequence. PEPCID® undergoes minimal firstpass metabolism. After oral doses, peak plasma
levels occu r in 1-3 hours. Plasma levels after
multiple doses are sim ilar to those after single
doses. Fifteen to 20% of PEPCID® in plasma is
protein bound. PEPCID® has an elimination half-life
of 2.5-3.5 hours. PEPCID® is eliminated by renal
(65-70%) and metabolic (30-35%) routes. Renal
clearance is 250-450 mL/m in., indicating some
tubular excretion.
Twenty-f ive to 30% of an oral dose and 65-70% of an
intravenous dose are recovered in the urine as
un changed co m p o u n d . The o n ly m e ta b o lite
identified in man is the S-oxide. There is a close
relationship between creatinine clearance values
and the elimination half-life of PEPCID®. In patients
w ith severe renal insufficiency, i.e., creatinine
clearance less than 10 mL/min., PEPCID® elim i
n a tio n h a lf- life m ay e xce e d 20 h o u rs and
adjustment of dosing intervals may be necessary
(see PRECAUTIONS, DOSAGE AND ADMINIS
TR A TIO N ). In e ld e rly patients, there are no
clinically significant age-related changes in the
pharmacokinetics of PEPCID®.

PRODUCT MONOGRAPH AVAILABLE
ON REQUEST
(320-a,9,87)
®Trademark Merck & Co., Inc./
Merck Frosst Canada Inc., R.U.
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CLASSIFIED ADVERTISING

As a further service to its readers the Canadian Journal o f Surgery is pleased to accept suitable classified advertisements. The deadline is 1
month before issue date. Regular classified rates (for each insertion): $55.00 for the first 40 words or less, additional words 70i£ each (additional
$21.00 for frame). Special Display under 100 words, 2>/s in X 2Vs in, $125.00. $15.00 charge (first insertion only) for CJS box numbers. Display
rates available on request. VISA, MASTERCARD AND AMERICAN EXPRESS ACCEPTED.
Copy should be mailed to the Canadian Journal o f Surgery, PO Box 8650, Ottawa, Ontario K1G 0G8.
Box replies should be addressed as follows: Box — , Canadian Journal of Surgery, PO Box 8650, Ottawa, Ontario K1G 0G8.

SURGICAL ONCOLOGIST

U n iv e rs ity o f M a n ito b a
D e p a rtm e n t o f S u rg e ry

T h e D e p a rtm e n t o f S urg e ry, F a c u lty o f M e d ic in e , U n ive rs ity o f M a n ito b a a n d th e H e a lth S c ie n c e s C e n tre a n d St. B o n ifa c e
G e n e ra l H o s p ita l a re s e e k in g a c o n tin g e n t g e o g ra p h ic a l fu ll-tim e s u rg ic a l o n c o lo g is t.
S p e c ific re s p o n s ib ilitie s in c lu d e :
C lin ic a l c a re in a d v a n c e d s u rg ic a l o n c o lo g y a n d la b o ra to ry o r c lin ic a l re s e a rc h ; te a c h in g u n d e rg ra d u a te a n d p o s tg ra d u a te
tra in e e s ; a n d a d m in is tra tiv e re sp o n s ib ilitie s .
C a n d id a te s m u s t h a v e s e n io r s p e c ia lty q u a lific a tio n s in g e n e ra l s u rg e ry in th e c o u n try o f c u rre n t p ra c tic e a n d m u s t be
e lig ib le fo r re g is tra tio n w ith th e C o lle g e o f P h ysicia n s a n d S u rg e o n s o f M a n ito b a . C e rtific a tio n in g e n e ra l s u rg e ry by th e
R o ya l C o lle g e o f P h y s icia n s a n d S u rg e o n s o f C a n a d a is p re fe rre d . A d d itio n a l c lin ic a l a n d /o r re se a rc h tra in in g in o n c o lo g y
is re q u ire d .
S a la ry a n d a c a d e m ic ra n k w ill b e c o m m e n s u ra te w ith e x p e rie n c e a n d q u a lific a tio n s .
T h e U n iv e rs ity o f M a n ito b a e n c o u ra g e s a p p lic a tio n s fro m q u a lifie d w o m e n a n d m e n , in c lu d in g m e m b e rs o f v is ib le
m in o ritie s , a b o rig in a l p e o p le , a n d p e rs o n s w ith d is a b ilitie s. T h e u n iv e rs ity p ro v id e s a s m o k e -fre e w o rk e n v iro n m e n t. In
a c c o rd a n c e w ith C a n a d ia n im m ig ra tio n re q u ire m e n ts , p rio rity w ill be g iv e n to C a n a d ia n c itiz e n s o r p e rm a n e n t re s id e n ts .
In te re s te d c a n d id a te s s h o u ld a p p ly, e n c lo s in g a c u rric u lu m v ita e in w ritin g to : Dr. R .J .W . B la n c h a rd , P ro fe s s o r a n d
H e a d , D e p a r tm e n t o f S u r g e r y , H e a lth S c ie n c e s C e n tr e , G C 4 1 1 -8 2 0 S h e rb ro o k S t., W in n ip e g , M a n ito b a ,
C A N A D A R 3A 1R 9.
A p p lic a tio n s w ill be a c c e p te d u n til th e p o s itio n is fille d .
—S9 1-44

HEAD
DIVISION OF PLASTIC SURGERY

Plastic
Surgeon

S unnybrook Health S cience Centre, a 1200 bed acute and
ch ro n ic fully affilitated hospital o f the U niversity o f Toronto,
and th e m ajor level one regional traum a unit fo r m etropolitan
T o ro n to and the University of Toronto, has initiated a search
fo r a Head of the Division of Plastic Surgery.

S u d b u r y G e n e ra l H o s p ita l, a 3 0 2 b e d
c o m m u n it y H o s p ita l a n d d e s ig n a te d tr a u m a
c e n tre f o r N o rth e a s te rn O n ta r io , re q u ire s a
s e c o n d P la s tic S u r g e o n .
A w id e s c o p e o f p r a c tic e is a v a ila b le
in c lu d in g c o s m e tic , h a n d , b u r n s a n d fa c ia l
t r a u m a s u rg e ry . S u d b u r y G e n e ra l is a w e ll
e q u ip p e d H o s p ita l w ith s o p h is tic a te d
d ia g n o s t ic a n d a ll s u p p o r t s e r v ic e s
U n d e r s e rv ic e d a re a g r a n ts a re a v a ila b le .
T h e S u d b u r y re g io n , w it h a p o p u la 
tio n o f 1 5 1 ,3 1 4 a n d to ta l c a tc h m e n t a re a o f
2 4 0 ,0 0 0 , is th e m a jo r c e n tre in N o rth e a s te rn
O n ta r io a n d o ffe r s an e x c e lle n t e n v ir o n m e n t
f o r f a m ily life p o s s e s s in g e x c e lle n t s u m m e r
a n d w in t e r re c r e a tio n a l fa c ilitie s , a s y m p h o n y ,
p r o fe s s io n a l liv e th e a tr e a n d a U n iv e r s ity .
F u rth e r in f o r m a t io n c a n be o b ta in e d
b y c o n ta c tin g :
D r . P . N e l i g a n - P la s tic S u rg e o n

or
D r . R . P a r r a g a - C h ie f o f S ta ff

A l w a y s th e r e to C are.
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SLDRURY
G en eral
HOTITAL
o f the I m m a c u l a t e
H ea rt o f M a r y

T h e Head should have e xhibited le a d e rsh ip and strong
interpersonal skills to direct this dynam ic division into the next
decade. The candidate should have expertise, and experience
in a t least one o f the follow ing: the hospital’s m ajor program s of
traum a, oncology, or th e departm ental program of hand sur
gery. S pecific expertise in cra n io m a xillo fa cia l tra u m a and re
co n stru c tive surgery is desirable since this C entre will becom e
th e designated adult craniofacial surgical c e n tre a t the Uni
ve rsity o f Toronto. The candidate could also have expertise
in head and neck cancer a n d /o r skin ca n ce r o r expertise in
hand surgery.
T h e c a n d id a te sh o u ld also have th e s k ills required to
guide the academ ic undergraduate and p o stgraduate teaching
program s, as w ell as th e research program s associated with
th e Division.
A ll interested candidates please reply by M arch 15th, 1991
to:

Reply to
D irector ot
Human
Resources
Sudbury
General Hospital
700 Pans Street
Sudbury. O ntario
P3E3B5

— S 9 1 -4 5

HEALTH
SC IEN C E
CENTRE

Chairm an of the S earch C om m ittee
Dr. Marvin Tile
Room 333
2075 B ayview A venue
T o ron to, O ntario
M4N 3M5
— S 9 1 -4 3
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University of Ottawa— Faculty of Medicine
Chair of the University Division of General Surgery

Universite d’Ottawa — Faculte de medecine
Chaire de la division universitaire de chirurgie generale

The University of Ottawa invites applications for the position of
Chairperson of the University Division of General Surgery.

L’Universite d’Ottawa accueille les candidatures a la direction de sa
chaire de chirurgie generale.
Les candidats et candidates doivent etre admissibles a exercer la
profession en Ontario et posseder I’agrement a titre de specialiste du
College royal des medecins et chirurgiens du Canada, tout en faisant
preuve de realisations et d’experience en chirurgie generale Clinique
et universitaire. Le poste comporte un role de direction dans les milieux
universitaire, hospitalier et communautaire et la preference sera
accordee a une personne competente qui s’est engagee dans la voie
de I’excellence universitaire en enseignement et en recherche.
La division a la responsabilite de fournir un enseignement de qualite
au niveau prediplome et postdoctoral dans les hopitaux affilies offrant
une_ formation en chirurgie generale soit I’Hopital Civic d’Ottawa,
I'Hopital General d ’Ottawa et I’Hopital pour enfants de I’ Est de
I’Ontario. La personne retenue assumera une double affectation a la
direction de la chaire de chirurgie generale de I’universite et a la
direction de chirurgie generale dans un des hopitaux d’enseignement
mentionnes.
La faculte est a la recherche d’une personne pour combler un poste
a temps complet. Le traitement et les avantages sont fonction de la
formation et de I’experience, conformement a I'echelle en vigueur a
I’Universite d’Ottawa.
En vertu des exigences canadiennes relatives a I’immigration, la
priorite est accordee aux personnes de citoyennete canadienne et de
residence permanente au Canada. L’universite a une politique d’egalite
en matiere d’emploi.
Une connaissance de I’anglais et du francais est desirable. Un
engagement a promouvoir le bilinguisme au sein de la faculte est
essentiel.
Priere d’envoyer les demandes, accompagnees d’un curriculum vitae
et du nom de trois repondants, a I’adresse ci-dessous avant le 15 mai
1991.

Applicants must be eligible to practise in Ontario and hold
certification of the Royal College of Physicians and Surgeons of
Canada in general surgery. The faculty is seeking an individual with
a track record of clinical and academic excellence, leadership
skills and potential to develop a strong research program in
general surgery.
The division is responsible for directing both undergraduate
teaching and postgraduate programs in general surgery in the
Ottawa Civic Hospital and Ottawa General Hospital and Children’s
Hospital of Eastern Ontario. The successful candidate will hold a
joint appointment as Chair of the University Department of General
Surgery and Head at one of the affiliated teaching hospitals.
The faculty is seeking an individual who will hold a full-time
U n iversity a p p o in tm e n t. Salary and frin g e b e n e fits are
commensurate with qualifications and experience, and are in
accordance with existing scales at the University of Ottawa.
Priority will be given to Canadian citizens and permanent residents
of Canada in accordance with Canadian immigration requirements.
Employment equity is university policy.
A working knowledge of both English and French is desirable and
a commitment to support bilingualism within the faculty is
essential.
Applicants are requested to forward their curriculum vitae and the
names of three referees prior to May 15, 1991.

John F. Seely, MD.
Dean, Faculty of Medicine
University of Ottawa
451 Smyth Road
Ottawa, Ontario
K1H 8M5

John F. Seely, MD
Doyen, Faculte de medecine
Universite d’Ottawa
451, chemin Smyth
Ottawa (Ontario)

The Department of Surgery
University of Toronto
announces
Post Graduate Courses
in Laparoscopic Cholecystectomy
for General Surgeons
The courses are scheduled between January and June 1991
and will be two days in duration. They will involve theoretical
and practical sessions in the surgical laboratory and in the
operating room.
r
A *-

For further information write or call:
Dr. Steven M. Strasberg - Course Director
Mount Sinai Hospital
Room 1225
600 University Avenue
Toronto, Ontario
M5G 1X5
Fax: (416) 586-8392
Tel: (416) 586-8420
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CLASSIFIED ADVERTISING

FELLOWSHIP, CARDIOPULMONARY
TRANSPLANTATION: ON - Busy heart,
heart-lung and lung transplant centre perform
ing 45-50 transplants a year requires a board
eligible/certified thoracic surgeon to work as
a transplant fellow commencing July 1991.
Responsibilities will include donor and recipi
ent operations, postoperative care and partic
ipating in ongoing experimental and clinical
research protocols. Contact: Dr. Neil
McKenzie, University Hospital, PO Box
5339, London, ON N6A 5A5.
-S91-46

GENERAL SURGEON: BC - In beautiful agri
cultural valley at south end of Kootenay Lake,
southeastern B.C. Referral population 15 000
with broad-based economy and mild climate.
Many recreational and cultural opportunities.
This 44-acute-bed-hospital staffed by six
GPs, three GP/anesthetists and one GP/OB/Gyn. Involved in UBC Family Practice Resi
dency program. Equipped with colonoscope,
gastroscope, and two operating rooms. Po
tential gross at least $250 000. Contact: Dr.
John Kennedy, Chief of Staff, Creston Val
ley Hospital, Bag 30 0 0, Creston, BC VOB
1 GO. Tel: (604) 4 2 8 -9 3 7 1 : or (604)
4 2 8 -3 5 6 2 , evenings.
-S 90-40
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The British Columbia Cancer Agency and its
Vancouver Clinic, and the Department of Surgery,
University of British Columbia, are seeking an out
standing academic surgical oncologist to serve as
the Head of Surgical Oncology. The individual we
seek is expected to plan, implement, and coordinate
clinical and academic programs that foster the
developm ent of surgical oncology in B ritish
Colum bia. The applicant should have attained
national and international stature in surgical oncol
ogy and demonstrate a record of excellence in
scholarship, clinical service and administration.
Anticipated start date is July 1,1991.
The British Columbia Cancer Agency and the
University of British Columbia are committed to
the Federal Government’s employment equity pro
gram and encourage applications from all qualified
individuals. In accordance with Canadian Immigra
tion requirements, priority will be given to Cana
dian citizens and permanent residents of Canada.
Interested applicants should forward a letter of
application and updated curriculum vitae, to Dr.
David Klaassen, Director, B.C. Cancer Agency &
Chair, Search Com m ittee for Head, Surgical
Oncology, at the address shown below.

4

Roussel Canada Inc.
Claforan

Head of
Surgical Oncology

30,81

BRITISH COLUMBIA
CANCER AGENCY
600 West 10th Avenue
Vancouver, British Columbia, Canada V5Z 4E6
S91-41

Syntex Inc.
Anaprox DS
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THE SURGEON S CHOICE
STERILE SINGLE USE SURGICAL BLADES & SCALPELS
SURGICAL BLADES

SCALPELS W ITH BLADES - SINGLE USE

Superb sharpness, foil wrapped individually in quickdispenser boxes. Made from the highest quality materials,
for assured uniformity.

Each scalpel is packed in a polyester and aluminum foil to
protect blade edges. Unique dispenser box of 20 scalpels.
Each scalpel in individually inspected.

Available in all sizes:

Available in all sizes:

#'s 10, 11, 12, 14, 15A, 15, 20,21,22, 23, 24 and 25.
Any size, 100 per box.

10, 11, 12, 14, 15A, 15, 20, 21,22, 23, 24 and 25.
Any size, 20 per box.

VERY SPECIAL:

$9.99/bx

REGULAR $17.95

SUPER SPECIAL:

$6.99

Box of 20

REGULAR $10.95

STAINLESS STEEL HANDLES
M ade from Rust-Free stainless steel. Arrow shaped design for assured grip. Sim ply Th e Finest. G uaranteed

VERY SPECIAL:

$6.95

-

MICROBLADES AND MICROKNIVES
These Microblades have been developed in conjunction with leading surgeons and have achieved the aim of
developing a well balanced instrument to ensure precision and consistency in microsurgery.
• Sterile and disposable.
• Microblade cutting edges are available in four standard angles.
• Blade after blade, cutting edges are precision-ground for sharpness
and consistent cutting angles.

MAXOM
polyglyconate monofilament absorbable suture

Easier
handling
first throw
to last

Maxon. A softer, more supple suture that offers strength,
superior handling characteristics and patient benefits.

DAVIS+GECK
MEDICAL DEVICE DIVISION
Cyanam id Canada Inc.

A World Leader in Wound Management

